data_2eri_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2eri _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.9 m . . . . . 0 CA--C 1.517 -0.313 0 CA-C-O 121.275 0.56 . . . . 0.0 109.721 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.21 -2.64 63.57 Favored Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.912 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 41.2 mt-10 -86.93 158.92 19.19 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.774 -0.713 . . . . 0.0 110.422 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.54 125.64 29.32 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.156 178.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.638 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.6 p -103.13 34.81 2.75 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 122.368 1.08 . . . . 0.0 109.047 179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.922 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 47.7 t -66.53 -42.93 90.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 113.759 -1.564 . . . . 0.0 110.667 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -109.34 -40.95 4.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.638 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.3 pt -134.89 153.08 78.44 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.063 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_exo -60.63 150.54 81.49 Favored 'Trans proline' 0 C--N 1.332 -0.331 0 C-N-CA 123.855 3.037 . . . . 0.0 112.27 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.5 m -53.71 146.08 14.26 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.786 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.422 ' N ' HD13 ' A' ' 11' ' ' ILE . 4.1 mp -88.2 -39.9 13.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.837 179.514 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.404 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.4 40.19 0.63 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.608 0.718 . . . . 0.0 110.514 179.421 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -68.48 -26.5 65.51 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 75.8 mt -63.16 -39.95 96.15 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.831 -1.531 . . . . 0.0 110.493 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 15' ' ' LEU . 2.2 tm? -72.91 -40.43 65.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.236 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 139.86 13.47 0.61 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.404 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.6 m -75.52 105.14 6.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.359 0.599 . . . . 0.0 110.346 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.5 m -97.3 143.32 28.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.737 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.85 115.93 12.74 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.953 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.3 ttmm -140.73 121.71 14.59 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.818 0.342 . . . . 0.0 110.945 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 42.3 t30 60.06 34.12 21.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.674 0.749 . . . . 0.0 109.583 -179.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.922 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 69.46 6.55 5.75 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.757 -179.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.474 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.6 t -119.29 144.33 28.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.098 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.912 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -94.68 127.55 40.73 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 -177.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.474 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 16.4 m-85 -132.41 148.42 52.41 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.093 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 26.6 ptt180 -109.81 158.12 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.587 178.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 55.67 35.58 25.54 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.687 0.756 . . . . 0.0 110.748 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.17 -60.34 3.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.849 -0.691 . . . . 0.0 114.781 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.9 m -140.44 34.88 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -178.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 51.0 mm -103.03 110.28 63.26 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 177.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo . . . . . 0 N--CA 1.464 -0.252 0 C-N-CA 122.578 2.185 . . . . 0.0 113.389 -178.532 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.5 m . . . . . 0 CA--C 1.518 -0.262 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.0 -3.96 60.68 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.94 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.6 mt-10 -88.14 164.77 15.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.617 -0.792 . . . . 0.0 111.059 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.97 126.34 15.77 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 177.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.695 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -105.34 34.27 3.32 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 122.275 1.036 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.963 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 44.3 t -61.98 -44.2 98.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 114.092 -1.413 . . . . 0.0 110.099 179.326 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -105.65 -42.62 5.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.207 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.695 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.3 pt -135.65 150.75 72.86 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 -179.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -57.84 154.6 37.1 Favored 'Trans proline' 0 N--CA 1.473 0.296 0 C-N-CA 124.243 3.296 . . . . 0.0 113.35 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.466 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.8 m -61.01 145.3 51.22 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.257 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.2 mt -93.98 -35.32 6.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.955 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -76.83 44.33 0.38 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.018 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.7 m -64.23 -25.78 68.22 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.4 mt -59.72 -36.87 77.43 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.003 -1.453 . . . . 0.0 110.995 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.504 ' N ' HD23 ' A' ' 15' ' ' LEU . 4.1 mm? -89.59 16.82 7.14 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.839 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.44 28.95 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.508 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 80.7 m -80.57 128.18 33.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.04 0.42 . . . . 0.0 110.135 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -133.14 155.51 49.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 47.9 m -62.5 118.47 7.6 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.998 -0.546 . . . . 0.0 112.184 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.648 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 12.7 tppt? -132.76 101.63 5.35 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.587 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.538 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 46.6 t30 61.54 34.31 17.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.873 -178.005 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.963 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 46.0 mmtt 80.73 -16.52 0.64 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.15 -1.387 . . . . 0.0 112.157 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.67 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.4 t -94.88 143.13 12.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 177.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.94 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -89.29 124.25 34.24 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 112.673 0.62 . . . . 0.0 112.673 -177.505 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.67 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 12.1 m-85 -130.03 150.22 51.4 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.451 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 23.1 ptt180 -112.28 161.01 17.08 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.854 179.383 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 55.55 33.14 20.5 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.187 0.518 . . . . 0.0 111.406 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.433 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 95.43 -64.05 1.35 Allowed Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.812 -0.708 . . . . 0.0 113.963 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.2 m -142.78 37.73 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 112.909 0.707 . . . . 0.0 112.909 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.451 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 49.6 mm -101.17 112.13 64.55 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 178.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.448 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 10.7 Cg_endo . . . . . 0 C--O 1.231 0.15 0 C-N-CA 122.932 2.422 . . . . 0.0 113.963 -178.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.2 m . . . . . 0 CA--C 1.517 -0.319 0 CA-C-O 121.345 0.593 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.71 -3.77 53.24 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 109.751 -1.339 . . . . 0.0 109.751 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.936 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.1 mt-10 -86.84 161.61 18.23 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 114.659 -0.771 . . . . 0.0 110.546 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -135.19 124.62 24.87 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.802 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.661 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.8 p -105.84 33.33 3.82 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 122.048 0.928 . . . . 0.0 109.503 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.703 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 36.9 t -61.43 -44.06 97.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.768 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -112.34 -39.89 4.29 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.431 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.661 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 22.3 pt -129.11 151.73 78.17 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.169 0.509 . . . . 0.0 111.556 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 25.4 Cg_exo -61.52 150.25 86.13 Favored 'Trans proline' 0 C--N 1.333 -0.275 0 C-N-CA 124.012 3.141 . . . . 0.0 112.537 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.4 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 2.6 m -57.09 146.05 28.87 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.81 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.436 ' C ' ' H ' ' A' ' 13' ' ' THR . 59.9 mt -89.05 -37.31 9.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.624 179.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.441 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 8.4 t -77.7 38.02 0.24 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.592 0.711 . . . . 0.0 111.006 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.436 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.7 OUTLIER -71.02 -25.73 62.8 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 177.635 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.3 mt -62.79 -41.54 99.31 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.829 -1.532 . . . . 0.0 110.536 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -74.31 -43.41 56.86 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.291 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.89 30.18 0.22 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.647 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.441 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.2 m -88.45 117.07 27.12 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.025 0.441 . . . . 0.0 110.189 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -104.47 147.73 27.25 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.572 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -77.95 112.97 15.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.505 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.446 ' O ' ' HD3' ' A' ' 20' ' ' LYS . 12.8 tmtt? -139.34 125.16 19.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.089 0.471 . . . . 0.0 110.949 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 58.54 33.59 23.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.089 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.768 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 10.5 mmpt? 71.64 0.83 3.64 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 115.355 -0.838 . . . . 0.0 111.646 -179.415 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.485 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 26.2 t -115.2 146.53 19.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.936 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.3 m -97.25 126.18 42.29 Favored 'General case' 0 C--N 1.312 -1.027 0 O-C-N 121.977 -0.452 . . . . 0.0 111.848 -178.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.485 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -127.26 152.07 47.9 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.172 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.573 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 29.6 ptt85 -116.33 150.44 37.67 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.339 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.601 ' HB3' HD12 ' A' ' 30' ' ' ILE . 1.8 t-20 59.71 34.05 21.98 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.692 0.62 . . . . 0.0 110.948 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.92 -88.38 0.53 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.376 -0.916 . . . . 0.0 113.339 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.8 m -128.68 32.87 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.021 0.748 . . . . 0.0 113.021 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.601 HD12 ' HB3' ' A' ' 27' ' ' ASN . 2.9 mp -94.3 110.8 50.66 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.041 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo . . . . . 0 C--O 1.232 0.184 0 C-N-CA 122.576 2.184 . . . . 0.0 113.691 -178.489 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.2 m . . . . . 0 CA--C 1.519 -0.231 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 94.61 -9.41 71.29 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.749 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 98.3 mt-10 -88.49 167.55 13.35 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.621 -0.789 . . . . 0.0 110.934 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -150.49 132.07 14.84 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.772 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.0 p -102.23 33.06 3.24 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.295 1.045 . . . . 0.0 109.37 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.542 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 45.7 t -62.48 -42.86 97.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.02 -1.445 . . . . 0.0 110.186 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -111.07 -40.35 4.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.099 179.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.772 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.0 pt -135.7 151.18 73.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.761 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.456 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 41.9 Cg_exo -57.19 154.6 33.28 Favored 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 124.128 3.219 . . . . 0.0 113.335 -179.445 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.465 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 7.0 m -59.76 150.2 28.72 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.585 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.456 HD12 HG23 ' A' ' 11' ' ' ILE . 59.3 mt -94.09 -46.23 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.201 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.541 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.54 44.12 0.51 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.645 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -62.93 -25.57 68.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.863 0.84 . . . . 0.0 108.926 178.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 66.3 mt -59.24 -37.68 78.15 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 113.925 -1.489 . . . . 0.0 110.893 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.423 ' HA ' HD12 ' A' ' 15' ' ' LEU . 4.2 mm? -89.96 19.85 4.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.043 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 73.1 25.12 74.31 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.868 -0.605 . . . . 0.0 113.81 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.541 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 93.6 m -75.38 110.71 9.97 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.4 m -114.6 164.3 14.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.658 -178.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -71.17 82.04 0.71 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.109 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.595 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 41.5 tptt -94.03 102.36 14.43 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 62.94 34.3 14.25 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -177.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.542 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 10.6 mtpt 73.88 -3.94 2.39 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 114.203 -1.362 . . . . 0.0 111.801 -178.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.881 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 15.7 t -101.52 144.42 13.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 177.552 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.749 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 72.3 m -87.96 117.5 26.87 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.881 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.5 m-85 -126.84 151.14 48.75 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-N 115.204 -0.907 . . . . 0.0 108.579 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.484 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 11.8 ptp180 -112.98 156.62 22.72 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.555 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.698 ' HB3' HD12 ' A' ' 30' ' ' ILE . 1.7 t-20 55.77 34.54 23.62 Favored 'General case' 0 C--N 1.326 -0.414 0 O-C-N 123.771 0.669 . . . . 0.0 111.376 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.448 ' O ' HG11 ' A' ' 29' ' ' VAL . . . 99.75 -63.06 0.68 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.648 -0.787 . . . . 0.0 114.812 178.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.448 HG11 ' O ' ' A' ' 28' ' ' GLY . 4.8 m -146.35 38.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.311 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.698 HD12 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -102.88 114.58 65.17 Favored Pre-proline 0 C--N 1.324 -0.536 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.152 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.443 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.4 Cg_endo . . . . . 0 CA--C 1.528 0.213 0 C-N-CA 122.747 2.298 . . . . 0.0 113.884 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 63.2 m . . . . . 0 CA--C 1.518 -0.281 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.97 -7.3 58.84 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -177.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.839 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 95.9 mt-10 -88.44 166.3 14.32 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.01 -1.095 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -146.58 133.15 19.79 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 177.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.729 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 30.5 p -104.77 30.79 5.19 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 122.134 0.969 . . . . 0.0 109.896 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.414 HG21 ' HB3' ' A' ' 22' ' ' LYS . 46.4 t -68.3 -39.09 80.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 113.991 -1.459 . . . . 0.0 110.377 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -111.18 -39.77 4.64 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.103 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.729 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -139.01 151.79 68.77 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.611 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.9 Cg_exo -57.55 154.48 36.09 Favored 'Trans proline' 0 C--N 1.333 -0.271 0 C-N-CA 123.993 3.129 . . . . 0.0 112.865 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.407 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 11.4 m -57.6 151.28 17.38 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.661 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.437 ' C ' ' H ' ' A' ' 13' ' ' THR . 61.3 mt -93.72 -49.41 12.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.402 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.68 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.29 38.15 0.28 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.515 0.674 . . . . 0.0 110.895 -179.858 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.437 ' H ' ' C ' ' A' ' 11' ' ' ILE . 27.0 m -67.99 -26.09 65.74 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 177.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.1 mt -63.04 -38.87 92.93 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 113.93 -1.486 . . . . 0.0 110.466 178.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.475 HD23 ' HA ' ' A' ' 15' ' ' LEU . 2.7 tm? -76.83 -46.78 23.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.322 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.63 24.69 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.082 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.68 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 87.7 m -84.85 131.94 34.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.957 0.378 . . . . 0.0 110.165 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -139.01 160.2 40.33 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.041 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.4 m -62.17 113.49 2.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.487 0.661 . . . . 0.0 112.043 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.669 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 13.4 tppt? -131.69 104.75 7.09 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.323 178.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.417 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.8 t30 62.17 32.22 17.41 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.219 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.417 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 30.6 mtmm 82.35 -19.57 0.4 Allowed 'General case' 0 N--CA 1.477 0.89 0 CA-C-N 114.581 -1.19 . . . . 0.0 110.894 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.804 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.7 t -93.44 149.03 4.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.839 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 91.9 m -89.97 121.28 31.92 Favored 'General case' 0 C--N 1.312 -1.038 0 O-C-N 121.796 -0.565 . . . . 0.0 112.221 -178.163 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.804 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.8 m-85 -124.9 152.19 44.39 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.477 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 11.6 ptt180 -114.19 157.12 23.08 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.807 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 55.81 38.34 29.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.679 0.752 . . . . 0.0 110.803 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.484 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 87.68 -62.05 4.04 Favored Glycine 0 N--CA 1.447 -0.568 0 CA-C-N 115.719 -0.673 . . . . 0.0 114.681 178.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.09 41.38 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -178.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.46 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.1 mm -109.15 112.64 59.58 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.1 Cg_endo . . . . . 0 C--O 1.234 0.289 0 C-N-CA 122.568 2.179 . . . . 0.0 113.643 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 62.5 m . . . . . 0 CA--C 1.519 -0.22 0 CA-C-O 121.309 0.576 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.33 63.3 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -178.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.921 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.8 mt-10 -87.28 165.19 15.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 114.765 -0.718 . . . . 0.0 110.675 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.38 127.6 16.7 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.716 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 32.1 p -103.98 32.07 4.16 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-O 121.943 0.878 . . . . 0.0 110.208 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.3 t -66.12 -37.96 80.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 114.196 -1.365 . . . . 0.0 110.188 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -111.3 -40.45 4.41 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.087 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.716 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.1 pt -139.38 150.01 62.46 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.723 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -58.94 152.2 59.91 Favored 'Trans proline' 0 C--N 1.334 -0.221 0 C-N-CA 124.049 3.166 . . . . 0.0 112.963 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.7 m -61.21 144.49 53.64 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.987 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 47.4 mm -93.0 -35.67 6.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.715 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.0 t -75.7 42.76 0.24 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.266 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 m -63.77 -26.21 68.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.006 0.908 . . . . 0.0 108.582 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.1 mt -59.34 -38.94 81.62 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 113.888 -1.506 . . . . 0.0 111.092 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.484 ' N ' HD21 ' A' ' 15' ' ' LEU . 4.0 mm? -88.53 16.33 6.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.15 26.44 68.53 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.359 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.3 m -80.76 129.33 34.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 117.097 0.448 . . . . 0.0 109.959 179.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.8 t -140.45 166.87 23.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.442 -179.156 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 m -65.53 111.74 3.26 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.821 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.516 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtp? -133.86 105.1 6.59 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.421 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 44.8 t30 64.8 31.54 11.63 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.402 -178.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.421 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 31.0 mtmm 81.75 -20.28 0.37 Allowed 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 114.747 -1.115 . . . . 0.0 110.878 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.782 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.8 t -95.3 149.78 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.921 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -90.87 121.43 32.72 Favored 'General case' 0 C--N 1.313 -0.989 0 O-C-N 121.834 -0.541 . . . . 0.0 112.144 -178.311 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.782 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.4 m-85 -128.1 155.75 43.92 Favored 'General case' 0 CA--C 1.512 -0.486 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.415 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.5 ptt85 -119.0 158.65 25.36 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.118 178.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 57.96 31.9 21.24 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.216 0.532 . . . . 0.0 110.939 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.17 -50.08 4.24 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 114.704 0.642 . . . . 0.0 114.704 179.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.4 m -141.13 38.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -177.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.425 ' HA ' ' HD2' ' A' ' 31' ' ' PRO . 47.3 mm -114.52 107.33 51.25 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.176 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 14.8 Cg_endo . . . . . 0 N--CA 1.465 -0.203 0 C-N-CA 122.81 2.34 . . . . 0.0 113.652 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 65.2 m . . . . . 0 CA--C 1.519 -0.243 0 CA-C-O 121.363 0.601 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.2 -4.49 64.96 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -178.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.799 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.0 mt-10 -87.88 163.33 16.45 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.878 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.07 127.3 30.08 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.322 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.647 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.4 p -107.45 32.36 4.73 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.055 0.931 . . . . 0.0 109.32 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.641 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.6 t -61.92 -43.77 97.95 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 114.096 -1.411 . . . . 0.0 110.942 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -110.08 -40.98 4.57 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.479 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.647 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 23.4 pt -130.04 154.22 81.2 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.323 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -59.12 153.08 54.72 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 123.975 3.116 . . . . 0.0 112.597 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 12.2 m -57.53 152.53 14.67 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.014 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.428 ' C ' ' H ' ' A' ' 13' ' ' THR . 61.8 mt -95.77 -46.06 13.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.044 179.626 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.525 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.6 t -76.18 41.89 0.25 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.966 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.428 ' H ' ' C ' ' A' ' 11' ' ' ILE . 29.9 m -64.49 -23.46 67.29 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.8 mt -61.36 -37.52 83.66 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 114.074 -1.421 . . . . 0.0 110.379 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.401 HD22 ' N ' ' A' ' 15' ' ' LEU . 4.0 mm? -89.38 15.05 9.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.563 179.414 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.429 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 77.43 26.44 61.36 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.711 -0.677 . . . . 0.0 113.766 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.525 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.5 m -79.73 112.48 17.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 117.425 0.613 . . . . 0.0 109.472 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 t -108.52 153.82 22.8 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.564 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.5 t -71.51 107.67 4.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.814 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.478 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 19.4 tptp -130.53 113.24 14.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.144 0.497 . . . . 0.0 111.205 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.44 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 5.8 t-20 60.22 35.54 20.94 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.431 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.757 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 9.9 mmpt? 74.45 -6.65 1.84 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.969 -1.014 . . . . 0.0 111.844 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.578 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.5 t -107.36 146.36 13.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.799 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 88.2 m -93.09 121.72 34.73 Favored 'General case' 0 C--N 1.315 -0.927 0 O-C-N 121.922 -0.486 . . . . 0.0 112.107 -178.344 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.578 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 21.8 m-85 -128.93 149.22 50.88 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.473 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 46.2 ptt85 -116.12 164.34 14.62 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.395 -0.821 . . . . 0.0 109.447 179.067 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 11.2 m120 57.92 27.41 14.64 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 123.382 0.426 . . . . 0.0 111.442 179.3 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.85 -64.26 0.64 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.863 -0.685 . . . . 0.0 113.638 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.28 37.3 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.409 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.4 mm -101.93 112.74 65.69 Favored Pre-proline 0 C--N 1.323 -0.562 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.574 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo . . . . . 0 N--CA 1.464 -0.213 0 C-N-CA 122.662 2.242 . . . . 0.0 113.653 -178.682 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.0 m . . . . . 0 CA--C 1.518 -0.277 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 105.04 -7.62 44.54 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -177.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.758 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 99.5 mt-10 -88.66 171.24 10.15 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.434 -0.883 . . . . 0.0 111.083 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.1 m -148.61 135.73 20.13 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 178.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.733 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 23.6 p -107.66 29.54 7.12 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.202 1.001 . . . . 0.0 109.543 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.6 t -66.41 -39.56 84.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 113.77 -1.559 . . . . 0.0 110.72 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -110.47 -40.73 4.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.716 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.733 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.8 pt -139.38 152.5 69.33 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.673 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 31.7 Cg_exo -57.94 155.37 33.6 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 123.989 3.126 . . . . 0.0 113.054 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.433 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 5.9 m -59.44 149.57 29.1 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.482 -179.581 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.425 ' C ' ' H ' ' A' ' 13' ' ' THR . 66.0 mt -96.96 -46.02 12.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.988 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.452 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -77.87 40.69 0.33 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.683 179.65 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.425 ' H ' ' C ' ' A' ' 11' ' ' ILE . 29.6 m -64.06 -23.09 67.2 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.065 0.936 . . . . 0.0 108.487 178.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.4 mt -61.58 -33.98 74.81 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.437 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 90.4 mt -94.52 23.3 5.38 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.738 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 74.18 26.24 68.97 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.651 -0.704 . . . . 0.0 114.332 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.452 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.2 m -82.68 131.09 35.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.652 0.726 . . . . 0.0 109.785 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.9 m -145.66 169.16 19.0 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.564 -178.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.5 m -63.2 106.31 0.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.982 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.461 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtm? -126.89 99.91 5.94 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.274 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.469 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 51.2 t30 65.58 33.27 8.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.792 -178.033 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 41.7 mtmt 80.22 -19.63 0.43 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 114.264 -1.335 . . . . 0.0 111.066 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.88 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -93.33 150.7 3.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.758 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 94.9 m -89.33 116.77 27.79 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 120.141 -0.624 . . . . 0.0 112.362 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.88 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -122.47 156.43 34.11 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.828 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.506 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 14.2 ptt180 -117.76 156.67 27.88 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.088 179.133 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 57.37 34.5 24.77 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.068 0.461 . . . . 0.0 111.304 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 81.61 -50.2 4.19 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 115.0 0.76 . . . . 0.0 115.0 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 m -143.08 41.16 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -178.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.478 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.3 mm -116.64 107.23 46.95 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.173 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.6 Cg_endo . . . . . 0 CA--C 1.528 0.207 0 C-N-CA 122.603 2.202 . . . . 0.0 113.627 -178.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 75.9 m . . . . . 0 CA--C 1.519 -0.236 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.31 -3.28 59.73 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.931 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 40.3 mt-10 -87.96 161.51 17.39 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.59 -0.805 . . . . 0.0 110.83 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.95 126.48 30.43 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.4 178.334 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.668 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 13.3 p -107.55 35.54 3.04 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.374 1.083 . . . . 0.0 109.055 179.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.464 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -64.94 -41.97 93.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 113.816 -1.538 . . . . 0.0 110.713 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -113.04 -39.91 4.09 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.156 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.668 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.6 pt -131.72 151.62 78.93 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.178 -179.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -60.24 152.14 68.52 Favored 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.953 3.102 . . . . 0.0 112.667 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -55.01 148.31 13.91 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 112.083 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.0 mt -89.18 -39.09 12.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.156 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.431 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 2.3 t -80.75 40.84 0.54 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.553 0.692 . . . . 0.0 110.696 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -70.4 -25.22 63.14 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.88 -41.23 97.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.902 -1.499 . . . . 0.0 110.451 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -74.33 -45.76 45.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.266 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 27.46 0.18 Allowed Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.537 -0.84 . . . . 0.0 112.979 179.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.431 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 90.2 m -84.86 113.28 21.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.377 0.608 . . . . 0.0 110.147 179.374 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 35.5 t -99.3 140.82 32.9 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.639 -179.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 45.9 t -70.79 117.97 12.99 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.989 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.07 114.92 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.811 -179.257 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 59.17 31.87 21.6 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.643 0.735 . . . . 0.0 109.464 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.464 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 55.2 mttm 70.86 13.35 7.1 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.705 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -121.34 136.6 57.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 176.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.931 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 76.8 m -89.9 126.46 35.73 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -131.51 147.65 52.56 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.702 178.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.562 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 20.2 ptt85 -111.79 155.23 23.88 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.421 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.755 ' HB3' HD12 ' A' ' 30' ' ' ILE . 3.8 t-20 58.25 33.49 23.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.85 -76.74 0.23 Allowed Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.681 179.289 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.8 m -139.64 32.49 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.755 HD12 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -91.34 113.87 59.87 Favored Pre-proline 0 C--N 1.325 -0.473 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.121 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.802 2.335 . . . . 0.0 114.348 -178.102 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.9 m . . . . . 0 CA--C 1.516 -0.342 0 CA-C-O 121.396 0.617 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.6 -6.82 57.55 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -177.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.807 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 97.6 mt-10 -87.54 165.2 15.66 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.196 -1.002 . . . . 0.0 110.509 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.26 127.35 14.66 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.164 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.79 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 20.3 p -100.86 34.96 2.31 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 122.395 1.093 . . . . 0.0 109.296 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.864 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 40.2 t -63.13 -44.14 99.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 113.912 -1.494 . . . . 0.0 110.176 179.579 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -114.62 -39.7 3.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.957 179.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.79 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -128.6 149.83 72.98 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.853 -179.291 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.93 158.57 24.42 Favored 'Trans proline' 0 C--N 1.332 -0.314 0 C-N-CA 124.142 3.228 . . . . 0.0 113.259 -179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.451 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 8.9 m -60.82 154.77 21.1 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.011 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.403 ' C ' ' H ' ' A' ' 13' ' ' THR . 61.4 mt -100.42 -48.38 11.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.039 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.69 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.9 t -77.17 41.49 0.3 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.357 0.599 . . . . 0.0 111.304 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.403 ' H ' ' C ' ' A' ' 11' ' ' ILE . 28.5 m -67.86 -24.57 65.26 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 73.0 mt -60.49 -41.01 93.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 114.151 -1.386 . . . . 0.0 110.14 178.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.41 HD12 ' HD2' ' A' ' 26' ' ' ARG . 1.8 tm? -76.94 -42.62 38.56 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.487 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.35 20.33 0.15 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.175 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.69 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 71.2 m -78.68 126.34 30.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.193 0.52 . . . . 0.0 110.426 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -140.0 154.73 47.23 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.901 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.9 m -55.82 121.67 9.76 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -179.107 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.593 ' HB2' ' CD1' ' A' ' 25' ' ' TYR . 39.3 mmtm -140.47 106.06 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.669 177.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.464 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 5.1 t-20 62.53 34.32 15.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.772 -177.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.864 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 30.0 mmmt 77.15 -17.05 0.59 Allowed 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.557 -1.202 . . . . 0.0 111.451 -178.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.847 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.0 t -92.45 153.99 3.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.807 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 99.2 m -96.81 123.84 40.62 Favored 'General case' 0 C--N 1.314 -0.945 0 O-C-N 121.372 -0.83 . . . . 0.0 112.327 -178.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.847 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.0 m-85 -126.52 153.86 44.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.219 178.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.537 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 28.9 ptt85 -116.59 156.32 27.21 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.952 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.759 ' HB3' HD12 ' A' ' 30' ' ' ILE . 3.6 t-20 58.3 33.37 23.07 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.539 0.685 . . . . 0.0 110.888 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.47 -66.73 0.27 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.898 179.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 p -150.99 39.25 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-O 121.738 0.78 . . . . 0.0 112.209 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.759 HD12 ' HB3' ' A' ' 27' ' ' ASN . 2.1 mp -98.39 116.25 65.55 Favored Pre-proline 0 C--N 1.322 -0.596 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 177.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 CA--C 1.528 0.225 0 C-N-CA 122.816 2.344 . . . . 0.0 114.228 -178.049 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.525 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 57.4 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.68 -5.92 64.64 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.815 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.7 mt-10 -89.09 165.8 14.27 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.166 -1.017 . . . . 0.0 110.653 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.32 134.5 21.67 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.721 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 31.3 p -106.5 30.65 5.83 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 122.018 0.913 . . . . 0.0 109.925 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.2 t -66.53 -38.41 81.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.985 -1.461 . . . . 0.0 110.394 179.203 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -110.78 -40.28 4.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.988 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.721 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 15.6 pt -140.56 151.4 63.53 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.609 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.4 Cg_exo -57.42 152.4 47.17 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 124.112 3.208 . . . . 0.0 112.947 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.612 ' HB2' HG22 ' A' ' 13' ' ' THR . 3.7 m -58.2 148.16 27.94 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.536 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.1 mm -89.1 -41.16 13.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.161 179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.526 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.1 t -83.2 40.02 0.68 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.483 0.659 . . . . 0.0 110.416 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.612 HG22 ' HB2' ' A' ' 10' ' ' CYS . 0.6 OUTLIER -68.8 -27.64 66.05 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 177.886 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.68 -39.6 94.73 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 113.725 -1.579 . . . . 0.0 110.758 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.449 ' HA ' HD21 ' A' ' 15' ' ' LEU . 2.6 tm? -74.98 -47.36 29.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.634 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.22 20.76 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.983 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 82.1 m -85.42 130.54 34.56 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.358 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.8 t -137.02 168.36 19.74 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.588 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.5 m -67.48 100.36 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.821 -179.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.554 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.3 tmtp? -119.08 102.38 8.69 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.856 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.478 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 9.0 t-20 62.88 36.33 12.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.946 -1.024 . . . . 0.0 108.795 -177.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.671 ' HB2' ' HZ3' ' A' ' 22' ' ' LYS . 7.7 mtmp? 79.31 -17.58 0.58 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.556 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.791 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 19.5 t -97.81 147.79 6.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.192 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.815 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 96.6 m -89.15 120.41 30.51 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -178.116 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.791 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.4 m-85 -127.67 154.09 45.7 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.406 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.525 ' CZ ' ' HA ' ' A' ' 1' ' ' CYS . 5.6 ptt180 -112.65 149.34 32.98 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.778 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 58.01 37.22 26.6 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.635 0.731 . . . . 0.0 110.11 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 78.35 -48.19 3.08 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 115.523 0.969 . . . . 0.0 115.523 178.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.5 m -138.59 35.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 114.887 1.44 . . . . 0.0 114.887 -177.288 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.427 ' HB ' ' HG3' ' A' ' 26' ' ' ARG . 63.1 mt -112.46 110.17 53.13 Favored Pre-proline 0 C--N 1.318 -0.797 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 177.392 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo . . . . . 0 C--O 1.232 0.204 0 C-N-CA 122.655 2.236 . . . . 0.0 113.458 -178.28 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.5 p . . . . . 0 N--CA 1.457 -0.122 0 CA-C-O 120.755 0.312 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 69.99 37.82 74.03 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.72 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.806 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 3.9 mm-40 -135.5 165.74 24.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.014 0.435 . . . . 0.0 110.271 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.55 126.4 8.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.508 178.411 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.654 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.7 p -106.2 36.74 2.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 122.383 1.087 . . . . 0.0 109.218 179.316 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.943 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 43.3 t -64.09 -44.3 97.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 113.854 -1.521 . . . . 0.0 110.751 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -104.12 -42.99 5.37 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.011 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.654 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.6 pt -138.1 156.07 74.12 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.104 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -55.91 150.18 47.67 Favored 'Trans proline' 0 C--O 1.234 0.275 0 C-N-CA 123.624 2.882 . . . . 0.0 112.487 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -58.92 146.0 39.34 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.127 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.415 ' C ' ' H ' ' A' ' 13' ' ' THR . 47.5 mm -88.88 -39.82 12.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.128 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.724 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.63 40.64 0.24 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.25 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.415 ' H ' ' C ' ' A' ' 11' ' ' ILE . 80.0 m -68.93 -23.76 64.21 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.7 mt -61.72 -41.02 97.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.432 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -75.3 -42.1 55.46 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.41 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 137.78 28.94 0.28 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.635 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.724 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 67.4 m -75.28 100.74 4.46 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.088 0.471 . . . . 0.0 110.698 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.3 m -101.3 139.31 37.14 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.108 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.0 m -61.29 121.79 13.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.231 0.539 . . . . 0.0 111.561 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.825 ' HZ3' ' HB2' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -142.87 110.67 5.89 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.158 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.451 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.3 t30 61.84 32.58 18.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 109.104 -178.303 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.943 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 77.45 -15.99 0.69 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.461 -179.232 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.502 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.4 t -94.07 152.76 3.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.806 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 62.2 m -98.3 128.01 44.52 Favored 'General case' 0 C--N 1.315 -0.896 0 O-C-N 121.451 -0.78 . . . . 0.0 111.99 -178.493 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.716 ' CD1' ' HB3' ' A' ' 20' ' ' LYS . 37.8 m-85 -128.14 154.65 45.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.392 178.737 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.454 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 34.9 ptt180 -113.78 154.97 26.49 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.78 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 56.58 35.55 26.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 0.0 110.745 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.76 -78.87 0.3 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.56 -0.829 . . . . 0.0 113.738 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.0 m -137.08 33.44 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.454 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -95.63 115.23 65.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.7 Cg_endo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.24 1.96 . . . . 0.0 111.781 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.9 p . . . . . 0 C--O 1.227 -0.086 0 CA-C-O 121.017 0.437 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 71.69 29.04 68.11 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.507 -0.77 . . . . 0.0 114.291 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.864 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 23.5 mt-10 -123.32 163.8 20.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.028 0.442 . . . . 0.0 110.415 178.473 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.34 126.14 16.12 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.557 178.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.679 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 4.9 p -102.17 34.27 2.78 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 122.381 1.086 . . . . 0.0 109.245 179.563 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.731 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 47.6 t -68.28 -40.62 82.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.637 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -109.67 -41.25 4.6 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.94 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.679 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.7 pt -137.74 152.89 73.42 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.462 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 36.7 Cg_exo -59.48 148.58 86.38 Favored 'Trans proline' 0 C--N 1.332 -0.309 0 C-N-CA 123.682 2.921 . . . . 0.0 112.432 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 m -54.46 147.05 14.64 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.857 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.4 mm -89.21 -44.43 15.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.904 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.576 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.03 39.14 0.49 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.444 0.64 . . . . 0.0 110.901 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 77.7 m -67.15 -25.44 66.17 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 177.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 69.2 mt -63.04 -41.28 99.46 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.533 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.49 -41.79 62.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.238 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.558 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 147.6 13.76 0.15 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.57 -0.824 . . . . 0.0 113.04 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 96.3 m -74.76 88.1 2.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.3 0.572 . . . . 0.0 110.835 179.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 58.9 p -88.32 135.45 33.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.839 179.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.5 t -64.3 119.33 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.445 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.435 ' HE2' ' HB2' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -136.44 117.78 14.64 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.524 -179.743 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 56.85 34.39 24.68 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 109.423 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.731 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 15.4 mtpt 69.99 8.42 6.68 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.801 -179.29 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.408 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 24.8 t -116.87 143.36 27.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 177.419 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.864 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -95.95 127.53 42.05 Favored 'General case' 0 C--N 1.313 -0.991 0 O-C-N 121.434 -0.791 . . . . 0.0 112.865 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.408 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 18.9 m-85 -130.45 151.21 51.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.201 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.558 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 37.7 ptt180 -114.84 154.14 29.15 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.187 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.644 ' HB3' HD11 ' A' ' 30' ' ' ILE . 2.1 t-20 57.94 33.31 23.06 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 123.656 0.597 . . . . 0.0 111.135 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 111.64 -86.53 0.43 Allowed Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.956 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.7 m -134.57 32.46 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -179.051 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.644 HD11 ' HB3' ' A' ' 27' ' ' ASN . 62.4 mt -93.15 110.31 45.41 Favored Pre-proline 0 C--N 1.327 -0.399 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo . . . . . 0 C--N 1.341 0.155 0 C-N-CA 122.222 1.948 . . . . 0.0 112.02 -179.356 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 71.5 m . . . . . 0 CA--C 1.516 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.34 -6.08 65.62 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -177.482 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.589 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.4 mt-10 -87.6 164.3 16.14 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 114.277 -0.961 . . . . 0.0 110.484 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -148.85 135.48 19.63 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.219 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.605 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.5 OUTLIER -105.25 26.21 9.66 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 122.644 1.211 . . . . 0.0 108.911 179.911 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.4 t -55.41 -43.18 70.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.124 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -107.03 -42.87 4.78 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.255 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.605 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.7 pt -145.95 158.45 48.84 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.07 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -58.73 145.44 95.96 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 123.622 2.881 . . . . 0.0 111.832 179.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.577 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 24.1 m -75.23 161.28 29.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.196 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.476 ' C ' ' H ' ' A' ' 13' ' ' THR . 56.1 mt -87.34 -36.15 9.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.45 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.413 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 8.5 t -77.31 30.92 0.14 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.678 0.751 . . . . 0.0 111.36 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.476 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.8 OUTLIER -71.06 -26.85 63.25 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.194 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.4 mt -64.41 -41.18 96.77 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.558 178.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.441 HD23 ' HA ' ' A' ' 15' ' ' LEU . 2.9 tm? -71.42 -42.18 68.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.435 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 22.72 0.24 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.429 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.413 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -82.16 93.85 7.14 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.388 0.614 . . . . 0.0 110.385 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 m -88.27 139.21 30.73 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.897 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.468 ' SG ' ' HA ' ' A' ' 22' ' ' LYS . 50.2 t -75.66 116.37 16.3 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.106 0.479 . . . . 0.0 111.275 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -128.01 127.77 43.79 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 177.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 56.85 33.56 23.31 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-O 121.69 0.757 . . . . 0.0 109.103 -178.225 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.468 ' HA ' ' SG ' ' A' ' 19' ' ' CYS . 14.4 mmmm 69.9 6.56 5.8 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 114.798 -1.092 . . . . 0.0 111.964 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -117.79 138.77 47.4 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.589 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 7.3 m -89.35 129.49 35.87 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -177.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -130.94 152.5 50.19 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.125 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 30.7 ptt85 -116.17 154.31 30.25 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.888 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.415 ' HB3' HD13 ' A' ' 30' ' ' ILE . 4.5 t-20 59.52 33.39 22.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.842 0.829 . . . . 0.0 110.402 -179.318 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.41 -55.69 4.5 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 115.113 0.805 . . . . 0.0 115.113 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.7 m -140.47 38.19 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -177.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.415 HD13 ' HB3' ' A' ' 27' ' ' ASN . 49.0 mt -112.44 110.54 52.91 Favored Pre-proline 0 C--N 1.318 -0.774 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 177.685 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo . . . . . 0 N--CA 1.464 -0.207 0 C-N-CA 122.598 2.199 . . . . 0.0 113.316 -178.615 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.523 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 74.4 m . . . . . 0 CA--C 1.517 -0.315 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.03 -7.32 58.74 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -177.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.785 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 26.3 mt-10 -88.89 165.66 14.48 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.119 -1.04 . . . . 0.0 110.835 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -146.31 127.7 14.94 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.037 178.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.739 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.9 p -104.64 34.35 3.18 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.17 0.985 . . . . 0.0 109.488 179.484 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.896 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -62.14 -39.24 83.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.369 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -114.43 -40.26 3.66 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.146 179.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.739 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 17.5 pt -134.0 149.6 72.08 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.855 -179.234 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 46.0 Cg_exo -56.62 152.85 38.89 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 124.255 3.303 . . . . 0.0 113.649 -179.277 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 m -60.1 149.94 31.02 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.592 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 62.0 mt -89.6 -41.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.486 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.549 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.39 40.83 0.67 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.538 0.685 . . . . 0.0 110.67 179.876 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -69.44 -27.11 64.97 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 177.682 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.5 mt -63.39 -40.64 97.78 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 113.773 -1.558 . . . . 0.0 110.62 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.435 HD23 ' HA ' ' A' ' 15' ' ' LEU . 2.8 tm? -73.51 -47.25 42.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.462 179.756 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.92 23.73 0.09 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.959 179.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.549 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 85.9 m -82.47 119.46 24.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.964 0.411 . . . . 0.0 110.165 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -116.61 156.1 27.6 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.937 -179.031 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.9 m -68.94 105.15 2.29 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.761 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.539 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 17.5 tptm -117.99 103.65 10.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.486 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 0.6 OUTLIER 61.96 32.63 17.74 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -178.143 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.896 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 28.1 mttt 78.31 -10.38 1.36 Allowed 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.348 -1.296 . . . . 0.0 111.754 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.788 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -97.12 143.87 11.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.753 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.785 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 71.0 m -88.81 122.34 32.11 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -177.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.788 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 5.7 m-85 -129.66 151.71 49.96 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.03 177.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.649 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 7.0 ptt180 -116.29 157.07 25.53 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.568 179.324 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 58.82 34.43 23.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.135 0.493 . . . . 0.0 111.463 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.51 -56.99 3.47 Favored Glycine 0 N--CA 1.45 -0.426 0 N-CA-C 114.963 0.745 . . . . 0.0 114.963 178.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.2 m -145.62 38.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.649 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 1.9 mp -106.84 112.51 63.38 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.68 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo . . . . . 0 C--O 1.232 0.191 0 C-N-CA 122.665 2.243 . . . . 0.0 113.787 -178.33 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.9 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.27 -5.01 60.72 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 -178.211 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.896 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.4 mt-10 -88.21 162.79 16.47 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 114.66 -0.77 . . . . 0.0 110.691 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.26 128.4 20.86 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 177.36 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.684 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.3 p -102.46 31.84 3.86 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.924 0.869 . . . . 0.0 110.203 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.0 t -68.48 -38.97 80.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.393 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -106.77 -41.35 5.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.008 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.684 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.3 pt -142.7 152.18 58.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.604 -179.388 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 34.5 Cg_exo -58.86 150.93 68.44 Favored 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.915 3.077 . . . . 0.0 112.621 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.424 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.7 m -58.57 144.76 41.75 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.653 -179.503 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.414 ' C ' ' H ' ' A' ' 13' ' ' THR . 43.7 mm -90.93 -37.96 10.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.461 179.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.481 ' HG ' ' HB2' ' A' ' 15' ' ' LEU . 15.6 t -75.95 40.48 0.2 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.227 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.414 ' H ' ' C ' ' A' ' 11' ' ' ILE . 3.0 p -66.19 -25.67 67.04 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.835 0.826 . . . . 0.0 108.801 177.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.34 -35.97 76.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.429 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.481 ' HB2' ' HG ' ' A' ' 12' ' ' SER . 3.6 mm? -92.17 19.94 6.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.654 179.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.442 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 71.34 30.21 67.34 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.856 -0.611 . . . . 0.0 114.004 178.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 99.9 m -84.0 127.48 33.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 117.289 0.544 . . . . 0.0 109.915 178.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 41.2 m -139.25 164.87 28.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.95 -178.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -67.76 101.31 1.04 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.019 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 7.8 tmtm? -128.53 118.99 23.97 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.452 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 30.7 t30 62.63 39.04 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -178.722 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.452 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 17.5 pttp 56.53 27.67 12.67 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.787 -179.03 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.921 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 44.4 t -142.83 155.04 17.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.896 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 79.6 m -89.61 119.93 30.46 Favored 'General case' 0 C--N 1.313 -0.978 0 O-C-N 121.485 -0.76 . . . . 0.0 112.294 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.921 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -126.79 154.89 43.66 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.019 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.494 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 13.2 ptt180 -116.23 156.42 26.59 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.207 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 56.94 34.53 25.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.15 0.5 . . . . 0.0 111.29 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 83.86 -55.53 5.02 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 114.759 0.663 . . . . 0.0 114.759 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.8 m -139.8 40.48 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -178.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.494 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.5 mm -113.22 106.44 54.7 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo . . . . . 0 C--O 1.233 0.239 0 C-N-CA 122.883 2.389 . . . . 0.0 113.785 -178.172 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.549 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 58.4 m . . . . . 0 CA--C 1.517 -0.306 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.2 -7.44 56.71 Favored Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -177.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.812 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.4 mt-10 -88.01 165.22 15.34 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.116 -1.042 . . . . 0.0 110.68 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -145.28 131.9 19.9 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.711 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -108.7 31.89 5.29 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.201 1.001 . . . . 0.0 109.606 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.2 t -60.32 -43.3 93.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.076 -1.42 . . . . 0.0 110.239 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.73 -41.94 5.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.261 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.711 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -135.31 150.77 73.52 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.883 -179.194 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -55.79 153.38 30.93 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 124.271 3.314 . . . . 0.0 113.773 -179.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 9.0 m -59.93 152.67 22.97 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.755 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.8 mt -93.71 -42.37 12.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.56 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.592 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.07 43.29 0.7 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.435 0.635 . . . . 0.0 110.714 179.909 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -68.0 -26.74 66.06 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.9 mt -62.43 -41.36 98.66 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.623 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' A' ' 15' ' ' LEU . 1.8 tm? -73.49 -43.95 58.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.304 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 140.69 26.08 0.22 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.819 179.176 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.592 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 77.1 m -82.95 121.24 26.73 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.853 0.358 . . . . 0.0 110.116 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.474 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 12.9 t -118.24 164.01 15.82 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 -178.71 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.7 m -73.36 74.05 1.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.644 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.661 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 13.2 tmtt? -89.15 103.79 16.39 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.455 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 23.4 t30 60.19 33.8 21.05 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.267 -178.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.455 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 22.9 mmtp 74.37 2.71 4.18 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.704 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.83 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -109.17 140.07 29.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.812 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 82.9 m -88.1 121.42 30.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -176.632 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.83 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -127.26 150.51 49.53 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 177.577 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.573 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 9.1 ptt180 -115.27 153.53 30.75 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.369 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.617 ' HB3' HD13 ' A' ' 30' ' ' ILE . 3.4 t-20 58.79 36.81 24.95 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.361 0.6 . . . . 0.0 111.16 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.85 -62.53 0.79 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.581 -0.819 . . . . 0.0 114.663 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -150.58 37.36 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-O 121.674 0.749 . . . . 0.0 112.693 -178.117 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.617 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -100.06 112.19 63.56 Favored Pre-proline 0 C--N 1.323 -0.577 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 177.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.8 Cg_endo . . . . . 0 C--O 1.232 0.197 0 C-N-CA 122.628 2.219 . . . . 0.0 113.551 -178.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 30.3 p . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.718 0.294 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 111.09 -12.27 29.07 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.937 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.801 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 5.6 mm-40 -85.1 159.94 20.07 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.545 0.688 . . . . 0.0 111.151 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.79 134.77 30.69 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.853 -1.067 . . . . 0.0 109.13 178.538 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.663 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 15.1 p -115.91 34.13 5.13 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 122.088 0.947 . . . . 0.0 109.231 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.602 ' HA ' ' HB3' ' A' ' 22' ' ' LYS . 28.9 t -63.92 -40.46 89.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 113.881 -1.509 . . . . 0.0 111.244 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -114.53 -38.94 3.9 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.065 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.663 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -136.51 153.43 76.09 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.504 -179.267 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 38.0 Cg_exo -58.52 148.66 79.97 Favored 'Trans proline' 0 C--N 1.332 -0.328 0 C-N-CA 123.717 2.945 . . . . 0.0 112.265 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -56.67 143.97 34.15 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.469 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.43 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.3 mp -89.75 -42.43 14.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.609 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.24 39.11 0.19 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.363 179.854 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.413 ' H ' ' C ' ' A' ' 11' ' ' ILE . 58.2 m -69.53 -23.42 63.59 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 177.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 77.2 mt -63.06 -40.83 98.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.489 178.528 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.421 ' O ' HD11 ' A' ' 15' ' ' LEU . 1.0 OUTLIER -73.12 -39.72 65.51 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.396 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.46 23.87 0.44 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.535 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.609 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 89.7 m -76.64 98.06 4.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.094 0.473 . . . . 0.0 110.669 179.532 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.44 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 13.6 m -88.56 132.93 34.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.937 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.2 t -73.82 117.2 15.32 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.087 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.65 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 11.6 tmtt? -141.97 119.1 11.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.525 0.679 . . . . 0.0 110.843 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 55.07 37.17 28.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.3 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.602 ' HB3' ' HA ' ' A' ' 6' ' ' VAL . 26.3 mtmm 75.88 1.43 3.51 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.08 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.7 t -118.32 137.25 52.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.801 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 30.1 m -95.52 128.37 42.33 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.702 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.65 ' CE1' ' HD2' ' A' ' 20' ' ' LYS . 2.1 m-85 -122.35 163.54 19.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.653 179.429 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.491 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.2 ptt180 -131.94 155.51 47.79 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 61.79 31.55 18.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.305 0.574 . . . . 0.0 111.211 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 109.69 -71.93 0.2 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.536 -0.84 . . . . 0.0 113.931 178.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 p -150.23 36.85 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 122.069 0.938 . . . . 0.0 111.099 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.491 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.9 mm -101.17 113.83 65.8 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.407 178.434 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.5 Cg_endo . . . . . 0 N--CA 1.463 -0.268 0 C-N-CA 122.203 1.935 . . . . 0.0 111.4 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.485 ' HB3' ' HD3' ' A' ' 26' ' ' ARG . 1.7 p . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.018 0.437 . . . . 0.0 110.828 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.33 31.6 80.98 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.491 -0.777 . . . . 0.0 113.166 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.839 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.5 mt-10 -124.42 165.93 16.88 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.074 0.464 . . . . 0.0 110.4 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.89 134.07 17.19 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.738 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.7 p -107.45 31.29 5.53 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 122.36 1.076 . . . . 0.0 109.605 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.885 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 46.7 t -61.72 -44.47 98.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 113.933 -1.485 . . . . 0.0 110.177 179.475 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -104.66 -43.59 5.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.158 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.738 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.5 pt -136.09 153.8 77.03 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.003 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 51.4 Cg_exo -55.45 153.98 26.34 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 124.11 3.207 . . . . 0.0 113.379 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.431 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 7.3 m -58.69 149.74 25.31 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.698 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.41 ' C ' ' H ' ' A' ' 13' ' ' THR . 4.2 mp -89.53 -46.35 15.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.859 179.324 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.683 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -79.24 41.24 0.45 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.442 0.639 . . . . 0.0 110.539 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.41 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.6 OUTLIER -68.61 -26.5 65.39 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.8 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.4 mt -61.98 -40.93 97.29 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 113.81 -1.541 . . . . 0.0 110.453 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.485 HD13 ' HD2' ' A' ' 26' ' ' ARG . 2.0 tm? -75.36 -46.33 33.82 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.58 26.38 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.543 -0.836 . . . . 0.0 113.259 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.683 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.1 m -80.35 120.96 25.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 117.169 0.485 . . . . 0.0 110.006 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.5 m -119.12 159.79 23.31 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.181 -178.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.2 m -69.35 84.96 0.4 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.752 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.557 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 46.7 tptt -96.66 98.4 10.15 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.596 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 0.6 OUTLIER 60.94 33.52 19.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.395 -0.82 . . . . 0.0 108.811 -178.362 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.885 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 40.4 mmtt 82.29 -10.99 1.05 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.319 -1.309 . . . . 0.0 112.414 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.812 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -99.22 141.45 16.64 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.165 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.839 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 73.1 m -89.65 122.54 32.87 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.812 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -127.43 151.07 49.29 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.726 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.485 ' HD2' HD13 ' A' ' 15' ' ' LEU . 28.1 ptt180 -112.24 153.61 26.86 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.115 179.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.522 ' HB3' HD13 ' A' ' 30' ' ' ILE . 25.3 t30 60.12 33.49 21.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.287 0.565 . . . . 0.0 111.264 179.709 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.89 -64.59 0.73 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.621 -0.8 . . . . 0.0 114.615 178.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.3 m -143.12 33.59 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.522 HD13 ' HB3' ' A' ' 27' ' ' ASN . 59.0 mt -101.56 108.42 55.54 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo . . . . . 0 N--CA 1.464 -0.238 0 C-N-CA 122.212 1.942 . . . . 0.0 112.347 -179.09 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 CA--C 1.516 -0.362 0 CA-C-O 121.372 0.606 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.48 -5.75 67.63 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -177.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.574 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 21.2 mt-10 -87.25 160.11 18.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 114.494 -0.853 . . . . 0.0 110.387 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 23' ' ' VAL . 0.7 OUTLIER -144.46 133.36 22.58 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.471 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.7 OUTLIER -98.68 26.97 5.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 122.157 0.98 . . . . 0.0 109.905 -179.572 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.7 t -61.03 -39.74 83.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 114.26 -1.336 . . . . 0.0 111.715 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.492 ' O ' HG22 ' A' ' 8' ' ' ILE . 27.2 m-85 -108.33 -42.03 4.71 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.44 -179.411 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.492 HG22 ' O ' ' A' ' 7' ' ' PHE . 13.5 pt -149.96 159.38 35.74 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.679 -178.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -59.55 143.6 99.64 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 123.342 2.695 . . . . 0.0 111.302 179.17 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.527 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 18.2 m -71.18 161.42 31.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.79 -178.229 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.442 ' C ' ' H ' ' A' ' 13' ' ' THR . 57.8 mt -87.03 -40.01 13.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.356 -0.838 . . . . 0.0 112.711 -178.082 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.594 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 3.1 t -79.32 35.87 0.28 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.714 0.768 . . . . 0.0 111.345 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.442 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.8 OUTLIER -70.52 -25.12 62.98 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 177.419 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 81.0 mt -63.86 -42.85 97.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 113.898 -1.501 . . . . 0.0 110.716 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.437 HD22 ' HA ' ' A' ' 15' ' ' LEU . 2.8 tm? -71.43 -43.31 66.97 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.584 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.452 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 144.46 20.66 0.17 Allowed Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.697 179.256 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -77.8 83.75 4.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.401 0.619 . . . . 0.0 110.425 179.491 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.4 m -86.18 136.2 33.29 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.454 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.6 t -68.6 127.94 34.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.162 0.506 . . . . 0.0 111.222 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -144.99 130.24 18.6 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.753 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 31.2 t30 56.81 38.93 29.79 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.304 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.753 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 2.1 pttm 60.84 13.3 4.34 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.156 1.382 . . . . 0.0 112.115 -179.159 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.439 HG12 ' O ' ' A' ' 3' ' ' GLU . 58.5 t -128.31 141.62 46.01 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.574 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 1.7 m -88.93 131.67 35.04 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.034 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -132.45 146.27 51.82 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.17 -0.923 . . . . 0.0 108.853 177.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 41.4 ptt85 -110.53 157.84 19.19 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.305 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 57.62 30.81 19.4 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.672 0.607 . . . . 0.0 111.256 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.59 -74.5 0.22 Allowed Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.548 -0.834 . . . . 0.0 113.462 179.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.51 32.52 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.411 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -92.44 113.1 58.35 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.197 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo . . . . . 0 N--CA 1.464 -0.227 0 C-N-CA 122.704 2.269 . . . . 0.0 113.558 -178.459 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.9 m . . . . . 0 CA--C 1.517 -0.313 0 CA-C-O 121.275 0.56 . . . . 0.0 109.721 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.21 -2.64 63.57 Favored Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.912 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 41.2 mt-10 -86.93 158.92 19.19 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.774 -0.713 . . . . 0.0 110.422 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.54 125.64 29.32 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.156 178.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.638 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.6 p -103.13 34.81 2.75 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 122.368 1.08 . . . . 0.0 109.047 179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.922 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 47.7 t -66.53 -42.93 90.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 113.759 -1.564 . . . . 0.0 110.667 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -109.34 -40.95 4.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.638 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.3 pt -134.89 153.08 78.44 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.063 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_exo -60.63 150.54 81.49 Favored 'Trans proline' 0 C--N 1.332 -0.331 0 C-N-CA 123.855 3.037 . . . . 0.0 112.27 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.5 m -53.71 146.08 14.26 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.786 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.422 ' N ' HD13 ' A' ' 11' ' ' ILE . 4.1 mp -88.2 -39.9 13.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.837 179.514 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.404 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.4 40.19 0.63 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.608 0.718 . . . . 0.0 110.514 179.421 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -68.48 -26.5 65.51 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 75.8 mt -63.16 -39.95 96.15 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.831 -1.531 . . . . 0.0 110.493 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 15' ' ' LEU . 2.2 tm? -72.91 -40.43 65.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.236 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 139.86 13.47 0.61 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.404 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.6 m -75.52 105.14 6.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.359 0.599 . . . . 0.0 110.346 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.5 m -97.3 143.32 28.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.737 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.85 115.93 12.74 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.953 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.3 ttmm -140.73 121.71 14.59 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.818 0.342 . . . . 0.0 110.945 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 42.3 t30 60.06 34.12 21.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.674 0.749 . . . . 0.0 109.583 -179.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.922 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 69.46 6.55 5.75 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.757 -179.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.474 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.6 t -119.29 144.33 28.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.098 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.912 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -94.68 127.55 40.73 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 -177.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.474 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 16.4 m-85 -132.41 148.42 52.41 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.093 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 26.6 ptt180 -109.81 158.12 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.587 178.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 55.67 35.58 25.54 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.687 0.756 . . . . 0.0 110.748 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.17 -60.34 3.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.849 -0.691 . . . . 0.0 114.781 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.9 m -140.44 34.88 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -178.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 51.0 mm -103.03 110.28 63.26 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 177.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo . . . . . 0 N--CA 1.464 -0.252 0 C-N-CA 122.578 2.185 . . . . 0.0 113.389 -178.532 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.5 m . . . . . 0 CA--C 1.518 -0.262 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.0 -3.96 60.68 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.94 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.6 mt-10 -88.14 164.77 15.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.617 -0.792 . . . . 0.0 111.059 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.97 126.34 15.77 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 177.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.695 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -105.34 34.27 3.32 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 122.275 1.036 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.963 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 44.3 t -61.98 -44.2 98.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 114.092 -1.413 . . . . 0.0 110.099 179.326 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -105.65 -42.62 5.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.207 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.695 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.3 pt -135.65 150.75 72.86 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 -179.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -57.84 154.6 37.1 Favored 'Trans proline' 0 N--CA 1.473 0.296 0 C-N-CA 124.243 3.296 . . . . 0.0 113.35 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.466 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.8 m -61.01 145.3 51.22 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.257 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.2 mt -93.98 -35.32 6.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.955 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -76.83 44.33 0.38 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.018 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.7 m -64.23 -25.78 68.22 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.4 mt -59.72 -36.87 77.43 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.003 -1.453 . . . . 0.0 110.995 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.504 ' N ' HD23 ' A' ' 15' ' ' LEU . 4.1 mm? -89.59 16.82 7.14 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.839 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.44 28.95 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.508 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 80.7 m -80.57 128.18 33.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.04 0.42 . . . . 0.0 110.135 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -133.14 155.51 49.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 47.9 m -62.5 118.47 7.6 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.998 -0.546 . . . . 0.0 112.184 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.648 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 12.7 tppt? -132.76 101.63 5.35 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.587 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.538 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 46.6 t30 61.54 34.31 17.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.873 -178.005 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.963 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 46.0 mmtt 80.73 -16.52 0.64 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.15 -1.387 . . . . 0.0 112.157 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.67 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.4 t -94.88 143.13 12.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 177.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.94 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -89.29 124.25 34.24 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 112.673 0.62 . . . . 0.0 112.673 -177.505 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.67 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 12.1 m-85 -130.03 150.22 51.4 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.451 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 23.1 ptt180 -112.28 161.01 17.08 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.854 179.383 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 55.55 33.14 20.5 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.187 0.518 . . . . 0.0 111.406 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.433 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 95.43 -64.05 1.35 Allowed Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.812 -0.708 . . . . 0.0 113.963 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.2 m -142.78 37.73 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 112.909 0.707 . . . . 0.0 112.909 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.451 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 49.6 mm -101.17 112.13 64.55 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 178.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.448 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 10.7 Cg_endo . . . . . 0 C--O 1.231 0.15 0 C-N-CA 122.932 2.422 . . . . 0.0 113.963 -178.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.2 m . . . . . 0 CA--C 1.517 -0.319 0 CA-C-O 121.345 0.593 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.71 -3.77 53.24 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 109.751 -1.339 . . . . 0.0 109.751 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.936 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.1 mt-10 -86.84 161.61 18.23 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 114.659 -0.771 . . . . 0.0 110.546 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -135.19 124.62 24.87 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.802 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.661 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.8 p -105.84 33.33 3.82 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 122.048 0.928 . . . . 0.0 109.503 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.703 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 36.9 t -61.43 -44.06 97.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.768 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -112.34 -39.89 4.29 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.431 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.661 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 22.3 pt -129.11 151.73 78.17 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.169 0.509 . . . . 0.0 111.556 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 25.4 Cg_exo -61.52 150.25 86.13 Favored 'Trans proline' 0 C--N 1.333 -0.275 0 C-N-CA 124.012 3.141 . . . . 0.0 112.537 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.4 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 2.6 m -57.09 146.05 28.87 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.81 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.436 ' C ' ' H ' ' A' ' 13' ' ' THR . 59.9 mt -89.05 -37.31 9.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.624 179.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.441 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 8.4 t -77.7 38.02 0.24 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.592 0.711 . . . . 0.0 111.006 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.436 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.7 OUTLIER -71.02 -25.73 62.8 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 177.635 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.3 mt -62.79 -41.54 99.31 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.829 -1.532 . . . . 0.0 110.536 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -74.31 -43.41 56.86 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.291 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.89 30.18 0.22 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.647 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.441 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.2 m -88.45 117.07 27.12 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.025 0.441 . . . . 0.0 110.189 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -104.47 147.73 27.25 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.572 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -77.95 112.97 15.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.505 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.446 ' O ' ' HD3' ' A' ' 20' ' ' LYS . 12.8 tmtt? -139.34 125.16 19.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.089 0.471 . . . . 0.0 110.949 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 58.54 33.59 23.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.089 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.768 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 10.5 mmpt? 71.64 0.83 3.64 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 115.355 -0.838 . . . . 0.0 111.646 -179.415 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.485 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 26.2 t -115.2 146.53 19.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.936 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.3 m -97.25 126.18 42.29 Favored 'General case' 0 C--N 1.312 -1.027 0 O-C-N 121.977 -0.452 . . . . 0.0 111.848 -178.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.485 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -127.26 152.07 47.9 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.172 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.573 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 29.6 ptt85 -116.33 150.44 37.67 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.339 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.601 ' HB3' HD12 ' A' ' 30' ' ' ILE . 1.8 t-20 59.71 34.05 21.98 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.692 0.62 . . . . 0.0 110.948 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.92 -88.38 0.53 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.376 -0.916 . . . . 0.0 113.339 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.8 m -128.68 32.87 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.021 0.748 . . . . 0.0 113.021 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.601 HD12 ' HB3' ' A' ' 27' ' ' ASN . 2.9 mp -94.3 110.8 50.66 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.041 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo . . . . . 0 C--O 1.232 0.184 0 C-N-CA 122.576 2.184 . . . . 0.0 113.691 -178.489 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.2 m . . . . . 0 CA--C 1.519 -0.231 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 94.61 -9.41 71.29 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.749 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 98.3 mt-10 -88.49 167.55 13.35 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.621 -0.789 . . . . 0.0 110.934 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -150.49 132.07 14.84 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.772 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.0 p -102.23 33.06 3.24 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.295 1.045 . . . . 0.0 109.37 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.542 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 45.7 t -62.48 -42.86 97.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.02 -1.445 . . . . 0.0 110.186 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -111.07 -40.35 4.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.099 179.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.772 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.0 pt -135.7 151.18 73.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.761 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.456 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 41.9 Cg_exo -57.19 154.6 33.28 Favored 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 124.128 3.219 . . . . 0.0 113.335 -179.445 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.465 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 7.0 m -59.76 150.2 28.72 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.585 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.456 HD12 HG23 ' A' ' 11' ' ' ILE . 59.3 mt -94.09 -46.23 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.201 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.541 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.54 44.12 0.51 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.645 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -62.93 -25.57 68.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.863 0.84 . . . . 0.0 108.926 178.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 66.3 mt -59.24 -37.68 78.15 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 113.925 -1.489 . . . . 0.0 110.893 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.423 ' HA ' HD12 ' A' ' 15' ' ' LEU . 4.2 mm? -89.96 19.85 4.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.043 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 73.1 25.12 74.31 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.868 -0.605 . . . . 0.0 113.81 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.541 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 93.6 m -75.38 110.71 9.97 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.4 m -114.6 164.3 14.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.658 -178.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -71.17 82.04 0.71 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.109 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.595 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 41.5 tptt -94.03 102.36 14.43 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 62.94 34.3 14.25 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -177.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.542 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 10.6 mtpt 73.88 -3.94 2.39 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 114.203 -1.362 . . . . 0.0 111.801 -178.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.881 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 15.7 t -101.52 144.42 13.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 177.552 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.749 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 72.3 m -87.96 117.5 26.87 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.881 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.5 m-85 -126.84 151.14 48.75 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-N 115.204 -0.907 . . . . 0.0 108.579 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.484 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 11.8 ptp180 -112.98 156.62 22.72 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.555 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.698 ' HB3' HD12 ' A' ' 30' ' ' ILE . 1.7 t-20 55.77 34.54 23.62 Favored 'General case' 0 C--N 1.326 -0.414 0 O-C-N 123.771 0.669 . . . . 0.0 111.376 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.448 ' O ' HG11 ' A' ' 29' ' ' VAL . . . 99.75 -63.06 0.68 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.648 -0.787 . . . . 0.0 114.812 178.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.448 HG11 ' O ' ' A' ' 28' ' ' GLY . 4.8 m -146.35 38.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.311 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.698 HD12 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -102.88 114.58 65.17 Favored Pre-proline 0 C--N 1.324 -0.536 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.152 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.443 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.4 Cg_endo . . . . . 0 CA--C 1.528 0.213 0 C-N-CA 122.747 2.298 . . . . 0.0 113.884 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 63.2 m . . . . . 0 CA--C 1.518 -0.281 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.97 -7.3 58.84 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -177.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.839 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 95.9 mt-10 -88.44 166.3 14.32 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.01 -1.095 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -146.58 133.15 19.79 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 177.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.729 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 30.5 p -104.77 30.79 5.19 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 122.134 0.969 . . . . 0.0 109.896 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.414 HG21 ' HB3' ' A' ' 22' ' ' LYS . 46.4 t -68.3 -39.09 80.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 113.991 -1.459 . . . . 0.0 110.377 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -111.18 -39.77 4.64 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.103 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.729 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -139.01 151.79 68.77 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.611 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.9 Cg_exo -57.55 154.48 36.09 Favored 'Trans proline' 0 C--N 1.333 -0.271 0 C-N-CA 123.993 3.129 . . . . 0.0 112.865 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.407 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 11.4 m -57.6 151.28 17.38 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.661 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.437 ' C ' ' H ' ' A' ' 13' ' ' THR . 61.3 mt -93.72 -49.41 12.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.402 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.68 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.29 38.15 0.28 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.515 0.674 . . . . 0.0 110.895 -179.858 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.437 ' H ' ' C ' ' A' ' 11' ' ' ILE . 27.0 m -67.99 -26.09 65.74 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 177.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.1 mt -63.04 -38.87 92.93 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 113.93 -1.486 . . . . 0.0 110.466 178.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.475 HD23 ' HA ' ' A' ' 15' ' ' LEU . 2.7 tm? -76.83 -46.78 23.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.322 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.63 24.69 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.082 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.68 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 87.7 m -84.85 131.94 34.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.957 0.378 . . . . 0.0 110.165 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -139.01 160.2 40.33 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.041 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.4 m -62.17 113.49 2.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.487 0.661 . . . . 0.0 112.043 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.669 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 13.4 tppt? -131.69 104.75 7.09 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.323 178.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.417 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.8 t30 62.17 32.22 17.41 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.219 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.417 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 30.6 mtmm 82.35 -19.57 0.4 Allowed 'General case' 0 N--CA 1.477 0.89 0 CA-C-N 114.581 -1.19 . . . . 0.0 110.894 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.804 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.7 t -93.44 149.03 4.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.839 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 91.9 m -89.97 121.28 31.92 Favored 'General case' 0 C--N 1.312 -1.038 0 O-C-N 121.796 -0.565 . . . . 0.0 112.221 -178.163 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.804 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.8 m-85 -124.9 152.19 44.39 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.477 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 11.6 ptt180 -114.19 157.12 23.08 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.807 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 55.81 38.34 29.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.679 0.752 . . . . 0.0 110.803 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.484 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 87.68 -62.05 4.04 Favored Glycine 0 N--CA 1.447 -0.568 0 CA-C-N 115.719 -0.673 . . . . 0.0 114.681 178.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.09 41.38 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -178.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.46 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.1 mm -109.15 112.64 59.58 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.1 Cg_endo . . . . . 0 C--O 1.234 0.289 0 C-N-CA 122.568 2.179 . . . . 0.0 113.643 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 62.5 m . . . . . 0 CA--C 1.519 -0.22 0 CA-C-O 121.309 0.576 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.33 63.3 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -178.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.921 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.8 mt-10 -87.28 165.19 15.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 114.765 -0.718 . . . . 0.0 110.675 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.38 127.6 16.7 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.716 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 32.1 p -103.98 32.07 4.16 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-O 121.943 0.878 . . . . 0.0 110.208 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.3 t -66.12 -37.96 80.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 114.196 -1.365 . . . . 0.0 110.188 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -111.3 -40.45 4.41 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.087 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.716 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.1 pt -139.38 150.01 62.46 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.723 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -58.94 152.2 59.91 Favored 'Trans proline' 0 C--N 1.334 -0.221 0 C-N-CA 124.049 3.166 . . . . 0.0 112.963 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.7 m -61.21 144.49 53.64 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.987 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 47.4 mm -93.0 -35.67 6.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.715 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.0 t -75.7 42.76 0.24 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.266 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 m -63.77 -26.21 68.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.006 0.908 . . . . 0.0 108.582 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.1 mt -59.34 -38.94 81.62 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 113.888 -1.506 . . . . 0.0 111.092 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.484 ' N ' HD21 ' A' ' 15' ' ' LEU . 4.0 mm? -88.53 16.33 6.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.15 26.44 68.53 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.359 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.3 m -80.76 129.33 34.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 117.097 0.448 . . . . 0.0 109.959 179.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.8 t -140.45 166.87 23.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.442 -179.156 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 m -65.53 111.74 3.26 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.821 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.516 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtp? -133.86 105.1 6.59 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.421 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 44.8 t30 64.8 31.54 11.63 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.402 -178.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.421 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 31.0 mtmm 81.75 -20.28 0.37 Allowed 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 114.747 -1.115 . . . . 0.0 110.878 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.782 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.8 t -95.3 149.78 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.921 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -90.87 121.43 32.72 Favored 'General case' 0 C--N 1.313 -0.989 0 O-C-N 121.834 -0.541 . . . . 0.0 112.144 -178.311 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.782 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.4 m-85 -128.1 155.75 43.92 Favored 'General case' 0 CA--C 1.512 -0.486 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.415 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.5 ptt85 -119.0 158.65 25.36 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.118 178.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 57.96 31.9 21.24 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.216 0.532 . . . . 0.0 110.939 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.17 -50.08 4.24 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 114.704 0.642 . . . . 0.0 114.704 179.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.4 m -141.13 38.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -177.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.425 ' HA ' ' HD2' ' A' ' 31' ' ' PRO . 47.3 mm -114.52 107.33 51.25 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.176 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 14.8 Cg_endo . . . . . 0 N--CA 1.465 -0.203 0 C-N-CA 122.81 2.34 . . . . 0.0 113.652 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 65.2 m . . . . . 0 CA--C 1.519 -0.243 0 CA-C-O 121.363 0.601 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.2 -4.49 64.96 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -178.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.799 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.0 mt-10 -87.88 163.33 16.45 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.878 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.07 127.3 30.08 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.322 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.647 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.4 p -107.45 32.36 4.73 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.055 0.931 . . . . 0.0 109.32 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.641 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.6 t -61.92 -43.77 97.95 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 114.096 -1.411 . . . . 0.0 110.942 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -110.08 -40.98 4.57 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.479 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.647 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 23.4 pt -130.04 154.22 81.2 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.323 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -59.12 153.08 54.72 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 123.975 3.116 . . . . 0.0 112.597 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 12.2 m -57.53 152.53 14.67 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.014 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.428 ' C ' ' H ' ' A' ' 13' ' ' THR . 61.8 mt -95.77 -46.06 13.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.044 179.626 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.525 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.6 t -76.18 41.89 0.25 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.966 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.428 ' H ' ' C ' ' A' ' 11' ' ' ILE . 29.9 m -64.49 -23.46 67.29 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.8 mt -61.36 -37.52 83.66 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 114.074 -1.421 . . . . 0.0 110.379 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.401 HD22 ' N ' ' A' ' 15' ' ' LEU . 4.0 mm? -89.38 15.05 9.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.563 179.414 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.429 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 77.43 26.44 61.36 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.711 -0.677 . . . . 0.0 113.766 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.525 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.5 m -79.73 112.48 17.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 117.425 0.613 . . . . 0.0 109.472 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 t -108.52 153.82 22.8 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.564 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.5 t -71.51 107.67 4.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.814 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.478 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 19.4 tptp -130.53 113.24 14.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.144 0.497 . . . . 0.0 111.205 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.44 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 5.8 t-20 60.22 35.54 20.94 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.431 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.757 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 9.9 mmpt? 74.45 -6.65 1.84 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.969 -1.014 . . . . 0.0 111.844 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.578 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.5 t -107.36 146.36 13.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.799 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 88.2 m -93.09 121.72 34.73 Favored 'General case' 0 C--N 1.315 -0.927 0 O-C-N 121.922 -0.486 . . . . 0.0 112.107 -178.344 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.578 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 21.8 m-85 -128.93 149.22 50.88 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.473 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 46.2 ptt85 -116.12 164.34 14.62 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.395 -0.821 . . . . 0.0 109.447 179.067 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 11.2 m120 57.92 27.41 14.64 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 123.382 0.426 . . . . 0.0 111.442 179.3 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.85 -64.26 0.64 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.863 -0.685 . . . . 0.0 113.638 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.28 37.3 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.409 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.4 mm -101.93 112.74 65.69 Favored Pre-proline 0 C--N 1.323 -0.562 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.574 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo . . . . . 0 N--CA 1.464 -0.213 0 C-N-CA 122.662 2.242 . . . . 0.0 113.653 -178.682 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.0 m . . . . . 0 CA--C 1.518 -0.277 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 105.04 -7.62 44.54 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -177.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.758 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 99.5 mt-10 -88.66 171.24 10.15 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.434 -0.883 . . . . 0.0 111.083 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.1 m -148.61 135.73 20.13 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 178.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.733 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 23.6 p -107.66 29.54 7.12 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.202 1.001 . . . . 0.0 109.543 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.6 t -66.41 -39.56 84.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 113.77 -1.559 . . . . 0.0 110.72 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -110.47 -40.73 4.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.716 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.733 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.8 pt -139.38 152.5 69.33 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.673 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 31.7 Cg_exo -57.94 155.37 33.6 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 123.989 3.126 . . . . 0.0 113.054 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.433 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 5.9 m -59.44 149.57 29.1 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.482 -179.581 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.425 ' C ' ' H ' ' A' ' 13' ' ' THR . 66.0 mt -96.96 -46.02 12.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.988 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.452 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -77.87 40.69 0.33 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.683 179.65 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.425 ' H ' ' C ' ' A' ' 11' ' ' ILE . 29.6 m -64.06 -23.09 67.2 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.065 0.936 . . . . 0.0 108.487 178.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.4 mt -61.58 -33.98 74.81 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.437 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 90.4 mt -94.52 23.3 5.38 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.738 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 74.18 26.24 68.97 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.651 -0.704 . . . . 0.0 114.332 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.452 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.2 m -82.68 131.09 35.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.652 0.726 . . . . 0.0 109.785 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.9 m -145.66 169.16 19.0 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.564 -178.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.5 m -63.2 106.31 0.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.982 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.461 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtm? -126.89 99.91 5.94 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.274 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.469 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 51.2 t30 65.58 33.27 8.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.792 -178.033 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 41.7 mtmt 80.22 -19.63 0.43 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 114.264 -1.335 . . . . 0.0 111.066 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.88 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -93.33 150.7 3.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.758 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 94.9 m -89.33 116.77 27.79 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 120.141 -0.624 . . . . 0.0 112.362 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.88 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -122.47 156.43 34.11 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.828 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.506 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 14.2 ptt180 -117.76 156.67 27.88 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.088 179.133 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 57.37 34.5 24.77 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.068 0.461 . . . . 0.0 111.304 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 81.61 -50.2 4.19 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 115.0 0.76 . . . . 0.0 115.0 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 m -143.08 41.16 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -178.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.478 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.3 mm -116.64 107.23 46.95 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.173 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.6 Cg_endo . . . . . 0 CA--C 1.528 0.207 0 C-N-CA 122.603 2.202 . . . . 0.0 113.627 -178.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 75.9 m . . . . . 0 CA--C 1.519 -0.236 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.31 -3.28 59.73 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.931 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 40.3 mt-10 -87.96 161.51 17.39 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.59 -0.805 . . . . 0.0 110.83 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.95 126.48 30.43 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.4 178.334 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.668 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 13.3 p -107.55 35.54 3.04 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.374 1.083 . . . . 0.0 109.055 179.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.464 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -64.94 -41.97 93.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 113.816 -1.538 . . . . 0.0 110.713 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -113.04 -39.91 4.09 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.156 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.668 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.6 pt -131.72 151.62 78.93 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.178 -179.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -60.24 152.14 68.52 Favored 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.953 3.102 . . . . 0.0 112.667 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -55.01 148.31 13.91 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 112.083 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.0 mt -89.18 -39.09 12.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.156 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.431 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 2.3 t -80.75 40.84 0.54 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.553 0.692 . . . . 0.0 110.696 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -70.4 -25.22 63.14 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.88 -41.23 97.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.902 -1.499 . . . . 0.0 110.451 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -74.33 -45.76 45.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.266 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 27.46 0.18 Allowed Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.537 -0.84 . . . . 0.0 112.979 179.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.431 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 90.2 m -84.86 113.28 21.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.377 0.608 . . . . 0.0 110.147 179.374 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 35.5 t -99.3 140.82 32.9 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.639 -179.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 45.9 t -70.79 117.97 12.99 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.989 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.07 114.92 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.811 -179.257 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 59.17 31.87 21.6 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.643 0.735 . . . . 0.0 109.464 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.464 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 55.2 mttm 70.86 13.35 7.1 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.705 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -121.34 136.6 57.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 176.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.931 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 76.8 m -89.9 126.46 35.73 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -131.51 147.65 52.56 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.702 178.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.562 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 20.2 ptt85 -111.79 155.23 23.88 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.421 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.755 ' HB3' HD12 ' A' ' 30' ' ' ILE . 3.8 t-20 58.25 33.49 23.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.85 -76.74 0.23 Allowed Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.681 179.289 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.8 m -139.64 32.49 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.755 HD12 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -91.34 113.87 59.87 Favored Pre-proline 0 C--N 1.325 -0.473 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.121 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.802 2.335 . . . . 0.0 114.348 -178.102 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.9 m . . . . . 0 CA--C 1.516 -0.342 0 CA-C-O 121.396 0.617 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.6 -6.82 57.55 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -177.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.807 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 97.6 mt-10 -87.54 165.2 15.66 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.196 -1.002 . . . . 0.0 110.509 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.26 127.35 14.66 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.164 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.79 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 20.3 p -100.86 34.96 2.31 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 122.395 1.093 . . . . 0.0 109.296 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.864 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 40.2 t -63.13 -44.14 99.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 113.912 -1.494 . . . . 0.0 110.176 179.579 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -114.62 -39.7 3.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.957 179.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.79 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -128.6 149.83 72.98 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.853 -179.291 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.93 158.57 24.42 Favored 'Trans proline' 0 C--N 1.332 -0.314 0 C-N-CA 124.142 3.228 . . . . 0.0 113.259 -179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.451 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 8.9 m -60.82 154.77 21.1 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.011 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.403 ' C ' ' H ' ' A' ' 13' ' ' THR . 61.4 mt -100.42 -48.38 11.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.039 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.69 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.9 t -77.17 41.49 0.3 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.357 0.599 . . . . 0.0 111.304 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.403 ' H ' ' C ' ' A' ' 11' ' ' ILE . 28.5 m -67.86 -24.57 65.26 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 73.0 mt -60.49 -41.01 93.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 114.151 -1.386 . . . . 0.0 110.14 178.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.41 HD12 ' HD2' ' A' ' 26' ' ' ARG . 1.8 tm? -76.94 -42.62 38.56 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.487 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.35 20.33 0.15 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.175 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.69 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 71.2 m -78.68 126.34 30.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.193 0.52 . . . . 0.0 110.426 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -140.0 154.73 47.23 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.901 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.9 m -55.82 121.67 9.76 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -179.107 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.593 ' HB2' ' CD1' ' A' ' 25' ' ' TYR . 39.3 mmtm -140.47 106.06 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.669 177.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.464 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 5.1 t-20 62.53 34.32 15.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.772 -177.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.864 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 30.0 mmmt 77.15 -17.05 0.59 Allowed 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.557 -1.202 . . . . 0.0 111.451 -178.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.847 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.0 t -92.45 153.99 3.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.807 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 99.2 m -96.81 123.84 40.62 Favored 'General case' 0 C--N 1.314 -0.945 0 O-C-N 121.372 -0.83 . . . . 0.0 112.327 -178.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.847 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.0 m-85 -126.52 153.86 44.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.219 178.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.537 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 28.9 ptt85 -116.59 156.32 27.21 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.952 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.759 ' HB3' HD12 ' A' ' 30' ' ' ILE . 3.6 t-20 58.3 33.37 23.07 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.539 0.685 . . . . 0.0 110.888 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.47 -66.73 0.27 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.898 179.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 p -150.99 39.25 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-O 121.738 0.78 . . . . 0.0 112.209 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.759 HD12 ' HB3' ' A' ' 27' ' ' ASN . 2.1 mp -98.39 116.25 65.55 Favored Pre-proline 0 C--N 1.322 -0.596 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 177.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 CA--C 1.528 0.225 0 C-N-CA 122.816 2.344 . . . . 0.0 114.228 -178.049 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.525 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 57.4 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.68 -5.92 64.64 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.815 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.7 mt-10 -89.09 165.8 14.27 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.166 -1.017 . . . . 0.0 110.653 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.32 134.5 21.67 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.721 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 31.3 p -106.5 30.65 5.83 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 122.018 0.913 . . . . 0.0 109.925 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.2 t -66.53 -38.41 81.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.985 -1.461 . . . . 0.0 110.394 179.203 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -110.78 -40.28 4.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.988 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.721 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 15.6 pt -140.56 151.4 63.53 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.609 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.4 Cg_exo -57.42 152.4 47.17 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 124.112 3.208 . . . . 0.0 112.947 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.612 ' HB2' HG22 ' A' ' 13' ' ' THR . 3.7 m -58.2 148.16 27.94 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.536 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.1 mm -89.1 -41.16 13.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.161 179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.526 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.1 t -83.2 40.02 0.68 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.483 0.659 . . . . 0.0 110.416 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.612 HG22 ' HB2' ' A' ' 10' ' ' CYS . 0.6 OUTLIER -68.8 -27.64 66.05 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 177.886 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.68 -39.6 94.73 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 113.725 -1.579 . . . . 0.0 110.758 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.449 ' HA ' HD21 ' A' ' 15' ' ' LEU . 2.6 tm? -74.98 -47.36 29.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.634 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.22 20.76 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.983 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 82.1 m -85.42 130.54 34.56 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.358 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.8 t -137.02 168.36 19.74 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.588 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.5 m -67.48 100.36 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.821 -179.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.554 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.3 tmtp? -119.08 102.38 8.69 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.856 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.478 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 9.0 t-20 62.88 36.33 12.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.946 -1.024 . . . . 0.0 108.795 -177.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.671 ' HB2' ' HZ3' ' A' ' 22' ' ' LYS . 7.7 mtmp? 79.31 -17.58 0.58 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.556 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.791 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 19.5 t -97.81 147.79 6.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.192 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.815 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 96.6 m -89.15 120.41 30.51 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -178.116 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.791 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.4 m-85 -127.67 154.09 45.7 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.406 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.525 ' CZ ' ' HA ' ' A' ' 1' ' ' CYS . 5.6 ptt180 -112.65 149.34 32.98 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.778 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 58.01 37.22 26.6 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.635 0.731 . . . . 0.0 110.11 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 78.35 -48.19 3.08 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 115.523 0.969 . . . . 0.0 115.523 178.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.5 m -138.59 35.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 114.887 1.44 . . . . 0.0 114.887 -177.288 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.427 ' HB ' ' HG3' ' A' ' 26' ' ' ARG . 63.1 mt -112.46 110.17 53.13 Favored Pre-proline 0 C--N 1.318 -0.797 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 177.392 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo . . . . . 0 C--O 1.232 0.204 0 C-N-CA 122.655 2.236 . . . . 0.0 113.458 -178.28 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.5 p . . . . . 0 N--CA 1.457 -0.122 0 CA-C-O 120.755 0.312 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 69.99 37.82 74.03 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.72 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.806 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 3.9 mm-40 -135.5 165.74 24.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.014 0.435 . . . . 0.0 110.271 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.55 126.4 8.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.508 178.411 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.654 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.7 p -106.2 36.74 2.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 122.383 1.087 . . . . 0.0 109.218 179.316 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.943 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 43.3 t -64.09 -44.3 97.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 113.854 -1.521 . . . . 0.0 110.751 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -104.12 -42.99 5.37 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.011 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.654 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.6 pt -138.1 156.07 74.12 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.104 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -55.91 150.18 47.67 Favored 'Trans proline' 0 C--O 1.234 0.275 0 C-N-CA 123.624 2.882 . . . . 0.0 112.487 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -58.92 146.0 39.34 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.127 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.415 ' C ' ' H ' ' A' ' 13' ' ' THR . 47.5 mm -88.88 -39.82 12.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.128 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.724 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.63 40.64 0.24 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.25 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.415 ' H ' ' C ' ' A' ' 11' ' ' ILE . 80.0 m -68.93 -23.76 64.21 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.7 mt -61.72 -41.02 97.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.432 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -75.3 -42.1 55.46 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.41 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 137.78 28.94 0.28 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.635 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.724 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 67.4 m -75.28 100.74 4.46 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.088 0.471 . . . . 0.0 110.698 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.3 m -101.3 139.31 37.14 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.108 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.0 m -61.29 121.79 13.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.231 0.539 . . . . 0.0 111.561 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.825 ' HZ3' ' HB2' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -142.87 110.67 5.89 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.158 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.451 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.3 t30 61.84 32.58 18.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 109.104 -178.303 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.943 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 77.45 -15.99 0.69 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.461 -179.232 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.502 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.4 t -94.07 152.76 3.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.806 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 62.2 m -98.3 128.01 44.52 Favored 'General case' 0 C--N 1.315 -0.896 0 O-C-N 121.451 -0.78 . . . . 0.0 111.99 -178.493 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.716 ' CD1' ' HB3' ' A' ' 20' ' ' LYS . 37.8 m-85 -128.14 154.65 45.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.392 178.737 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.454 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 34.9 ptt180 -113.78 154.97 26.49 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.78 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 56.58 35.55 26.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 0.0 110.745 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.76 -78.87 0.3 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.56 -0.829 . . . . 0.0 113.738 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.0 m -137.08 33.44 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.454 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -95.63 115.23 65.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.7 Cg_endo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.24 1.96 . . . . 0.0 111.781 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.9 p . . . . . 0 C--O 1.227 -0.086 0 CA-C-O 121.017 0.437 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 71.69 29.04 68.11 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.507 -0.77 . . . . 0.0 114.291 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.864 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 23.5 mt-10 -123.32 163.8 20.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.028 0.442 . . . . 0.0 110.415 178.473 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.34 126.14 16.12 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.557 178.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.679 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 4.9 p -102.17 34.27 2.78 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 122.381 1.086 . . . . 0.0 109.245 179.563 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.731 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 47.6 t -68.28 -40.62 82.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.637 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -109.67 -41.25 4.6 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.94 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.679 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.7 pt -137.74 152.89 73.42 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.462 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 36.7 Cg_exo -59.48 148.58 86.38 Favored 'Trans proline' 0 C--N 1.332 -0.309 0 C-N-CA 123.682 2.921 . . . . 0.0 112.432 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 m -54.46 147.05 14.64 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.857 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.4 mm -89.21 -44.43 15.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.904 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.576 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.03 39.14 0.49 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.444 0.64 . . . . 0.0 110.901 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 77.7 m -67.15 -25.44 66.17 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 177.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 69.2 mt -63.04 -41.28 99.46 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.533 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.49 -41.79 62.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.238 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.558 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 147.6 13.76 0.15 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.57 -0.824 . . . . 0.0 113.04 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 96.3 m -74.76 88.1 2.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.3 0.572 . . . . 0.0 110.835 179.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 58.9 p -88.32 135.45 33.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.839 179.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.5 t -64.3 119.33 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.445 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.435 ' HE2' ' HB2' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -136.44 117.78 14.64 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.524 -179.743 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 56.85 34.39 24.68 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 109.423 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.731 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 15.4 mtpt 69.99 8.42 6.68 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.801 -179.29 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.408 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 24.8 t -116.87 143.36 27.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 177.419 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.864 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -95.95 127.53 42.05 Favored 'General case' 0 C--N 1.313 -0.991 0 O-C-N 121.434 -0.791 . . . . 0.0 112.865 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.408 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 18.9 m-85 -130.45 151.21 51.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.201 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.558 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 37.7 ptt180 -114.84 154.14 29.15 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.187 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.644 ' HB3' HD11 ' A' ' 30' ' ' ILE . 2.1 t-20 57.94 33.31 23.06 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 123.656 0.597 . . . . 0.0 111.135 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 111.64 -86.53 0.43 Allowed Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.956 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.7 m -134.57 32.46 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -179.051 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.644 HD11 ' HB3' ' A' ' 27' ' ' ASN . 62.4 mt -93.15 110.31 45.41 Favored Pre-proline 0 C--N 1.327 -0.399 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo . . . . . 0 C--N 1.341 0.155 0 C-N-CA 122.222 1.948 . . . . 0.0 112.02 -179.356 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 71.5 m . . . . . 0 CA--C 1.516 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.34 -6.08 65.62 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -177.482 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.589 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.4 mt-10 -87.6 164.3 16.14 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 114.277 -0.961 . . . . 0.0 110.484 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -148.85 135.48 19.63 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.219 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.605 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.5 OUTLIER -105.25 26.21 9.66 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 122.644 1.211 . . . . 0.0 108.911 179.911 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.4 t -55.41 -43.18 70.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.124 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -107.03 -42.87 4.78 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.255 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.605 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.7 pt -145.95 158.45 48.84 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.07 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -58.73 145.44 95.96 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 123.622 2.881 . . . . 0.0 111.832 179.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.577 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 24.1 m -75.23 161.28 29.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.196 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.476 ' C ' ' H ' ' A' ' 13' ' ' THR . 56.1 mt -87.34 -36.15 9.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.45 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.413 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 8.5 t -77.31 30.92 0.14 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.678 0.751 . . . . 0.0 111.36 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.476 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.8 OUTLIER -71.06 -26.85 63.25 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.194 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.4 mt -64.41 -41.18 96.77 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.558 178.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.441 HD23 ' HA ' ' A' ' 15' ' ' LEU . 2.9 tm? -71.42 -42.18 68.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.435 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 22.72 0.24 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.429 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.413 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -82.16 93.85 7.14 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.388 0.614 . . . . 0.0 110.385 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 m -88.27 139.21 30.73 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.897 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.468 ' SG ' ' HA ' ' A' ' 22' ' ' LYS . 50.2 t -75.66 116.37 16.3 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.106 0.479 . . . . 0.0 111.275 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -128.01 127.77 43.79 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 177.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 56.85 33.56 23.31 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-O 121.69 0.757 . . . . 0.0 109.103 -178.225 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.468 ' HA ' ' SG ' ' A' ' 19' ' ' CYS . 14.4 mmmm 69.9 6.56 5.8 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 114.798 -1.092 . . . . 0.0 111.964 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -117.79 138.77 47.4 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.589 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 7.3 m -89.35 129.49 35.87 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -177.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -130.94 152.5 50.19 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.125 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 30.7 ptt85 -116.17 154.31 30.25 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.888 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.415 ' HB3' HD13 ' A' ' 30' ' ' ILE . 4.5 t-20 59.52 33.39 22.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.842 0.829 . . . . 0.0 110.402 -179.318 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.41 -55.69 4.5 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 115.113 0.805 . . . . 0.0 115.113 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.7 m -140.47 38.19 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -177.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.415 HD13 ' HB3' ' A' ' 27' ' ' ASN . 49.0 mt -112.44 110.54 52.91 Favored Pre-proline 0 C--N 1.318 -0.774 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 177.685 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo . . . . . 0 N--CA 1.464 -0.207 0 C-N-CA 122.598 2.199 . . . . 0.0 113.316 -178.615 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.523 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 74.4 m . . . . . 0 CA--C 1.517 -0.315 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.03 -7.32 58.74 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -177.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.785 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 26.3 mt-10 -88.89 165.66 14.48 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.119 -1.04 . . . . 0.0 110.835 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -146.31 127.7 14.94 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.037 178.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.739 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.9 p -104.64 34.35 3.18 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.17 0.985 . . . . 0.0 109.488 179.484 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.896 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -62.14 -39.24 83.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.369 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -114.43 -40.26 3.66 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.146 179.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.739 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 17.5 pt -134.0 149.6 72.08 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.855 -179.234 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 46.0 Cg_exo -56.62 152.85 38.89 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 124.255 3.303 . . . . 0.0 113.649 -179.277 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 m -60.1 149.94 31.02 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.592 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 62.0 mt -89.6 -41.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.486 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.549 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.39 40.83 0.67 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.538 0.685 . . . . 0.0 110.67 179.876 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -69.44 -27.11 64.97 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 177.682 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.5 mt -63.39 -40.64 97.78 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 113.773 -1.558 . . . . 0.0 110.62 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.435 HD23 ' HA ' ' A' ' 15' ' ' LEU . 2.8 tm? -73.51 -47.25 42.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.462 179.756 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.92 23.73 0.09 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.959 179.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.549 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 85.9 m -82.47 119.46 24.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.964 0.411 . . . . 0.0 110.165 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -116.61 156.1 27.6 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.937 -179.031 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.9 m -68.94 105.15 2.29 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.761 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.539 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 17.5 tptm -117.99 103.65 10.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.486 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 0.6 OUTLIER 61.96 32.63 17.74 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -178.143 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.896 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 28.1 mttt 78.31 -10.38 1.36 Allowed 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.348 -1.296 . . . . 0.0 111.754 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.788 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -97.12 143.87 11.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.753 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.785 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 71.0 m -88.81 122.34 32.11 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -177.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.788 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 5.7 m-85 -129.66 151.71 49.96 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.03 177.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.649 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 7.0 ptt180 -116.29 157.07 25.53 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.568 179.324 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 58.82 34.43 23.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.135 0.493 . . . . 0.0 111.463 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.51 -56.99 3.47 Favored Glycine 0 N--CA 1.45 -0.426 0 N-CA-C 114.963 0.745 . . . . 0.0 114.963 178.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.2 m -145.62 38.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.649 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 1.9 mp -106.84 112.51 63.38 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.68 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo . . . . . 0 C--O 1.232 0.191 0 C-N-CA 122.665 2.243 . . . . 0.0 113.787 -178.33 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.9 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.27 -5.01 60.72 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 -178.211 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.896 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.4 mt-10 -88.21 162.79 16.47 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 114.66 -0.77 . . . . 0.0 110.691 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.26 128.4 20.86 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 177.36 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.684 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.3 p -102.46 31.84 3.86 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.924 0.869 . . . . 0.0 110.203 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.0 t -68.48 -38.97 80.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.393 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -106.77 -41.35 5.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.008 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.684 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.3 pt -142.7 152.18 58.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.604 -179.388 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 34.5 Cg_exo -58.86 150.93 68.44 Favored 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.915 3.077 . . . . 0.0 112.621 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.424 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.7 m -58.57 144.76 41.75 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.653 -179.503 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.414 ' C ' ' H ' ' A' ' 13' ' ' THR . 43.7 mm -90.93 -37.96 10.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.461 179.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.481 ' HG ' ' HB2' ' A' ' 15' ' ' LEU . 15.6 t -75.95 40.48 0.2 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.227 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.414 ' H ' ' C ' ' A' ' 11' ' ' ILE . 3.0 p -66.19 -25.67 67.04 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.835 0.826 . . . . 0.0 108.801 177.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.34 -35.97 76.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.429 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.481 ' HB2' ' HG ' ' A' ' 12' ' ' SER . 3.6 mm? -92.17 19.94 6.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.654 179.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.442 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 71.34 30.21 67.34 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.856 -0.611 . . . . 0.0 114.004 178.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 99.9 m -84.0 127.48 33.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 117.289 0.544 . . . . 0.0 109.915 178.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 41.2 m -139.25 164.87 28.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.95 -178.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -67.76 101.31 1.04 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.019 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 7.8 tmtm? -128.53 118.99 23.97 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.452 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 30.7 t30 62.63 39.04 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -178.722 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.452 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 17.5 pttp 56.53 27.67 12.67 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.787 -179.03 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.921 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 44.4 t -142.83 155.04 17.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.896 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 79.6 m -89.61 119.93 30.46 Favored 'General case' 0 C--N 1.313 -0.978 0 O-C-N 121.485 -0.76 . . . . 0.0 112.294 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.921 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -126.79 154.89 43.66 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.019 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.494 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 13.2 ptt180 -116.23 156.42 26.59 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.207 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 56.94 34.53 25.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.15 0.5 . . . . 0.0 111.29 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 83.86 -55.53 5.02 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 114.759 0.663 . . . . 0.0 114.759 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.8 m -139.8 40.48 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -178.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.494 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.5 mm -113.22 106.44 54.7 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo . . . . . 0 C--O 1.233 0.239 0 C-N-CA 122.883 2.389 . . . . 0.0 113.785 -178.172 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.549 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 58.4 m . . . . . 0 CA--C 1.517 -0.306 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.2 -7.44 56.71 Favored Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -177.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.812 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.4 mt-10 -88.01 165.22 15.34 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.116 -1.042 . . . . 0.0 110.68 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -145.28 131.9 19.9 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.711 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -108.7 31.89 5.29 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.201 1.001 . . . . 0.0 109.606 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.2 t -60.32 -43.3 93.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.076 -1.42 . . . . 0.0 110.239 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.73 -41.94 5.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.261 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.711 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -135.31 150.77 73.52 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.883 -179.194 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -55.79 153.38 30.93 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 124.271 3.314 . . . . 0.0 113.773 -179.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 9.0 m -59.93 152.67 22.97 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.755 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.8 mt -93.71 -42.37 12.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.56 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.592 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.07 43.29 0.7 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.435 0.635 . . . . 0.0 110.714 179.909 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -68.0 -26.74 66.06 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.9 mt -62.43 -41.36 98.66 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.623 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' A' ' 15' ' ' LEU . 1.8 tm? -73.49 -43.95 58.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.304 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 140.69 26.08 0.22 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.819 179.176 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.592 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 77.1 m -82.95 121.24 26.73 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.853 0.358 . . . . 0.0 110.116 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.474 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 12.9 t -118.24 164.01 15.82 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 -178.71 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.7 m -73.36 74.05 1.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.644 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.661 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 13.2 tmtt? -89.15 103.79 16.39 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.455 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 23.4 t30 60.19 33.8 21.05 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.267 -178.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.455 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 22.9 mmtp 74.37 2.71 4.18 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.704 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.83 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -109.17 140.07 29.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.812 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 82.9 m -88.1 121.42 30.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -176.632 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.83 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -127.26 150.51 49.53 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 177.577 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.573 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 9.1 ptt180 -115.27 153.53 30.75 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.369 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.617 ' HB3' HD13 ' A' ' 30' ' ' ILE . 3.4 t-20 58.79 36.81 24.95 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.361 0.6 . . . . 0.0 111.16 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.85 -62.53 0.79 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.581 -0.819 . . . . 0.0 114.663 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -150.58 37.36 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-O 121.674 0.749 . . . . 0.0 112.693 -178.117 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.617 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -100.06 112.19 63.56 Favored Pre-proline 0 C--N 1.323 -0.577 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 177.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.8 Cg_endo . . . . . 0 C--O 1.232 0.197 0 C-N-CA 122.628 2.219 . . . . 0.0 113.551 -178.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 30.3 p . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.718 0.294 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 111.09 -12.27 29.07 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.937 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.801 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 5.6 mm-40 -85.1 159.94 20.07 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.545 0.688 . . . . 0.0 111.151 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.79 134.77 30.69 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.853 -1.067 . . . . 0.0 109.13 178.538 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.663 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 15.1 p -115.91 34.13 5.13 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 122.088 0.947 . . . . 0.0 109.231 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.602 ' HA ' ' HB3' ' A' ' 22' ' ' LYS . 28.9 t -63.92 -40.46 89.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 113.881 -1.509 . . . . 0.0 111.244 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -114.53 -38.94 3.9 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.065 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.663 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -136.51 153.43 76.09 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.504 -179.267 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 38.0 Cg_exo -58.52 148.66 79.97 Favored 'Trans proline' 0 C--N 1.332 -0.328 0 C-N-CA 123.717 2.945 . . . . 0.0 112.265 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -56.67 143.97 34.15 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.469 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.43 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.3 mp -89.75 -42.43 14.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.609 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.24 39.11 0.19 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.363 179.854 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.413 ' H ' ' C ' ' A' ' 11' ' ' ILE . 58.2 m -69.53 -23.42 63.59 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 177.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 77.2 mt -63.06 -40.83 98.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.489 178.528 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.421 ' O ' HD11 ' A' ' 15' ' ' LEU . 1.0 OUTLIER -73.12 -39.72 65.51 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.396 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.46 23.87 0.44 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.535 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.609 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 89.7 m -76.64 98.06 4.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.094 0.473 . . . . 0.0 110.669 179.532 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.44 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 13.6 m -88.56 132.93 34.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.937 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.2 t -73.82 117.2 15.32 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.087 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.65 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 11.6 tmtt? -141.97 119.1 11.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.525 0.679 . . . . 0.0 110.843 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 55.07 37.17 28.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.3 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.602 ' HB3' ' HA ' ' A' ' 6' ' ' VAL . 26.3 mtmm 75.88 1.43 3.51 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.08 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.7 t -118.32 137.25 52.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.801 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 30.1 m -95.52 128.37 42.33 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.702 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.65 ' CE1' ' HD2' ' A' ' 20' ' ' LYS . 2.1 m-85 -122.35 163.54 19.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.653 179.429 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.491 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.2 ptt180 -131.94 155.51 47.79 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 61.79 31.55 18.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.305 0.574 . . . . 0.0 111.211 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 109.69 -71.93 0.2 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.536 -0.84 . . . . 0.0 113.931 178.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 p -150.23 36.85 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 122.069 0.938 . . . . 0.0 111.099 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.491 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.9 mm -101.17 113.83 65.8 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.407 178.434 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.5 Cg_endo . . . . . 0 N--CA 1.463 -0.268 0 C-N-CA 122.203 1.935 . . . . 0.0 111.4 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.485 ' HB3' ' HD3' ' A' ' 26' ' ' ARG . 1.7 p . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.018 0.437 . . . . 0.0 110.828 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.33 31.6 80.98 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.491 -0.777 . . . . 0.0 113.166 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.839 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.5 mt-10 -124.42 165.93 16.88 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.074 0.464 . . . . 0.0 110.4 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.89 134.07 17.19 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.738 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.7 p -107.45 31.29 5.53 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 122.36 1.076 . . . . 0.0 109.605 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.885 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 46.7 t -61.72 -44.47 98.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 113.933 -1.485 . . . . 0.0 110.177 179.475 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -104.66 -43.59 5.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.158 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.738 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.5 pt -136.09 153.8 77.03 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.003 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 51.4 Cg_exo -55.45 153.98 26.34 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 124.11 3.207 . . . . 0.0 113.379 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.431 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 7.3 m -58.69 149.74 25.31 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.698 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.41 ' C ' ' H ' ' A' ' 13' ' ' THR . 4.2 mp -89.53 -46.35 15.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.859 179.324 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.683 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -79.24 41.24 0.45 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.442 0.639 . . . . 0.0 110.539 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.41 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.6 OUTLIER -68.61 -26.5 65.39 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.8 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.4 mt -61.98 -40.93 97.29 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 113.81 -1.541 . . . . 0.0 110.453 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.485 HD13 ' HD2' ' A' ' 26' ' ' ARG . 2.0 tm? -75.36 -46.33 33.82 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.58 26.38 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.543 -0.836 . . . . 0.0 113.259 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.683 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.1 m -80.35 120.96 25.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 117.169 0.485 . . . . 0.0 110.006 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.5 m -119.12 159.79 23.31 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.181 -178.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.2 m -69.35 84.96 0.4 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.752 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.557 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 46.7 tptt -96.66 98.4 10.15 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.596 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 0.6 OUTLIER 60.94 33.52 19.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.395 -0.82 . . . . 0.0 108.811 -178.362 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.885 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 40.4 mmtt 82.29 -10.99 1.05 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.319 -1.309 . . . . 0.0 112.414 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.812 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -99.22 141.45 16.64 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.165 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.839 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 73.1 m -89.65 122.54 32.87 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.812 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -127.43 151.07 49.29 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.726 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.485 ' HD2' HD13 ' A' ' 15' ' ' LEU . 28.1 ptt180 -112.24 153.61 26.86 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.115 179.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.522 ' HB3' HD13 ' A' ' 30' ' ' ILE . 25.3 t30 60.12 33.49 21.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.287 0.565 . . . . 0.0 111.264 179.709 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.89 -64.59 0.73 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.621 -0.8 . . . . 0.0 114.615 178.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.3 m -143.12 33.59 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.522 HD13 ' HB3' ' A' ' 27' ' ' ASN . 59.0 mt -101.56 108.42 55.54 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo . . . . . 0 N--CA 1.464 -0.238 0 C-N-CA 122.212 1.942 . . . . 0.0 112.347 -179.09 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 CA--C 1.516 -0.362 0 CA-C-O 121.372 0.606 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.48 -5.75 67.63 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -177.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.574 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 21.2 mt-10 -87.25 160.11 18.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 114.494 -0.853 . . . . 0.0 110.387 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 23' ' ' VAL . 0.7 OUTLIER -144.46 133.36 22.58 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.471 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.7 OUTLIER -98.68 26.97 5.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 122.157 0.98 . . . . 0.0 109.905 -179.572 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.7 t -61.03 -39.74 83.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 114.26 -1.336 . . . . 0.0 111.715 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.492 ' O ' HG22 ' A' ' 8' ' ' ILE . 27.2 m-85 -108.33 -42.03 4.71 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.44 -179.411 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.492 HG22 ' O ' ' A' ' 7' ' ' PHE . 13.5 pt -149.96 159.38 35.74 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.679 -178.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -59.55 143.6 99.64 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 123.342 2.695 . . . . 0.0 111.302 179.17 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.527 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 18.2 m -71.18 161.42 31.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.79 -178.229 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.442 ' C ' ' H ' ' A' ' 13' ' ' THR . 57.8 mt -87.03 -40.01 13.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.356 -0.838 . . . . 0.0 112.711 -178.082 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.594 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 3.1 t -79.32 35.87 0.28 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.714 0.768 . . . . 0.0 111.345 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.442 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.8 OUTLIER -70.52 -25.12 62.98 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 177.419 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 81.0 mt -63.86 -42.85 97.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 113.898 -1.501 . . . . 0.0 110.716 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.437 HD22 ' HA ' ' A' ' 15' ' ' LEU . 2.8 tm? -71.43 -43.31 66.97 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.584 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.452 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 144.46 20.66 0.17 Allowed Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.697 179.256 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -77.8 83.75 4.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.401 0.619 . . . . 0.0 110.425 179.491 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.4 m -86.18 136.2 33.29 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.454 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.6 t -68.6 127.94 34.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.162 0.506 . . . . 0.0 111.222 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -144.99 130.24 18.6 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.753 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 31.2 t30 56.81 38.93 29.79 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.304 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.753 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 2.1 pttm 60.84 13.3 4.34 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.156 1.382 . . . . 0.0 112.115 -179.159 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.439 HG12 ' O ' ' A' ' 3' ' ' GLU . 58.5 t -128.31 141.62 46.01 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.574 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 1.7 m -88.93 131.67 35.04 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.034 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -132.45 146.27 51.82 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.17 -0.923 . . . . 0.0 108.853 177.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 41.4 ptt85 -110.53 157.84 19.19 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.305 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 57.62 30.81 19.4 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.672 0.607 . . . . 0.0 111.256 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.59 -74.5 0.22 Allowed Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.548 -0.834 . . . . 0.0 113.462 179.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.51 32.52 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.411 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -92.44 113.1 58.35 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.197 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo . . . . . 0 N--CA 1.464 -0.227 0 C-N-CA 122.704 2.269 . . . . 0.0 113.558 -178.459 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.9 m . . . . . 0 CA--C 1.517 -0.313 0 CA-C-O 121.275 0.56 . . . . 0.0 109.721 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.21 -2.64 63.57 Favored Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.95 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 41.2 mt-10 -86.93 158.92 19.19 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.774 -0.713 . . . . 0.0 110.422 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.54 125.64 29.32 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.156 178.082 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.665 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.6 p -103.13 34.81 2.75 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 122.368 1.08 . . . . 0.0 109.047 179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.936 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 47.7 t -66.53 -42.93 90.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 113.759 -1.564 . . . . 0.0 110.667 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -109.34 -40.95 4.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.665 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.3 pt -134.89 153.08 78.44 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.063 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_exo -60.63 150.54 81.49 Favored 'Trans proline' 0 C--N 1.332 -0.331 0 C-N-CA 123.855 3.037 . . . . 0.0 112.27 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.478 ' HB2' HG23 ' A' ' 13' ' ' THR . 2.5 m -53.71 146.08 14.26 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.786 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.41 ' N ' HD12 ' A' ' 11' ' ' ILE . 4.1 mp -88.2 -39.9 13.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.837 179.514 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.414 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.4 40.19 0.63 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.608 0.718 . . . . 0.0 110.514 179.421 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.478 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.5 OUTLIER -68.48 -26.5 65.51 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.798 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 75.8 mt -63.16 -39.95 96.15 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.831 -1.531 . . . . 0.0 110.493 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.2 tm? -72.91 -40.43 65.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.236 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 139.86 13.47 0.61 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.414 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.6 m -75.52 105.14 6.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.359 0.599 . . . . 0.0 110.346 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.5 m -97.3 143.32 28.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.737 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.85 115.93 12.74 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.953 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.3 ttmm -140.73 121.71 14.59 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.818 0.342 . . . . 0.0 110.945 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 42.3 t30 60.06 34.12 21.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.674 0.749 . . . . 0.0 109.583 -179.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.936 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 69.46 6.55 5.75 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.757 -179.536 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.482 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.6 t -119.29 144.33 28.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.098 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.95 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -94.68 127.55 40.73 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 -177.782 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.482 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 16.4 m-85 -132.41 148.42 52.41 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.093 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.402 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 26.6 ptt180 -109.81 158.12 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.587 178.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.67 35.58 25.54 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.687 0.756 . . . . 0.0 110.748 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.17 -60.34 3.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.849 -0.691 . . . . 0.0 114.781 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.9 m -140.44 34.88 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -178.132 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 51.0 mm -103.03 110.28 63.26 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 177.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.1 Cg_endo . . . . . 0 N--CA 1.464 -0.252 0 C-N-CA 122.578 2.185 . . . . 0.0 113.389 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.5 m . . . . . 0 CA--C 1.518 -0.262 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.0 -3.96 60.68 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.961 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.6 mt-10 -88.14 164.77 15.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.617 -0.792 . . . . 0.0 111.059 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.97 126.34 15.77 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 177.453 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.726 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -105.34 34.27 3.32 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 122.275 1.036 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.964 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 44.3 t -61.98 -44.2 98.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 114.092 -1.413 . . . . 0.0 110.099 179.326 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -105.65 -42.62 5.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.207 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.726 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.3 pt -135.65 150.75 72.86 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 -179.223 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -57.84 154.6 37.1 Favored 'Trans proline' 0 N--CA 1.473 0.296 0 C-N-CA 124.243 3.296 . . . . 0.0 113.35 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.482 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.8 m -61.01 145.3 51.22 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.257 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.2 mt -93.98 -35.32 6.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.955 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -76.83 44.33 0.38 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.018 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.7 m -64.23 -25.78 68.22 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.372 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.4 mt -59.72 -36.87 77.43 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.003 -1.453 . . . . 0.0 110.995 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -89.59 16.82 7.14 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.839 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 71.44 28.95 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.508 179.265 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 80.7 m -80.57 128.18 33.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.04 0.42 . . . . 0.0 110.135 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -133.14 155.51 49.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.028 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 47.9 m -62.5 118.47 7.6 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.998 -0.546 . . . . 0.0 112.184 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.663 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 12.7 tppt? -132.76 101.63 5.35 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.587 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.546 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 46.6 t30 61.54 34.31 17.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.873 -178.005 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.964 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 46.0 mmtt 80.73 -16.52 0.64 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.15 -1.387 . . . . 0.0 112.157 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.679 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.4 t -94.88 143.13 12.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 177.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.961 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -89.29 124.25 34.24 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 112.673 0.62 . . . . 0.0 112.673 -177.505 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.679 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 12.1 m-85 -130.03 150.22 51.4 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.46 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 23.1 ptt180 -112.28 161.01 17.08 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.854 179.383 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 55.55 33.14 20.5 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.187 0.518 . . . . 0.0 111.406 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.449 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 95.43 -64.05 1.35 Allowed Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.812 -0.708 . . . . 0.0 113.963 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.2 m -142.78 37.73 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 112.909 0.707 . . . . 0.0 112.909 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.46 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 49.6 mm -101.17 112.13 64.55 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 178.353 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 10.7 Cg_endo . . . . . 0 C--O 1.231 0.15 0 C-N-CA 122.932 2.422 . . . . 0.0 113.963 -178.201 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.2 m . . . . . 0 CA--C 1.517 -0.319 0 CA-C-O 121.345 0.593 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.71 -3.77 53.24 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 109.751 -1.339 . . . . 0.0 109.751 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.986 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.1 mt-10 -86.84 161.61 18.23 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 114.659 -0.771 . . . . 0.0 110.546 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -135.19 124.62 24.87 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.802 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.692 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.8 p -105.84 33.33 3.82 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 122.048 0.928 . . . . 0.0 109.503 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.703 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 36.9 t -61.43 -44.06 97.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.768 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -112.34 -39.89 4.29 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.431 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.692 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 22.3 pt -129.11 151.73 78.17 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.169 0.509 . . . . 0.0 111.556 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 25.4 Cg_exo -61.52 150.25 86.13 Favored 'Trans proline' 0 C--N 1.333 -0.275 0 C-N-CA 124.012 3.141 . . . . 0.0 112.537 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.415 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 2.6 m -57.09 146.05 28.87 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.81 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.401 ' C ' ' H ' ' A' ' 13' ' ' THR . 59.9 mt -89.05 -37.31 9.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.624 179.061 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.434 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 8.4 t -77.7 38.02 0.24 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.592 0.711 . . . . 0.0 111.006 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.401 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.7 OUTLIER -71.02 -25.73 62.8 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 177.635 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.3 mt -62.79 -41.54 99.31 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.829 -1.532 . . . . 0.0 110.536 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -74.31 -43.41 56.86 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.291 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.89 30.18 0.22 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.647 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.434 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.2 m -88.45 117.07 27.12 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.025 0.441 . . . . 0.0 110.189 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -104.47 147.73 27.25 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.572 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -77.95 112.97 15.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.505 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.452 ' O ' ' HD3' ' A' ' 20' ' ' LYS . 12.8 tmtt? -139.34 125.16 19.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.089 0.471 . . . . 0.0 110.949 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 58.54 33.59 23.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.089 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.791 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 10.5 mmpt? 71.64 0.83 3.64 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 115.355 -0.838 . . . . 0.0 111.646 -179.415 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.495 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 26.2 t -115.2 146.53 19.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.829 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.986 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.3 m -97.25 126.18 42.29 Favored 'General case' 0 C--N 1.312 -1.027 0 O-C-N 121.977 -0.452 . . . . 0.0 111.848 -178.602 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.495 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -127.26 152.07 47.9 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.172 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.592 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 29.6 ptt85 -116.33 150.44 37.67 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.339 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.644 ' HB3' HD13 ' A' ' 30' ' ' ILE . 1.8 t-20 59.71 34.05 21.98 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.692 0.62 . . . . 0.0 110.948 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.92 -88.38 0.53 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.376 -0.916 . . . . 0.0 113.339 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.8 m -128.68 32.87 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.021 0.748 . . . . 0.0 113.021 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.644 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.9 mp -94.3 110.8 50.66 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.041 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo . . . . . 0 C--O 1.232 0.184 0 C-N-CA 122.576 2.184 . . . . 0.0 113.691 -178.489 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.2 m . . . . . 0 CA--C 1.519 -0.231 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 94.61 -9.41 71.29 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.799 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 98.3 mt-10 -88.49 167.55 13.35 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.621 -0.789 . . . . 0.0 110.934 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -150.49 132.07 14.84 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.796 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.0 p -102.23 33.06 3.24 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.295 1.045 . . . . 0.0 109.37 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.541 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 45.7 t -62.48 -42.86 97.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.02 -1.445 . . . . 0.0 110.186 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -111.07 -40.35 4.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.099 179.197 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.796 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.0 pt -135.7 151.18 73.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.761 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 41.9 Cg_exo -57.19 154.6 33.28 Favored 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 124.128 3.219 . . . . 0.0 113.335 -179.445 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.469 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 7.0 m -59.76 150.2 28.72 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.585 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.3 mt -94.09 -46.23 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.201 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.543 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.54 44.12 0.51 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.645 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -62.93 -25.57 68.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.863 0.84 . . . . 0.0 108.926 178.293 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 66.3 mt -59.24 -37.68 78.15 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 113.925 -1.489 . . . . 0.0 110.893 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 15' ' ' LEU . 4.2 mm? -89.96 19.85 4.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.043 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 73.1 25.12 74.31 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.868 -0.605 . . . . 0.0 113.81 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 93.6 m -75.38 110.71 9.97 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.412 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 13.4 m -114.6 164.3 14.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.658 -178.113 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -71.17 82.04 0.71 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.109 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.607 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 41.5 tptt -94.03 102.36 14.43 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 62.94 34.3 14.25 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -177.705 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.541 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 10.6 mtpt 73.88 -3.94 2.39 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 114.203 -1.362 . . . . 0.0 111.801 -178.81 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.887 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 15.7 t -101.52 144.42 13.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 177.552 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.799 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 72.3 m -87.96 117.5 26.87 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.887 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.5 m-85 -126.84 151.14 48.75 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-N 115.204 -0.907 . . . . 0.0 108.579 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.506 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 11.8 ptp180 -112.98 156.62 22.72 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.555 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.783 ' HB3' HD13 ' A' ' 30' ' ' ILE . 1.7 t-20 55.77 34.54 23.62 Favored 'General case' 0 C--N 1.326 -0.414 0 O-C-N 123.771 0.669 . . . . 0.0 111.376 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.75 -63.06 0.68 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.648 -0.787 . . . . 0.0 114.812 178.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.8 m -146.35 38.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.311 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.783 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -102.88 114.58 65.17 Favored Pre-proline 0 C--N 1.324 -0.536 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.152 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.434 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.4 Cg_endo . . . . . 0 CA--C 1.528 0.213 0 C-N-CA 122.747 2.298 . . . . 0.0 113.884 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.435 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 63.2 m . . . . . 0 CA--C 1.518 -0.281 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.97 -7.3 58.84 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -177.497 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.888 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 95.9 mt-10 -88.44 166.3 14.32 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.01 -1.095 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -146.58 133.15 19.79 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 177.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.758 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 30.5 p -104.77 30.79 5.19 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 122.134 0.969 . . . . 0.0 109.896 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.545 HG22 ' HB3' ' A' ' 22' ' ' LYS . 46.4 t -68.3 -39.09 80.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 113.991 -1.459 . . . . 0.0 110.377 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -111.18 -39.77 4.64 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.103 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.758 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -139.01 151.79 68.77 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.611 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.9 Cg_exo -57.55 154.48 36.09 Favored 'Trans proline' 0 C--N 1.333 -0.271 0 C-N-CA 123.993 3.129 . . . . 0.0 112.865 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.411 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 11.4 m -57.6 151.28 17.38 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.661 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.402 ' C ' ' H ' ' A' ' 13' ' ' THR . 61.3 mt -93.72 -49.41 12.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.402 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.692 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.29 38.15 0.28 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.515 0.674 . . . . 0.0 110.895 -179.858 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.402 ' H ' ' C ' ' A' ' 11' ' ' ILE . 27.0 m -67.99 -26.09 65.74 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 177.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.1 mt -63.04 -38.87 92.93 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 113.93 -1.486 . . . . 0.0 110.466 178.556 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -76.83 -46.78 23.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.322 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.63 24.69 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.082 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.692 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 87.7 m -84.85 131.94 34.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.957 0.378 . . . . 0.0 110.165 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -139.01 160.2 40.33 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.041 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.4 m -62.17 113.49 2.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.487 0.661 . . . . 0.0 112.043 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.68 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 13.4 tppt? -131.69 104.75 7.09 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.323 178.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.8 t30 62.17 32.22 17.41 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.219 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.545 ' HB3' HG22 ' A' ' 6' ' ' VAL . 30.6 mtmm 82.35 -19.57 0.4 Allowed 'General case' 0 N--CA 1.477 0.89 0 CA-C-N 114.581 -1.19 . . . . 0.0 110.894 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.812 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.7 t -93.44 149.03 4.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.856 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.888 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 91.9 m -89.97 121.28 31.92 Favored 'General case' 0 C--N 1.312 -1.038 0 O-C-N 121.796 -0.565 . . . . 0.0 112.221 -178.163 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.812 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.8 m-85 -124.9 152.19 44.39 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.154 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.495 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 11.6 ptt180 -114.19 157.12 23.08 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.807 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.81 38.34 29.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.679 0.752 . . . . 0.0 110.803 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.494 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 87.68 -62.05 4.04 Favored Glycine 0 N--CA 1.447 -0.568 0 CA-C-N 115.719 -0.673 . . . . 0.0 114.681 178.901 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.09 41.38 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -178.047 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.472 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.1 mm -109.15 112.64 59.58 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.1 Cg_endo . . . . . 0 C--O 1.234 0.289 0 C-N-CA 122.568 2.179 . . . . 0.0 113.643 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 62.5 m . . . . . 0 CA--C 1.519 -0.22 0 CA-C-O 121.309 0.576 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.33 63.3 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -178.256 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.938 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.8 mt-10 -87.28 165.19 15.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 114.765 -0.718 . . . . 0.0 110.675 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.38 127.6 16.7 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.745 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 32.1 p -103.98 32.07 4.16 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-O 121.943 0.878 . . . . 0.0 110.208 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.443 HG22 ' HB3' ' A' ' 22' ' ' LYS . 46.3 t -66.12 -37.96 80.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 114.196 -1.365 . . . . 0.0 110.188 179.121 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -111.3 -40.45 4.41 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.087 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.745 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.1 pt -139.38 150.01 62.46 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.723 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 33.9 Cg_exo -58.94 152.2 59.91 Favored 'Trans proline' 0 C--N 1.334 -0.221 0 C-N-CA 124.049 3.166 . . . . 0.0 112.963 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.7 m -61.21 144.49 53.64 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.987 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 47.4 mm -93.0 -35.67 6.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.715 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.0 t -75.7 42.76 0.24 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.266 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 m -63.77 -26.21 68.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.006 0.908 . . . . 0.0 108.582 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.1 mt -59.34 -38.94 81.62 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 113.888 -1.506 . . . . 0.0 111.092 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -88.53 16.33 6.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.15 26.44 68.53 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.359 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.3 m -80.76 129.33 34.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 117.097 0.448 . . . . 0.0 109.959 179.078 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.8 t -140.45 166.87 23.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.442 -179.156 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 m -65.53 111.74 3.26 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.821 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.524 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtp? -133.86 105.1 6.59 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.413 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 44.8 t30 64.8 31.54 11.63 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.402 -178.351 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.443 ' HB3' HG22 ' A' ' 6' ' ' VAL . 31.0 mtmm 81.75 -20.28 0.37 Allowed 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 114.747 -1.115 . . . . 0.0 110.878 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.792 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.8 t -95.3 149.78 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.938 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -90.87 121.43 32.72 Favored 'General case' 0 C--N 1.313 -0.989 0 O-C-N 121.834 -0.541 . . . . 0.0 112.144 -178.311 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.792 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.4 m-85 -128.1 155.75 43.92 Favored 'General case' 0 CA--C 1.512 -0.486 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.43 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.5 ptt85 -119.0 158.65 25.36 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.118 178.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 57.96 31.9 21.24 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.216 0.532 . . . . 0.0 110.939 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.17 -50.08 4.24 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 114.704 0.642 . . . . 0.0 114.704 179.022 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.473 HG12 ' NZ ' ' A' ' 20' ' ' LYS . 16.4 m -141.13 38.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -177.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.43 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 47.3 mm -114.52 107.33 51.25 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.176 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 14.8 Cg_endo . . . . . 0 N--CA 1.465 -0.203 0 C-N-CA 122.81 2.34 . . . . 0.0 113.652 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 65.2 m . . . . . 0 CA--C 1.519 -0.243 0 CA-C-O 121.363 0.601 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.2 -4.49 64.96 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -178.2 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.855 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.0 mt-10 -87.88 163.33 16.45 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.878 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.07 127.3 30.08 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.322 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.681 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.4 p -107.45 32.36 4.73 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.055 0.931 . . . . 0.0 109.32 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.647 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.6 t -61.92 -43.77 97.95 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 114.096 -1.411 . . . . 0.0 110.942 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -110.08 -40.98 4.57 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.479 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.681 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 23.4 pt -130.04 154.22 81.2 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.323 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -59.12 153.08 54.72 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 123.975 3.116 . . . . 0.0 112.597 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 12.2 m -57.53 152.53 14.67 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.014 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 61.8 mt -95.77 -46.06 13.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.044 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.526 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.6 t -76.18 41.89 0.25 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.966 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.9 m -64.49 -23.46 67.29 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.8 mt -61.36 -37.52 83.66 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 114.074 -1.421 . . . . 0.0 110.379 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.432 HD13 ' HA ' ' A' ' 15' ' ' LEU . 4.0 mm? -89.38 15.05 9.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.563 179.414 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.446 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 77.43 26.44 61.36 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.711 -0.677 . . . . 0.0 113.766 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.5 m -79.73 112.48 17.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 117.425 0.613 . . . . 0.0 109.472 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 t -108.52 153.82 22.8 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.564 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.5 t -71.51 107.67 4.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.814 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.491 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 19.4 tptp -130.53 113.24 14.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.144 0.497 . . . . 0.0 111.205 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.438 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 5.8 t-20 60.22 35.54 20.94 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.431 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.77 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 9.9 mmpt? 74.45 -6.65 1.84 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.969 -1.014 . . . . 0.0 111.844 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.589 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.5 t -107.36 146.36 13.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.618 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.855 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 88.2 m -93.09 121.72 34.73 Favored 'General case' 0 C--N 1.315 -0.927 0 O-C-N 121.922 -0.486 . . . . 0.0 112.107 -178.344 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.589 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 21.8 m-85 -128.93 149.22 50.88 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.473 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 46.2 ptt85 -116.12 164.34 14.62 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.395 -0.821 . . . . 0.0 109.447 179.067 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 57.92 27.41 14.64 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 123.382 0.426 . . . . 0.0 111.442 179.3 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.85 -64.26 0.64 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.863 -0.685 . . . . 0.0 113.638 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.28 37.3 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.419 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.4 mm -101.93 112.74 65.69 Favored Pre-proline 0 C--N 1.323 -0.562 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.574 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo . . . . . 0 N--CA 1.464 -0.213 0 C-N-CA 122.662 2.242 . . . . 0.0 113.653 -178.682 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.0 m . . . . . 0 CA--C 1.518 -0.277 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 105.04 -7.62 44.54 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -177.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.807 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 99.5 mt-10 -88.66 171.24 10.15 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.434 -0.883 . . . . 0.0 111.083 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.1 m -148.61 135.73 20.13 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 178.074 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.754 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 23.6 p -107.66 29.54 7.12 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.202 1.001 . . . . 0.0 109.543 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.45 HG22 ' HB3' ' A' ' 22' ' ' LYS . 61.6 t -66.41 -39.56 84.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 113.77 -1.559 . . . . 0.0 110.72 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -110.47 -40.73 4.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.716 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.754 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.8 pt -139.38 152.5 69.33 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.673 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 31.7 Cg_exo -57.94 155.37 33.6 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 123.989 3.126 . . . . 0.0 113.054 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.439 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 5.9 m -59.44 149.57 29.1 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.482 -179.581 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 66.0 mt -96.96 -46.02 12.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.988 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.455 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -77.87 40.69 0.33 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.683 179.65 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.6 m -64.06 -23.09 67.2 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.065 0.936 . . . . 0.0 108.487 178.36 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.4 mt -61.58 -33.98 74.81 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.437 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 90.4 mt -94.52 23.3 5.38 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.738 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 74.18 26.24 68.97 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.651 -0.704 . . . . 0.0 114.332 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.2 m -82.68 131.09 35.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.652 0.726 . . . . 0.0 109.785 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.9 m -145.66 169.16 19.0 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.564 -178.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.5 m -63.2 106.31 0.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.982 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.472 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtm? -126.89 99.91 5.94 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.274 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.461 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 51.2 t30 65.58 33.27 8.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.792 -178.033 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 41.7 mtmt 80.22 -19.63 0.43 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 114.264 -1.335 . . . . 0.0 111.066 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.894 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -93.33 150.7 3.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.807 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 94.9 m -89.33 116.77 27.79 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 120.141 -0.624 . . . . 0.0 112.362 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.894 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -122.47 156.43 34.11 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.828 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.528 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 14.2 ptt180 -117.76 156.67 27.88 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.088 179.133 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 57.37 34.5 24.77 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.068 0.461 . . . . 0.0 111.304 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 81.61 -50.2 4.19 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 115.0 0.76 . . . . 0.0 115.0 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 m -143.08 41.16 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -178.042 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.486 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.3 mm -116.64 107.23 46.95 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.173 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo . . . . . 0 CA--C 1.528 0.207 0 C-N-CA 122.603 2.202 . . . . 0.0 113.627 -178.115 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 75.9 m . . . . . 0 CA--C 1.519 -0.236 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.31 -3.28 59.73 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.955 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 40.3 mt-10 -87.96 161.51 17.39 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.59 -0.805 . . . . 0.0 110.83 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.95 126.48 30.43 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.4 178.334 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.704 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 13.3 p -107.55 35.54 3.04 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.374 1.083 . . . . 0.0 109.055 179.486 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.46 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -64.94 -41.97 93.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 113.816 -1.538 . . . . 0.0 110.713 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -113.04 -39.91 4.09 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.156 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.704 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.6 pt -131.72 151.62 78.93 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.178 -179.026 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -60.24 152.14 68.52 Favored 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.953 3.102 . . . . 0.0 112.667 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -55.01 148.31 13.91 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 112.083 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.0 mt -89.18 -39.09 12.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.156 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.437 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 2.3 t -80.75 40.84 0.54 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.553 0.692 . . . . 0.0 110.696 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -70.4 -25.22 63.14 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.646 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.88 -41.23 97.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.902 -1.499 . . . . 0.0 110.451 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -74.33 -45.76 45.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.266 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 27.46 0.18 Allowed Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.537 -0.84 . . . . 0.0 112.979 179.156 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.437 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 90.2 m -84.86 113.28 21.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.377 0.608 . . . . 0.0 110.147 179.374 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 35.5 t -99.3 140.82 32.9 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.639 -179.308 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 45.9 t -70.79 117.97 12.99 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.989 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.417 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 0.3 OUTLIER -136.07 114.92 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.811 -179.257 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 34.8 t-20 59.17 31.87 21.6 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.643 0.735 . . . . 0.0 109.464 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.46 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 55.2 mttm 70.86 13.35 7.1 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.705 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -121.34 136.6 57.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 176.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.955 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 76.8 m -89.9 126.46 35.73 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.417 ' CD1' ' HB3' ' A' ' 20' ' ' LYS . 32.5 m-85 -131.51 147.65 52.56 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.702 178.487 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.586 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 20.2 ptt85 -111.79 155.23 23.88 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.421 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.748 ' HB3' HD13 ' A' ' 30' ' ' ILE . 0.1 OUTLIER 58.25 33.49 23.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -179.794 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.85 -76.74 0.23 Allowed Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.681 179.289 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.8 m -139.64 32.49 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.748 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -91.34 113.87 59.87 Favored Pre-proline 0 C--N 1.325 -0.473 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.121 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.802 2.335 . . . . 0.0 114.348 -178.102 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.9 m . . . . . 0 CA--C 1.516 -0.342 0 CA-C-O 121.396 0.617 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.6 -6.82 57.55 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -177.291 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.859 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 97.6 mt-10 -87.54 165.2 15.66 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.196 -1.002 . . . . 0.0 110.509 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.26 127.35 14.66 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.164 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.818 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 20.3 p -100.86 34.96 2.31 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 122.395 1.093 . . . . 0.0 109.296 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.893 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 40.2 t -63.13 -44.14 99.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 113.912 -1.494 . . . . 0.0 110.176 179.579 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -114.62 -39.7 3.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.957 179.177 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.818 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -128.6 149.83 72.98 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.853 -179.291 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 31.2 Cg_exo -58.93 158.57 24.42 Favored 'Trans proline' 0 C--N 1.332 -0.314 0 C-N-CA 124.142 3.228 . . . . 0.0 113.259 -179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.457 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 8.9 m -60.82 154.77 21.1 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.011 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 61.4 mt -100.42 -48.38 11.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.039 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.702 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.9 t -77.17 41.49 0.3 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.357 0.599 . . . . 0.0 111.304 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 28.5 m -67.86 -24.57 65.26 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 73.0 mt -60.49 -41.01 93.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 114.151 -1.386 . . . . 0.0 110.14 178.402 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.522 HD12 ' HD2' ' A' ' 26' ' ' ARG . 1.8 tm? -76.94 -42.62 38.56 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.35 20.33 0.15 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.175 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.702 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 71.2 m -78.68 126.34 30.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.193 0.52 . . . . 0.0 110.426 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -140.0 154.73 47.23 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.901 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.9 m -55.82 121.67 9.76 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -179.107 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.611 ' HB2' ' CD1' ' A' ' 25' ' ' TYR . 39.3 mmtm -140.47 106.06 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.669 177.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.46 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 0.1 OUTLIER 62.53 34.32 15.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.772 -177.777 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.893 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 30.0 mmmt 77.15 -17.05 0.59 Allowed 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.557 -1.202 . . . . 0.0 111.451 -178.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.856 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.0 t -92.45 153.99 3.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.859 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 99.2 m -96.81 123.84 40.62 Favored 'General case' 0 C--N 1.314 -0.945 0 O-C-N 121.372 -0.83 . . . . 0.0 112.327 -178.353 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.856 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.0 m-85 -126.52 153.86 44.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.219 178.632 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.559 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 28.9 ptt85 -116.59 156.32 27.21 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.952 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.763 ' HB3' HD13 ' A' ' 30' ' ' ILE . 0.1 OUTLIER 58.3 33.37 23.07 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.539 0.685 . . . . 0.0 110.888 179.888 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.47 -66.73 0.27 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.898 179.108 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 p -150.99 39.25 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-O 121.738 0.78 . . . . 0.0 112.209 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.763 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.1 mp -98.39 116.25 65.55 Favored Pre-proline 0 C--N 1.322 -0.596 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 177.833 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 CA--C 1.528 0.225 0 C-N-CA 122.816 2.344 . . . . 0.0 114.228 -178.049 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.54 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 57.4 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.68 -5.92 64.64 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.853 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.7 mt-10 -89.09 165.8 14.27 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.166 -1.017 . . . . 0.0 110.653 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.32 134.5 21.67 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.746 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 31.3 p -106.5 30.65 5.83 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 122.018 0.913 . . . . 0.0 109.925 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.421 HG22 ' HB3' ' A' ' 22' ' ' LYS . 47.2 t -66.53 -38.41 81.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.985 -1.461 . . . . 0.0 110.394 179.203 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -110.78 -40.28 4.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.988 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.746 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 15.6 pt -140.56 151.4 63.53 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.609 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.4 Cg_exo -57.42 152.4 47.17 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 124.112 3.208 . . . . 0.0 112.947 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.603 ' HB2' HG23 ' A' ' 13' ' ' THR . 3.7 m -58.2 148.16 27.94 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.536 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.1 mm -89.1 -41.16 13.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.161 179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.532 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.1 t -83.2 40.02 0.68 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.483 0.659 . . . . 0.0 110.416 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.603 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.6 OUTLIER -68.8 -27.64 66.05 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 177.886 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.68 -39.6 94.73 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 113.725 -1.579 . . . . 0.0 110.758 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -74.98 -47.36 29.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.634 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.22 20.76 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.983 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 82.1 m -85.42 130.54 34.56 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.358 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.8 t -137.02 168.36 19.74 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.588 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.5 m -67.48 100.36 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.821 -179.803 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.561 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.3 tmtp? -119.08 102.38 8.69 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.856 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.467 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 9.0 t-20 62.88 36.33 12.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.946 -1.024 . . . . 0.0 108.795 -177.86 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 7.7 mtmp? 79.31 -17.58 0.58 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.556 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.798 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 19.5 t -97.81 147.79 6.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.192 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.853 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 96.6 m -89.15 120.41 30.51 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -178.116 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.798 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.4 m-85 -127.67 154.09 45.7 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.406 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.54 ' CZ ' ' HA ' ' A' ' 1' ' ' CYS . 5.6 ptt180 -112.65 149.34 32.98 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.778 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 58.01 37.22 26.6 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.635 0.731 . . . . 0.0 110.11 -178.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 78.35 -48.19 3.08 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 115.523 0.969 . . . . 0.0 115.523 178.846 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.517 HG12 ' NZ ' ' A' ' 20' ' ' LYS . 18.5 m -138.59 35.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 114.887 1.44 . . . . 0.0 114.887 -177.288 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.453 ' HB ' ' HG3' ' A' ' 26' ' ' ARG . 63.1 mt -112.46 110.17 53.13 Favored Pre-proline 0 C--N 1.318 -0.797 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 177.392 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo . . . . . 0 C--O 1.232 0.204 0 C-N-CA 122.655 2.236 . . . . 0.0 113.458 -178.28 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.5 p . . . . . 0 N--CA 1.457 -0.122 0 CA-C-O 120.755 0.312 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 69.99 37.82 74.03 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.72 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.842 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 3.9 mm-40 -135.5 165.74 24.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.014 0.435 . . . . 0.0 110.271 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.55 126.4 8.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.508 178.411 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.685 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.7 p -106.2 36.74 2.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 122.383 1.087 . . . . 0.0 109.218 179.316 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.966 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 43.3 t -64.09 -44.3 97.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 113.854 -1.521 . . . . 0.0 110.751 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -104.12 -42.99 5.37 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.011 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.685 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.6 pt -138.1 156.07 74.12 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.104 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -55.91 150.18 47.67 Favored 'Trans proline' 0 C--O 1.234 0.275 0 C-N-CA 123.624 2.882 . . . . 0.0 112.487 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -58.92 146.0 39.34 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.127 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 47.5 mm -88.88 -39.82 12.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.731 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.63 40.64 0.24 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.25 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 80.0 m -68.93 -23.76 64.21 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.7 mt -61.72 -41.02 97.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.432 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -75.3 -42.1 55.46 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 137.78 28.94 0.28 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.635 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.731 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 67.4 m -75.28 100.74 4.46 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.088 0.471 . . . . 0.0 110.698 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.3 m -101.3 139.31 37.14 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.108 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.0 m -61.29 121.79 13.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.231 0.539 . . . . 0.0 111.561 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.729 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -142.87 110.67 5.89 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.158 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.445 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.3 t30 61.84 32.58 18.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 109.104 -178.303 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.966 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 77.45 -15.99 0.69 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.461 -179.232 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.511 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.4 t -94.07 152.76 3.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.842 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 62.2 m -98.3 128.01 44.52 Favored 'General case' 0 C--N 1.315 -0.896 0 O-C-N 121.451 -0.78 . . . . 0.0 111.99 -178.493 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.729 ' CD1' ' HB3' ' A' ' 20' ' ' LYS . 37.8 m-85 -128.14 154.65 45.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.392 178.737 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.465 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 34.9 ptt180 -113.78 154.97 26.49 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.78 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.58 35.55 26.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 0.0 110.745 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.76 -78.87 0.3 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.56 -0.829 . . . . 0.0 113.738 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.0 m -137.08 33.44 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.441 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -95.63 115.23 65.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.7 Cg_endo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.24 1.96 . . . . 0.0 111.781 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.9 p . . . . . 0 C--O 1.227 -0.086 0 CA-C-O 121.017 0.437 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 71.69 29.04 68.11 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.507 -0.77 . . . . 0.0 114.291 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.908 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 23.5 mt-10 -123.32 163.8 20.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.028 0.442 . . . . 0.0 110.415 178.473 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.34 126.14 16.12 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.557 178.454 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.721 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 4.9 p -102.17 34.27 2.78 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 122.381 1.086 . . . . 0.0 109.245 179.563 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.737 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 47.6 t -68.28 -40.62 82.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.637 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -109.67 -41.25 4.6 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.94 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.721 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.7 pt -137.74 152.89 73.42 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.462 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 36.7 Cg_exo -59.48 148.58 86.38 Favored 'Trans proline' 0 C--N 1.332 -0.309 0 C-N-CA 123.682 2.921 . . . . 0.0 112.432 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 m -54.46 147.05 14.64 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.857 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.4 mm -89.21 -44.43 15.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.904 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.589 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.03 39.14 0.49 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.444 0.64 . . . . 0.0 110.901 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 77.7 m -67.15 -25.44 66.17 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 177.777 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 69.2 mt -63.04 -41.28 99.46 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.533 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.49 -41.79 62.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.238 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.571 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 147.6 13.76 0.15 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.57 -0.824 . . . . 0.0 113.04 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.589 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 96.3 m -74.76 88.1 2.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.3 0.572 . . . . 0.0 110.835 179.733 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 58.9 p -88.32 135.45 33.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.839 179.486 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.5 t -64.3 119.33 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.445 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.434 ' HE2' ' HB2' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -136.44 117.78 14.64 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.524 -179.743 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.85 34.39 24.68 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 109.423 -179.304 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.737 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 15.4 mtpt 69.99 8.42 6.68 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.801 -179.29 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.415 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 24.8 t -116.87 143.36 27.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 177.419 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.908 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -95.95 127.53 42.05 Favored 'General case' 0 C--N 1.313 -0.991 0 O-C-N 121.434 -0.791 . . . . 0.0 112.865 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.415 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 18.9 m-85 -130.45 151.21 51.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.201 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.571 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 37.7 ptt180 -114.84 154.14 29.15 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.187 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.431 ' HB3' HD12 ' A' ' 30' ' ' ILE . 2.1 t-20 57.94 33.31 23.06 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 123.656 0.597 . . . . 0.0 111.135 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 111.64 -86.53 0.43 Allowed Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.956 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.7 m -134.57 32.46 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -179.051 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.459 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 62.4 mt -93.15 110.31 45.41 Favored Pre-proline 0 C--N 1.327 -0.399 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo . . . . . 0 C--N 1.341 0.155 0 C-N-CA 122.222 1.948 . . . . 0.0 112.02 -179.356 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 71.5 m . . . . . 0 CA--C 1.516 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.34 -6.08 65.62 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -177.482 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.651 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.4 mt-10 -87.6 164.3 16.14 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 114.277 -0.961 . . . . 0.0 110.484 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' SER . . . . . 0.444 ' HB3' HG23 ' A' ' 6' ' ' VAL . 0.9 OUTLIER -148.85 135.48 19.63 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.219 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.5 OUTLIER -105.25 26.21 9.66 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 122.644 1.211 . . . . 0.0 108.911 179.911 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.444 HG23 ' HB3' ' A' ' 4' ' ' SER . 55.4 t -55.41 -43.18 70.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.124 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -107.03 -42.87 4.78 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.255 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.64 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.7 pt -145.95 158.45 48.84 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.07 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -58.73 145.44 95.96 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 123.622 2.881 . . . . 0.0 111.832 179.514 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.589 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 24.1 m -75.23 161.28 29.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.196 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.442 ' C ' ' H ' ' A' ' 13' ' ' THR . 56.1 mt -87.34 -36.15 9.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.45 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.415 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 8.5 t -77.31 30.92 0.14 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.678 0.751 . . . . 0.0 111.36 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.442 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.8 OUTLIER -71.06 -26.85 63.25 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.194 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.4 mt -64.41 -41.18 96.77 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.558 178.832 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -71.42 -42.18 68.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.435 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 22.72 0.24 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.429 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.404 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -82.16 93.85 7.14 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.388 0.614 . . . . 0.0 110.385 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 m -88.27 139.21 30.73 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.897 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.471 ' SG ' ' HA ' ' A' ' 22' ' ' LYS . 50.2 t -75.66 116.37 16.3 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.106 0.479 . . . . 0.0 111.275 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -128.01 127.77 43.79 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 177.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 56.85 33.56 23.31 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-O 121.69 0.757 . . . . 0.0 109.103 -178.225 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.471 ' HA ' ' SG ' ' A' ' 19' ' ' CYS . 14.4 mmmm 69.9 6.56 5.8 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 114.798 -1.092 . . . . 0.0 111.964 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -117.79 138.77 47.4 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.651 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 7.3 m -89.35 129.49 35.87 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -177.86 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -130.94 152.5 50.19 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.125 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 30.7 ptt85 -116.17 154.31 30.25 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.888 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 59.52 33.39 22.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.842 0.829 . . . . 0.0 110.402 -179.318 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.41 -55.69 4.5 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 115.113 0.805 . . . . 0.0 115.113 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.7 m -140.47 38.19 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -177.727 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.0 mt -112.44 110.54 52.91 Favored Pre-proline 0 C--N 1.318 -0.774 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 177.685 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo . . . . . 0 N--CA 1.464 -0.207 0 C-N-CA 122.598 2.199 . . . . 0.0 113.316 -178.615 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.532 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 74.4 m . . . . . 0 CA--C 1.517 -0.315 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.03 -7.32 58.74 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -177.749 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.819 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 26.3 mt-10 -88.89 165.66 14.48 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.119 -1.04 . . . . 0.0 110.835 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -146.31 127.7 14.94 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.037 178.269 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.774 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.9 p -104.64 34.35 3.18 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.17 0.985 . . . . 0.0 109.488 179.484 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.907 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -62.14 -39.24 83.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.369 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -114.43 -40.26 3.66 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.146 179.483 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.774 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 17.5 pt -134.0 149.6 72.08 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.855 -179.234 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -56.62 152.85 38.89 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 124.255 3.303 . . . . 0.0 113.649 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.47 ' HB2' HG23 ' A' ' 13' ' ' THR . 4.2 m -60.1 149.94 31.02 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.592 -179.663 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 62.0 mt -89.6 -41.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.486 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.556 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.39 40.83 0.67 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.538 0.685 . . . . 0.0 110.67 179.876 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.47 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.7 OUTLIER -69.44 -27.11 64.97 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 177.682 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.5 mt -63.39 -40.64 97.78 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 113.773 -1.558 . . . . 0.0 110.62 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -73.51 -47.25 42.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.462 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.92 23.73 0.09 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.959 179.196 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.556 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 85.9 m -82.47 119.46 24.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.964 0.411 . . . . 0.0 110.165 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -116.61 156.1 27.6 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.937 -179.031 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.9 m -68.94 105.15 2.29 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.761 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.553 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 17.5 tptm -117.99 103.65 10.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.483 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 38.3 t-20 61.96 32.63 17.74 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -178.143 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.907 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 28.1 mttt 78.31 -10.38 1.36 Allowed 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.348 -1.296 . . . . 0.0 111.754 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.796 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -97.12 143.87 11.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.753 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.819 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 71.0 m -88.81 122.34 32.11 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -177.196 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.796 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 5.7 m-85 -129.66 151.71 49.96 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.03 177.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.664 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 7.0 ptt180 -116.29 157.07 25.53 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.568 179.324 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.611 ' HB2' HD13 ' A' ' 30' ' ' ILE . 73.4 m-20 58.82 34.43 23.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.135 0.493 . . . . 0.0 111.463 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.51 -56.99 3.47 Favored Glycine 0 N--CA 1.45 -0.426 0 N-CA-C 114.963 0.745 . . . . 0.0 114.963 178.44 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.2 m -145.62 38.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.664 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 1.9 mp -106.84 112.51 63.38 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.68 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo . . . . . 0 C--O 1.232 0.191 0 C-N-CA 122.665 2.243 . . . . 0.0 113.787 -178.33 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.9 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.27 -5.01 60.72 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 -178.211 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.935 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.4 mt-10 -88.21 162.79 16.47 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 114.66 -0.77 . . . . 0.0 110.691 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.26 128.4 20.86 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 177.36 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.712 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.3 p -102.46 31.84 3.86 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.924 0.869 . . . . 0.0 110.203 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.0 t -68.48 -38.97 80.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.393 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -106.77 -41.35 5.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.008 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.712 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.3 pt -142.7 152.18 58.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.604 -179.388 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 34.5 Cg_exo -58.86 150.93 68.44 Favored 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.915 3.077 . . . . 0.0 112.621 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.439 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.7 m -58.57 144.76 41.75 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.653 -179.503 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.7 mm -90.93 -37.96 10.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.461 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.6 t -75.95 40.48 0.2 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.227 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 p -66.19 -25.67 67.04 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.835 0.826 . . . . 0.0 108.801 177.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.34 -35.97 76.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.429 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -92.17 19.94 6.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.654 179.573 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 71.34 30.21 67.34 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.856 -0.611 . . . . 0.0 114.004 178.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 99.9 m -84.0 127.48 33.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 117.289 0.544 . . . . 0.0 109.915 178.709 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 41.2 m -139.25 164.87 28.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.95 -178.779 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -67.76 101.31 1.04 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.019 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.534 ' HE2' HG12 ' A' ' 29' ' ' VAL . 7.8 tmtm? -128.53 118.99 23.97 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.492 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.47 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 30.7 t30 62.63 39.04 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -178.722 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.47 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 17.5 pttp 56.53 27.67 12.67 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.787 -179.03 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.929 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 44.4 t -142.83 155.04 17.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.935 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 79.6 m -89.61 119.93 30.46 Favored 'General case' 0 C--N 1.313 -0.978 0 O-C-N 121.485 -0.76 . . . . 0.0 112.294 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.929 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -126.79 154.89 43.66 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.019 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.504 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 13.2 ptt180 -116.23 156.42 26.59 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.207 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 56.94 34.53 25.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.15 0.5 . . . . 0.0 111.29 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 83.86 -55.53 5.02 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 114.759 0.663 . . . . 0.0 114.759 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.534 HG12 ' HE2' ' A' ' 20' ' ' LYS . 10.8 m -139.8 40.48 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -178.011 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.504 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.5 mm -113.22 106.44 54.7 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo . . . . . 0 C--O 1.233 0.239 0 C-N-CA 122.883 2.389 . . . . 0.0 113.785 -178.172 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.561 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 58.4 m . . . . . 0 CA--C 1.517 -0.306 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.2 -7.44 56.71 Favored Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -177.721 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.851 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.4 mt-10 -88.01 165.22 15.34 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.116 -1.042 . . . . 0.0 110.68 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -145.28 131.9 19.9 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.744 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -108.7 31.89 5.29 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.201 1.001 . . . . 0.0 109.606 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.2 t -60.32 -43.3 93.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.076 -1.42 . . . . 0.0 110.239 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.73 -41.94 5.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.261 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.744 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -135.31 150.77 73.52 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.883 -179.194 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 52.6 Cg_exo -55.79 153.38 30.93 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 124.271 3.314 . . . . 0.0 113.773 -179.168 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 9.0 m -59.93 152.67 22.97 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.755 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.8 mt -93.71 -42.37 12.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.56 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.605 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.07 43.29 0.7 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.435 0.635 . . . . 0.0 110.714 179.909 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -68.0 -26.74 66.06 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.9 mt -62.43 -41.36 98.66 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.623 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.401 HD22 ' HA ' ' A' ' 15' ' ' LEU . 1.8 tm? -73.49 -43.95 58.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.304 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 140.69 26.08 0.22 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.819 179.176 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.605 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 77.1 m -82.95 121.24 26.73 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.853 0.358 . . . . 0.0 110.116 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 12.9 t -118.24 164.01 15.82 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 -178.71 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.7 m -73.36 74.05 1.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.644 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.679 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 13.2 tmtt? -89.15 103.79 16.39 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.457 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 23.4 t30 60.19 33.8 21.05 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.267 -178.611 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 22.9 mmtp 74.37 2.71 4.18 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.704 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.834 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -109.17 140.07 29.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.546 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.851 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 82.9 m -88.1 121.42 30.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -176.632 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.834 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -127.26 150.51 49.53 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 177.577 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.595 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 9.1 ptt180 -115.27 153.53 30.75 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.369 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.753 ' HB3' HD13 ' A' ' 30' ' ' ILE . 0.1 OUTLIER 58.79 36.81 24.95 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.361 0.6 . . . . 0.0 111.16 179.829 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.85 -62.53 0.79 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.581 -0.819 . . . . 0.0 114.663 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -150.58 37.36 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-O 121.674 0.749 . . . . 0.0 112.693 -178.117 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.753 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -100.06 112.19 63.56 Favored Pre-proline 0 C--N 1.323 -0.577 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 177.601 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 C--O 1.232 0.197 0 C-N-CA 122.628 2.219 . . . . 0.0 113.551 -178.391 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 30.3 p . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.718 0.294 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 111.09 -12.27 29.07 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.937 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.841 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 5.6 mm-40 -85.1 159.94 20.07 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.545 0.688 . . . . 0.0 111.151 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.79 134.77 30.69 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.853 -1.067 . . . . 0.0 109.13 178.538 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.702 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 15.1 p -115.91 34.13 5.13 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 122.088 0.947 . . . . 0.0 109.231 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.614 ' HA ' ' HB3' ' A' ' 22' ' ' LYS . 28.9 t -63.92 -40.46 89.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 113.881 -1.509 . . . . 0.0 111.244 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -114.53 -38.94 3.9 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.065 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.702 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -136.51 153.43 76.09 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.504 -179.267 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -58.52 148.66 79.97 Favored 'Trans proline' 0 C--N 1.332 -0.328 0 C-N-CA 123.717 2.945 . . . . 0.0 112.265 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -56.67 143.97 34.15 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.469 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 4.3 mp -89.75 -42.43 14.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.618 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.24 39.11 0.19 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.363 179.854 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 58.2 m -69.53 -23.42 63.59 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 177.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 77.2 mt -63.06 -40.83 98.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.489 178.528 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.455 HD22 ' HA ' ' A' ' 15' ' ' LEU . 1.0 OUTLIER -73.12 -39.72 65.51 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.396 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.46 23.87 0.44 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.535 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.618 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 89.7 m -76.64 98.06 4.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.094 0.473 . . . . 0.0 110.669 179.532 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.459 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 13.6 m -88.56 132.93 34.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.937 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.2 t -73.82 117.2 15.32 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.087 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.672 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 11.6 tmtt? -141.97 119.1 11.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.525 0.679 . . . . 0.0 110.843 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 55.07 37.17 28.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.3 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.614 ' HB3' ' HA ' ' A' ' 6' ' ' VAL . 26.3 mtmm 75.88 1.43 3.51 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.08 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.7 t -118.32 137.25 52.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.001 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.841 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 30.1 m -95.52 128.37 42.33 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.702 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.672 ' CE1' ' HD2' ' A' ' 20' ' ' LYS . 2.1 m-85 -122.35 163.54 19.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.653 179.429 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.5 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.2 ptt180 -131.94 155.51 47.79 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 61.79 31.55 18.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.305 0.574 . . . . 0.0 111.211 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 109.69 -71.93 0.2 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.536 -0.84 . . . . 0.0 113.931 178.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 p -150.23 36.85 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 122.069 0.938 . . . . 0.0 111.099 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.5 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.9 mm -101.17 113.83 65.8 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.407 178.434 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.5 Cg_endo . . . . . 0 N--CA 1.463 -0.268 0 C-N-CA 122.203 1.935 . . . . 0.0 111.4 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.473 ' HB3' ' HD3' ' A' ' 26' ' ' ARG . 1.7 p . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.018 0.437 . . . . 0.0 110.828 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.33 31.6 80.98 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.491 -0.777 . . . . 0.0 113.166 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.88 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.5 mt-10 -124.42 165.93 16.88 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.074 0.464 . . . . 0.0 110.4 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.89 134.07 17.19 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.771 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.7 p -107.45 31.29 5.53 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 122.36 1.076 . . . . 0.0 109.605 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.902 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 46.7 t -61.72 -44.47 98.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 113.933 -1.485 . . . . 0.0 110.177 179.475 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -104.66 -43.59 5.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.158 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.771 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.5 pt -136.09 153.8 77.03 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.003 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 51.4 Cg_exo -55.45 153.98 26.34 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 124.11 3.207 . . . . 0.0 113.379 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.62 ' HB2' HG23 ' A' ' 13' ' ' THR . 7.3 m -58.69 149.74 25.31 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.698 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.406 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.2 mp -89.53 -46.35 15.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.859 179.324 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.694 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -79.24 41.24 0.45 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.442 0.639 . . . . 0.0 110.539 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.62 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.6 OUTLIER -68.61 -26.5 65.39 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.8 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.4 mt -61.98 -40.93 97.29 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 113.81 -1.541 . . . . 0.0 110.453 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -75.36 -46.33 33.82 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.455 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.58 26.38 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.543 -0.836 . . . . 0.0 113.259 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.694 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.1 m -80.35 120.96 25.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 117.169 0.485 . . . . 0.0 110.006 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.5 m -119.12 159.79 23.31 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.181 -178.691 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.2 m -69.35 84.96 0.4 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.752 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.57 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 46.7 tptt -96.66 98.4 10.15 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.596 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 38.7 t-20 60.94 33.52 19.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.395 -0.82 . . . . 0.0 108.811 -178.362 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.902 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 40.4 mmtt 82.29 -10.99 1.05 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.319 -1.309 . . . . 0.0 112.414 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.823 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -99.22 141.45 16.64 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.165 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.88 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 73.1 m -89.65 122.54 32.87 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.823 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -127.43 151.07 49.29 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.726 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.473 ' HD3' ' HB3' ' A' ' 1' ' ' CYS . 28.1 ptt180 -112.24 153.61 26.86 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.115 179.876 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.3 t30 60.12 33.49 21.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.287 0.565 . . . . 0.0 111.264 179.709 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.89 -64.59 0.73 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.621 -0.8 . . . . 0.0 114.615 178.672 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.3 m -143.12 33.59 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.437 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 59.0 mt -101.56 108.42 55.54 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo . . . . . 0 N--CA 1.464 -0.238 0 C-N-CA 122.212 1.942 . . . . 0.0 112.347 -179.09 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 CA--C 1.516 -0.362 0 CA-C-O 121.372 0.606 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.48 -5.75 67.63 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -177.539 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.638 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 21.2 mt-10 -87.25 160.11 18.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 114.494 -0.853 . . . . 0.0 110.387 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' SER . . . . . 0.425 ' HA ' ' HA ' ' A' ' 23' ' ' VAL . 0.7 OUTLIER -144.46 133.36 22.58 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.471 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.488 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.7 OUTLIER -98.68 26.97 5.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 122.157 0.98 . . . . 0.0 109.905 -179.572 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.7 t -61.03 -39.74 83.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 114.26 -1.336 . . . . 0.0 111.715 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -108.33 -42.03 4.71 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.44 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.488 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 13.5 pt -149.96 159.38 35.74 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.679 -178.688 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -59.55 143.6 99.64 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 123.342 2.695 . . . . 0.0 111.302 179.17 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.538 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 18.2 m -71.18 161.42 31.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.79 -178.229 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 57.8 mt -87.03 -40.01 13.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.356 -0.838 . . . . 0.0 112.711 -178.082 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.594 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 3.1 t -79.32 35.87 0.28 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.714 0.768 . . . . 0.0 111.345 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -70.52 -25.12 62.98 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 177.419 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 81.0 mt -63.86 -42.85 97.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 113.898 -1.501 . . . . 0.0 110.716 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -71.43 -43.31 66.97 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.584 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.465 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 144.46 20.66 0.17 Allowed Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.697 179.256 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -77.8 83.75 4.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.401 0.619 . . . . 0.0 110.425 179.491 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.4 m -86.18 136.2 33.29 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.454 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.6 t -68.6 127.94 34.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.162 0.506 . . . . 0.0 111.222 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -144.99 130.24 18.6 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.746 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 31.2 t30 56.81 38.93 29.79 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.304 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.746 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 2.1 pttm 60.84 13.3 4.34 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.156 1.382 . . . . 0.0 112.115 -179.159 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 4' ' ' SER . 58.5 t -128.31 141.62 46.01 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.638 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 1.7 m -88.93 131.67 35.04 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.034 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -132.45 146.27 51.82 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.17 -0.923 . . . . 0.0 108.853 177.868 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.465 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 41.4 ptt85 -110.53 157.84 19.19 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.305 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 57.62 30.81 19.4 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.672 0.607 . . . . 0.0 111.256 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.59 -74.5 0.22 Allowed Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.548 -0.834 . . . . 0.0 113.462 179.283 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.51 32.52 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.423 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -92.44 113.1 58.35 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.197 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo . . . . . 0 N--CA 1.464 -0.227 0 C-N-CA 122.704 2.269 . . . . 0.0 113.558 -178.459 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.9 m . . . . . 0 CA--C 1.517 -0.313 0 CA-C-O 121.275 0.56 . . . . 0.0 109.721 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.21 -2.64 63.57 Favored Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.95 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 41.2 mt-10 -86.93 158.92 19.19 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.774 -0.713 . . . . 0.0 110.422 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.54 125.64 29.32 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.156 178.082 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.665 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.6 p -103.13 34.81 2.75 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 122.368 1.08 . . . . 0.0 109.047 179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.936 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 47.7 t -66.53 -42.93 90.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 113.759 -1.564 . . . . 0.0 110.667 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -109.34 -40.95 4.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.665 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.3 pt -134.89 153.08 78.44 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.063 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_exo -60.63 150.54 81.49 Favored 'Trans proline' 0 C--N 1.332 -0.331 0 C-N-CA 123.855 3.037 . . . . 0.0 112.27 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.478 ' HB2' HG23 ' A' ' 13' ' ' THR . 2.5 m -53.71 146.08 14.26 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.786 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.41 ' N ' HD12 ' A' ' 11' ' ' ILE . 4.1 mp -88.2 -39.9 13.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.837 179.514 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.414 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.4 40.19 0.63 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.608 0.718 . . . . 0.0 110.514 179.421 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.478 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.5 OUTLIER -68.48 -26.5 65.51 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.798 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 75.8 mt -63.16 -39.95 96.15 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.831 -1.531 . . . . 0.0 110.493 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.2 tm? -72.91 -40.43 65.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.236 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 139.86 13.47 0.61 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.414 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.6 m -75.52 105.14 6.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.359 0.599 . . . . 0.0 110.346 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.5 m -97.3 143.32 28.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.737 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.85 115.93 12.74 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.953 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.3 ttmm -140.73 121.71 14.59 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.818 0.342 . . . . 0.0 110.945 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 42.3 t30 60.06 34.12 21.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.674 0.749 . . . . 0.0 109.583 -179.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.936 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 69.46 6.55 5.75 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.757 -179.536 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.482 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.6 t -119.29 144.33 28.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.098 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.95 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -94.68 127.55 40.73 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 -177.782 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.482 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 16.4 m-85 -132.41 148.42 52.41 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.093 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.402 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 26.6 ptt180 -109.81 158.12 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.587 178.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.67 35.58 25.54 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.687 0.756 . . . . 0.0 110.748 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.17 -60.34 3.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.849 -0.691 . . . . 0.0 114.781 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.9 m -140.44 34.88 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -178.132 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 51.0 mm -103.03 110.28 63.26 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 177.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.1 Cg_endo . . . . . 0 N--CA 1.464 -0.252 0 C-N-CA 122.578 2.185 . . . . 0.0 113.389 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.5 m . . . . . 0 CA--C 1.518 -0.262 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.0 -3.96 60.68 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.961 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.6 mt-10 -88.14 164.77 15.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.617 -0.792 . . . . 0.0 111.059 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.97 126.34 15.77 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 177.453 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.726 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -105.34 34.27 3.32 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 122.275 1.036 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.964 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 44.3 t -61.98 -44.2 98.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 114.092 -1.413 . . . . 0.0 110.099 179.326 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -105.65 -42.62 5.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.207 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.726 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.3 pt -135.65 150.75 72.86 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 -179.223 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -57.84 154.6 37.1 Favored 'Trans proline' 0 N--CA 1.473 0.296 0 C-N-CA 124.243 3.296 . . . . 0.0 113.35 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.482 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.8 m -61.01 145.3 51.22 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.257 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.2 mt -93.98 -35.32 6.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.955 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -76.83 44.33 0.38 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.018 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.7 m -64.23 -25.78 68.22 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.372 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.4 mt -59.72 -36.87 77.43 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.003 -1.453 . . . . 0.0 110.995 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -89.59 16.82 7.14 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.839 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 71.44 28.95 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.508 179.265 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 80.7 m -80.57 128.18 33.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.04 0.42 . . . . 0.0 110.135 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -133.14 155.51 49.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.028 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 47.9 m -62.5 118.47 7.6 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.998 -0.546 . . . . 0.0 112.184 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.663 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 12.7 tppt? -132.76 101.63 5.35 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.587 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.546 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 46.6 t30 61.54 34.31 17.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.873 -178.005 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.964 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 46.0 mmtt 80.73 -16.52 0.64 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.15 -1.387 . . . . 0.0 112.157 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.679 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.4 t -94.88 143.13 12.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 177.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.961 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -89.29 124.25 34.24 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 112.673 0.62 . . . . 0.0 112.673 -177.505 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.679 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 12.1 m-85 -130.03 150.22 51.4 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.46 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 23.1 ptt180 -112.28 161.01 17.08 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.854 179.383 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 55.55 33.14 20.5 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.187 0.518 . . . . 0.0 111.406 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.449 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 95.43 -64.05 1.35 Allowed Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.812 -0.708 . . . . 0.0 113.963 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.2 m -142.78 37.73 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 112.909 0.707 . . . . 0.0 112.909 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.46 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 49.6 mm -101.17 112.13 64.55 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 178.353 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 10.7 Cg_endo . . . . . 0 C--O 1.231 0.15 0 C-N-CA 122.932 2.422 . . . . 0.0 113.963 -178.201 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.2 m . . . . . 0 CA--C 1.517 -0.319 0 CA-C-O 121.345 0.593 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.71 -3.77 53.24 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 109.751 -1.339 . . . . 0.0 109.751 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.986 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.1 mt-10 -86.84 161.61 18.23 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 114.659 -0.771 . . . . 0.0 110.546 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -135.19 124.62 24.87 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.802 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.692 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.8 p -105.84 33.33 3.82 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 122.048 0.928 . . . . 0.0 109.503 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.703 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 36.9 t -61.43 -44.06 97.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.768 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -112.34 -39.89 4.29 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.431 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.692 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 22.3 pt -129.11 151.73 78.17 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.169 0.509 . . . . 0.0 111.556 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 25.4 Cg_exo -61.52 150.25 86.13 Favored 'Trans proline' 0 C--N 1.333 -0.275 0 C-N-CA 124.012 3.141 . . . . 0.0 112.537 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.415 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 2.6 m -57.09 146.05 28.87 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.81 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.401 ' C ' ' H ' ' A' ' 13' ' ' THR . 59.9 mt -89.05 -37.31 9.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.624 179.061 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.434 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 8.4 t -77.7 38.02 0.24 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.592 0.711 . . . . 0.0 111.006 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.401 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.7 OUTLIER -71.02 -25.73 62.8 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 177.635 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.3 mt -62.79 -41.54 99.31 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.829 -1.532 . . . . 0.0 110.536 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -74.31 -43.41 56.86 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.291 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.89 30.18 0.22 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.647 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.434 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.2 m -88.45 117.07 27.12 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.025 0.441 . . . . 0.0 110.189 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -104.47 147.73 27.25 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.572 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -77.95 112.97 15.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.505 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.452 ' O ' ' HD3' ' A' ' 20' ' ' LYS . 12.8 tmtt? -139.34 125.16 19.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.089 0.471 . . . . 0.0 110.949 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 58.54 33.59 23.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.089 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.791 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 10.5 mmpt? 71.64 0.83 3.64 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 115.355 -0.838 . . . . 0.0 111.646 -179.415 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.495 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 26.2 t -115.2 146.53 19.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.829 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.986 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.3 m -97.25 126.18 42.29 Favored 'General case' 0 C--N 1.312 -1.027 0 O-C-N 121.977 -0.452 . . . . 0.0 111.848 -178.602 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.495 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -127.26 152.07 47.9 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.172 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.592 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 29.6 ptt85 -116.33 150.44 37.67 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.339 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.644 ' HB3' HD13 ' A' ' 30' ' ' ILE . 1.8 t-20 59.71 34.05 21.98 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.692 0.62 . . . . 0.0 110.948 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.92 -88.38 0.53 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.376 -0.916 . . . . 0.0 113.339 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.8 m -128.68 32.87 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.021 0.748 . . . . 0.0 113.021 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.644 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.9 mp -94.3 110.8 50.66 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.041 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo . . . . . 0 C--O 1.232 0.184 0 C-N-CA 122.576 2.184 . . . . 0.0 113.691 -178.489 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.2 m . . . . . 0 CA--C 1.519 -0.231 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 94.61 -9.41 71.29 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.799 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 98.3 mt-10 -88.49 167.55 13.35 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.621 -0.789 . . . . 0.0 110.934 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -150.49 132.07 14.84 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.796 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.0 p -102.23 33.06 3.24 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.295 1.045 . . . . 0.0 109.37 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.541 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 45.7 t -62.48 -42.86 97.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.02 -1.445 . . . . 0.0 110.186 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -111.07 -40.35 4.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.099 179.197 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.796 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.0 pt -135.7 151.18 73.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.761 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 41.9 Cg_exo -57.19 154.6 33.28 Favored 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 124.128 3.219 . . . . 0.0 113.335 -179.445 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.469 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 7.0 m -59.76 150.2 28.72 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.585 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.3 mt -94.09 -46.23 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.201 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.543 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.54 44.12 0.51 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.645 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -62.93 -25.57 68.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.863 0.84 . . . . 0.0 108.926 178.293 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 66.3 mt -59.24 -37.68 78.15 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 113.925 -1.489 . . . . 0.0 110.893 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 15' ' ' LEU . 4.2 mm? -89.96 19.85 4.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.043 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 73.1 25.12 74.31 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.868 -0.605 . . . . 0.0 113.81 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 93.6 m -75.38 110.71 9.97 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.412 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 13.4 m -114.6 164.3 14.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.658 -178.113 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -71.17 82.04 0.71 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.109 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.607 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 41.5 tptt -94.03 102.36 14.43 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 62.94 34.3 14.25 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -177.705 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.541 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 10.6 mtpt 73.88 -3.94 2.39 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 114.203 -1.362 . . . . 0.0 111.801 -178.81 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.887 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 15.7 t -101.52 144.42 13.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 177.552 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.799 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 72.3 m -87.96 117.5 26.87 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.887 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.5 m-85 -126.84 151.14 48.75 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-N 115.204 -0.907 . . . . 0.0 108.579 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.506 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 11.8 ptp180 -112.98 156.62 22.72 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.555 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.783 ' HB3' HD13 ' A' ' 30' ' ' ILE . 1.7 t-20 55.77 34.54 23.62 Favored 'General case' 0 C--N 1.326 -0.414 0 O-C-N 123.771 0.669 . . . . 0.0 111.376 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.75 -63.06 0.68 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.648 -0.787 . . . . 0.0 114.812 178.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.8 m -146.35 38.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.311 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.783 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -102.88 114.58 65.17 Favored Pre-proline 0 C--N 1.324 -0.536 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.152 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.434 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.4 Cg_endo . . . . . 0 CA--C 1.528 0.213 0 C-N-CA 122.747 2.298 . . . . 0.0 113.884 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.435 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 63.2 m . . . . . 0 CA--C 1.518 -0.281 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.97 -7.3 58.84 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -177.497 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.888 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 95.9 mt-10 -88.44 166.3 14.32 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.01 -1.095 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -146.58 133.15 19.79 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 177.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.758 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 30.5 p -104.77 30.79 5.19 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 122.134 0.969 . . . . 0.0 109.896 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.545 HG22 ' HB3' ' A' ' 22' ' ' LYS . 46.4 t -68.3 -39.09 80.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 113.991 -1.459 . . . . 0.0 110.377 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -111.18 -39.77 4.64 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.103 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.758 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -139.01 151.79 68.77 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.611 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.9 Cg_exo -57.55 154.48 36.09 Favored 'Trans proline' 0 C--N 1.333 -0.271 0 C-N-CA 123.993 3.129 . . . . 0.0 112.865 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.411 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 11.4 m -57.6 151.28 17.38 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.661 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.402 ' C ' ' H ' ' A' ' 13' ' ' THR . 61.3 mt -93.72 -49.41 12.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.402 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.692 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.29 38.15 0.28 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.515 0.674 . . . . 0.0 110.895 -179.858 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.402 ' H ' ' C ' ' A' ' 11' ' ' ILE . 27.0 m -67.99 -26.09 65.74 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 177.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.1 mt -63.04 -38.87 92.93 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 113.93 -1.486 . . . . 0.0 110.466 178.556 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -76.83 -46.78 23.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.322 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.63 24.69 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.082 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.692 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 87.7 m -84.85 131.94 34.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.957 0.378 . . . . 0.0 110.165 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -139.01 160.2 40.33 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.041 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.4 m -62.17 113.49 2.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.487 0.661 . . . . 0.0 112.043 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.68 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 13.4 tppt? -131.69 104.75 7.09 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.323 178.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.8 t30 62.17 32.22 17.41 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.219 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.545 ' HB3' HG22 ' A' ' 6' ' ' VAL . 30.6 mtmm 82.35 -19.57 0.4 Allowed 'General case' 0 N--CA 1.477 0.89 0 CA-C-N 114.581 -1.19 . . . . 0.0 110.894 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.812 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.7 t -93.44 149.03 4.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.856 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.888 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 91.9 m -89.97 121.28 31.92 Favored 'General case' 0 C--N 1.312 -1.038 0 O-C-N 121.796 -0.565 . . . . 0.0 112.221 -178.163 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.812 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.8 m-85 -124.9 152.19 44.39 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.495 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 11.6 ptt180 -114.19 157.12 23.08 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.807 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.81 38.34 29.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.679 0.752 . . . . 0.0 110.803 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.494 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 87.68 -62.05 4.04 Favored Glycine 0 N--CA 1.447 -0.568 0 CA-C-N 115.719 -0.673 . . . . 0.0 114.681 178.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.09 41.38 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -178.047 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.472 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.1 mm -109.15 112.64 59.58 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.1 Cg_endo . . . . . 0 C--O 1.234 0.289 0 C-N-CA 122.568 2.179 . . . . 0.0 113.643 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 62.5 m . . . . . 0 CA--C 1.519 -0.22 0 CA-C-O 121.309 0.576 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.33 63.3 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -178.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.938 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.8 mt-10 -87.28 165.19 15.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 114.765 -0.718 . . . . 0.0 110.675 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.38 127.6 16.7 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.745 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 32.1 p -103.98 32.07 4.16 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-O 121.943 0.878 . . . . 0.0 110.208 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.443 HG22 ' HB3' ' A' ' 22' ' ' LYS . 46.3 t -66.12 -37.96 80.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 114.196 -1.365 . . . . 0.0 110.188 179.121 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -111.3 -40.45 4.41 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.087 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.745 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.1 pt -139.38 150.01 62.46 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.723 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 33.9 Cg_exo -58.94 152.2 59.91 Favored 'Trans proline' 0 C--N 1.334 -0.221 0 C-N-CA 124.049 3.166 . . . . 0.0 112.963 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.7 m -61.21 144.49 53.64 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.987 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 47.4 mm -93.0 -35.67 6.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.715 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.0 t -75.7 42.76 0.24 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.266 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 m -63.77 -26.21 68.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.006 0.908 . . . . 0.0 108.582 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.1 mt -59.34 -38.94 81.62 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 113.888 -1.506 . . . . 0.0 111.092 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -88.53 16.33 6.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.15 26.44 68.53 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.359 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.3 m -80.76 129.33 34.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 117.097 0.448 . . . . 0.0 109.959 179.078 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.8 t -140.45 166.87 23.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.442 -179.156 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 m -65.53 111.74 3.26 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.821 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.524 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtp? -133.86 105.1 6.59 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.413 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 44.8 t30 64.8 31.54 11.63 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.402 -178.351 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.443 ' HB3' HG22 ' A' ' 6' ' ' VAL . 31.0 mtmm 81.75 -20.28 0.37 Allowed 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 114.747 -1.115 . . . . 0.0 110.878 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.792 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.8 t -95.3 149.78 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.938 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -90.87 121.43 32.72 Favored 'General case' 0 C--N 1.313 -0.989 0 O-C-N 121.834 -0.541 . . . . 0.0 112.144 -178.311 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.792 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.4 m-85 -128.1 155.75 43.92 Favored 'General case' 0 CA--C 1.512 -0.486 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.43 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.5 ptt85 -119.0 158.65 25.36 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.118 178.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 57.96 31.9 21.24 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.216 0.532 . . . . 0.0 110.939 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.17 -50.08 4.24 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 114.704 0.642 . . . . 0.0 114.704 179.022 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.473 HG12 ' NZ ' ' A' ' 20' ' ' LYS . 16.4 m -141.13 38.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -177.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.43 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 47.3 mm -114.52 107.33 51.25 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.176 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 14.8 Cg_endo . . . . . 0 N--CA 1.465 -0.203 0 C-N-CA 122.81 2.34 . . . . 0.0 113.652 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 65.2 m . . . . . 0 CA--C 1.519 -0.243 0 CA-C-O 121.363 0.601 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.2 -4.49 64.96 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -178.2 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.855 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.0 mt-10 -87.88 163.33 16.45 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.878 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.07 127.3 30.08 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.322 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.681 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.4 p -107.45 32.36 4.73 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.055 0.931 . . . . 0.0 109.32 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.647 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.6 t -61.92 -43.77 97.95 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 114.096 -1.411 . . . . 0.0 110.942 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -110.08 -40.98 4.57 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.479 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.681 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 23.4 pt -130.04 154.22 81.2 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.323 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -59.12 153.08 54.72 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 123.975 3.116 . . . . 0.0 112.597 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 12.2 m -57.53 152.53 14.67 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.014 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 61.8 mt -95.77 -46.06 13.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.044 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.526 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.6 t -76.18 41.89 0.25 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.966 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.9 m -64.49 -23.46 67.29 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.8 mt -61.36 -37.52 83.66 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 114.074 -1.421 . . . . 0.0 110.379 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.432 HD13 ' HA ' ' A' ' 15' ' ' LEU . 4.0 mm? -89.38 15.05 9.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.563 179.414 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.446 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 77.43 26.44 61.36 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.711 -0.677 . . . . 0.0 113.766 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.5 m -79.73 112.48 17.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 117.425 0.613 . . . . 0.0 109.472 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 t -108.52 153.82 22.8 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.564 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.5 t -71.51 107.67 4.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.814 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.491 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 19.4 tptp -130.53 113.24 14.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.144 0.497 . . . . 0.0 111.205 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.438 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 5.8 t-20 60.22 35.54 20.94 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.431 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.77 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 9.9 mmpt? 74.45 -6.65 1.84 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.969 -1.014 . . . . 0.0 111.844 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.589 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.5 t -107.36 146.36 13.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.618 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.855 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 88.2 m -93.09 121.72 34.73 Favored 'General case' 0 C--N 1.315 -0.927 0 O-C-N 121.922 -0.486 . . . . 0.0 112.107 -178.344 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.589 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 21.8 m-85 -128.93 149.22 50.88 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.473 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 46.2 ptt85 -116.12 164.34 14.62 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.395 -0.821 . . . . 0.0 109.447 179.067 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 57.92 27.41 14.64 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 123.382 0.426 . . . . 0.0 111.442 179.3 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.85 -64.26 0.64 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.863 -0.685 . . . . 0.0 113.638 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.28 37.3 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.419 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.4 mm -101.93 112.74 65.69 Favored Pre-proline 0 C--N 1.323 -0.562 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.574 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo . . . . . 0 N--CA 1.464 -0.213 0 C-N-CA 122.662 2.242 . . . . 0.0 113.653 -178.682 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.0 m . . . . . 0 CA--C 1.518 -0.277 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 105.04 -7.62 44.54 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -177.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.807 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 99.5 mt-10 -88.66 171.24 10.15 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.434 -0.883 . . . . 0.0 111.083 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.1 m -148.61 135.73 20.13 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 178.074 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.754 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 23.6 p -107.66 29.54 7.12 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.202 1.001 . . . . 0.0 109.543 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.45 HG22 ' HB3' ' A' ' 22' ' ' LYS . 61.6 t -66.41 -39.56 84.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 113.77 -1.559 . . . . 0.0 110.72 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -110.47 -40.73 4.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.716 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.754 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.8 pt -139.38 152.5 69.33 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.673 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 31.7 Cg_exo -57.94 155.37 33.6 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 123.989 3.126 . . . . 0.0 113.054 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.439 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 5.9 m -59.44 149.57 29.1 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.482 -179.581 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 66.0 mt -96.96 -46.02 12.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.988 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.455 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -77.87 40.69 0.33 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.683 179.65 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.6 m -64.06 -23.09 67.2 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.065 0.936 . . . . 0.0 108.487 178.36 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.4 mt -61.58 -33.98 74.81 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.437 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 90.4 mt -94.52 23.3 5.38 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.738 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 74.18 26.24 68.97 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.651 -0.704 . . . . 0.0 114.332 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.2 m -82.68 131.09 35.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.652 0.726 . . . . 0.0 109.785 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.9 m -145.66 169.16 19.0 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.564 -178.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.5 m -63.2 106.31 0.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.982 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.472 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtm? -126.89 99.91 5.94 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.274 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.461 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 51.2 t30 65.58 33.27 8.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.792 -178.033 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 41.7 mtmt 80.22 -19.63 0.43 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 114.264 -1.335 . . . . 0.0 111.066 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.894 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -93.33 150.7 3.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.807 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 94.9 m -89.33 116.77 27.79 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 120.141 -0.624 . . . . 0.0 112.362 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.894 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -122.47 156.43 34.11 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.828 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.528 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 14.2 ptt180 -117.76 156.67 27.88 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.088 179.133 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 57.37 34.5 24.77 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.068 0.461 . . . . 0.0 111.304 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 81.61 -50.2 4.19 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 115.0 0.76 . . . . 0.0 115.0 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 m -143.08 41.16 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -178.042 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.486 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.3 mm -116.64 107.23 46.95 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.173 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo . . . . . 0 CA--C 1.528 0.207 0 C-N-CA 122.603 2.202 . . . . 0.0 113.627 -178.115 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 75.9 m . . . . . 0 CA--C 1.519 -0.236 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.31 -3.28 59.73 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.955 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 40.3 mt-10 -87.96 161.51 17.39 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.59 -0.805 . . . . 0.0 110.83 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.95 126.48 30.43 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.4 178.334 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.704 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 13.3 p -107.55 35.54 3.04 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.374 1.083 . . . . 0.0 109.055 179.486 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.46 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -64.94 -41.97 93.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 113.816 -1.538 . . . . 0.0 110.713 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -113.04 -39.91 4.09 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.156 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.704 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.6 pt -131.72 151.62 78.93 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.178 -179.026 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -60.24 152.14 68.52 Favored 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.953 3.102 . . . . 0.0 112.667 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -55.01 148.31 13.91 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 112.083 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.0 mt -89.18 -39.09 12.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.156 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.437 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 2.3 t -80.75 40.84 0.54 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.553 0.692 . . . . 0.0 110.696 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -70.4 -25.22 63.14 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.646 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.88 -41.23 97.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.902 -1.499 . . . . 0.0 110.451 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -74.33 -45.76 45.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.266 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 27.46 0.18 Allowed Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.537 -0.84 . . . . 0.0 112.979 179.156 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.437 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 90.2 m -84.86 113.28 21.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.377 0.608 . . . . 0.0 110.147 179.374 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 35.5 t -99.3 140.82 32.9 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.639 -179.308 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 45.9 t -70.79 117.97 12.99 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.989 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.417 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 0.3 OUTLIER -136.07 114.92 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.811 -179.257 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 34.8 t-20 59.17 31.87 21.6 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.643 0.735 . . . . 0.0 109.464 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.46 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 55.2 mttm 70.86 13.35 7.1 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.705 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -121.34 136.6 57.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 176.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.955 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 76.8 m -89.9 126.46 35.73 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.417 ' CD1' ' HB3' ' A' ' 20' ' ' LYS . 32.5 m-85 -131.51 147.65 52.56 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.702 178.487 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.586 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 20.2 ptt85 -111.79 155.23 23.88 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.421 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.748 ' HB3' HD13 ' A' ' 30' ' ' ILE . 0.1 OUTLIER 58.25 33.49 23.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -179.794 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.85 -76.74 0.23 Allowed Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.681 179.289 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.8 m -139.64 32.49 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.748 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -91.34 113.87 59.87 Favored Pre-proline 0 C--N 1.325 -0.473 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.121 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.802 2.335 . . . . 0.0 114.348 -178.102 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.9 m . . . . . 0 CA--C 1.516 -0.342 0 CA-C-O 121.396 0.617 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.6 -6.82 57.55 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -177.291 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.859 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 97.6 mt-10 -87.54 165.2 15.66 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.196 -1.002 . . . . 0.0 110.509 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.26 127.35 14.66 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.164 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.818 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 20.3 p -100.86 34.96 2.31 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 122.395 1.093 . . . . 0.0 109.296 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.893 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 40.2 t -63.13 -44.14 99.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 113.912 -1.494 . . . . 0.0 110.176 179.579 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -114.62 -39.7 3.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.957 179.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.818 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -128.6 149.83 72.98 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.853 -179.291 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 31.2 Cg_exo -58.93 158.57 24.42 Favored 'Trans proline' 0 C--N 1.332 -0.314 0 C-N-CA 124.142 3.228 . . . . 0.0 113.259 -179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.457 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 8.9 m -60.82 154.77 21.1 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.011 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 61.4 mt -100.42 -48.38 11.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.039 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.702 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.9 t -77.17 41.49 0.3 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.357 0.599 . . . . 0.0 111.304 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 28.5 m -67.86 -24.57 65.26 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 73.0 mt -60.49 -41.01 93.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 114.151 -1.386 . . . . 0.0 110.14 178.402 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.522 HD12 ' HD2' ' A' ' 26' ' ' ARG . 1.8 tm? -76.94 -42.62 38.56 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.35 20.33 0.15 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.175 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.702 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 71.2 m -78.68 126.34 30.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.193 0.52 . . . . 0.0 110.426 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -140.0 154.73 47.23 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.901 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.9 m -55.82 121.67 9.76 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -179.107 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.611 ' HB2' ' CD1' ' A' ' 25' ' ' TYR . 39.3 mmtm -140.47 106.06 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.669 177.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.46 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 0.1 OUTLIER 62.53 34.32 15.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.772 -177.777 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.893 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 30.0 mmmt 77.15 -17.05 0.59 Allowed 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.557 -1.202 . . . . 0.0 111.451 -178.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.856 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.0 t -92.45 153.99 3.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.859 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 99.2 m -96.81 123.84 40.62 Favored 'General case' 0 C--N 1.314 -0.945 0 O-C-N 121.372 -0.83 . . . . 0.0 112.327 -178.353 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.856 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.0 m-85 -126.52 153.86 44.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.219 178.632 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.559 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 28.9 ptt85 -116.59 156.32 27.21 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.952 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.763 ' HB3' HD13 ' A' ' 30' ' ' ILE . 0.1 OUTLIER 58.3 33.37 23.07 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.539 0.685 . . . . 0.0 110.888 179.888 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.47 -66.73 0.27 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.898 179.108 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 p -150.99 39.25 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-O 121.738 0.78 . . . . 0.0 112.209 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.763 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.1 mp -98.39 116.25 65.55 Favored Pre-proline 0 C--N 1.322 -0.596 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 177.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 CA--C 1.528 0.225 0 C-N-CA 122.816 2.344 . . . . 0.0 114.228 -178.049 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.54 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 57.4 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.68 -5.92 64.64 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.853 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.7 mt-10 -89.09 165.8 14.27 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.166 -1.017 . . . . 0.0 110.653 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.32 134.5 21.67 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.746 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 31.3 p -106.5 30.65 5.83 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 122.018 0.913 . . . . 0.0 109.925 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.421 HG22 ' HB3' ' A' ' 22' ' ' LYS . 47.2 t -66.53 -38.41 81.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.985 -1.461 . . . . 0.0 110.394 179.203 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -110.78 -40.28 4.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.988 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.746 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 15.6 pt -140.56 151.4 63.53 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.609 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.4 Cg_exo -57.42 152.4 47.17 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 124.112 3.208 . . . . 0.0 112.947 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.603 ' HB2' HG23 ' A' ' 13' ' ' THR . 3.7 m -58.2 148.16 27.94 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.536 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.1 mm -89.1 -41.16 13.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.161 179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.532 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.1 t -83.2 40.02 0.68 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.483 0.659 . . . . 0.0 110.416 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.603 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.6 OUTLIER -68.8 -27.64 66.05 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 177.886 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.68 -39.6 94.73 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 113.725 -1.579 . . . . 0.0 110.758 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -74.98 -47.36 29.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.634 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.22 20.76 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.983 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 82.1 m -85.42 130.54 34.56 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.358 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.8 t -137.02 168.36 19.74 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.588 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.5 m -67.48 100.36 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.821 -179.803 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.561 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.3 tmtp? -119.08 102.38 8.69 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.856 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.467 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 9.0 t-20 62.88 36.33 12.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.946 -1.024 . . . . 0.0 108.795 -177.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 7.7 mtmp? 79.31 -17.58 0.58 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.556 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.798 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 19.5 t -97.81 147.79 6.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.192 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.853 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 96.6 m -89.15 120.41 30.51 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -178.116 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.798 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.4 m-85 -127.67 154.09 45.7 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.406 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.54 ' CZ ' ' HA ' ' A' ' 1' ' ' CYS . 5.6 ptt180 -112.65 149.34 32.98 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.778 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 58.01 37.22 26.6 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.635 0.731 . . . . 0.0 110.11 -178.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 78.35 -48.19 3.08 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 115.523 0.969 . . . . 0.0 115.523 178.846 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.517 HG12 ' NZ ' ' A' ' 20' ' ' LYS . 18.5 m -138.59 35.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 114.887 1.44 . . . . 0.0 114.887 -177.288 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.453 ' HB ' ' HG3' ' A' ' 26' ' ' ARG . 63.1 mt -112.46 110.17 53.13 Favored Pre-proline 0 C--N 1.318 -0.797 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 177.392 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo . . . . . 0 C--O 1.232 0.204 0 C-N-CA 122.655 2.236 . . . . 0.0 113.458 -178.28 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.5 p . . . . . 0 N--CA 1.457 -0.122 0 CA-C-O 120.755 0.312 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 69.99 37.82 74.03 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.72 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.842 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 3.9 mm-40 -135.5 165.74 24.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.014 0.435 . . . . 0.0 110.271 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.55 126.4 8.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.508 178.411 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.685 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.7 p -106.2 36.74 2.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 122.383 1.087 . . . . 0.0 109.218 179.316 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.966 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 43.3 t -64.09 -44.3 97.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 113.854 -1.521 . . . . 0.0 110.751 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -104.12 -42.99 5.37 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.011 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.685 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.6 pt -138.1 156.07 74.12 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.104 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -55.91 150.18 47.67 Favored 'Trans proline' 0 C--O 1.234 0.275 0 C-N-CA 123.624 2.882 . . . . 0.0 112.487 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -58.92 146.0 39.34 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.127 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 47.5 mm -88.88 -39.82 12.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.731 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.63 40.64 0.24 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.25 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 80.0 m -68.93 -23.76 64.21 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.7 mt -61.72 -41.02 97.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.432 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -75.3 -42.1 55.46 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 137.78 28.94 0.28 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.635 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.731 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 67.4 m -75.28 100.74 4.46 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.088 0.471 . . . . 0.0 110.698 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.3 m -101.3 139.31 37.14 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.108 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.0 m -61.29 121.79 13.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.231 0.539 . . . . 0.0 111.561 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.729 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -142.87 110.67 5.89 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.158 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.445 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.3 t30 61.84 32.58 18.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 109.104 -178.303 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.966 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 77.45 -15.99 0.69 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.461 -179.232 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.511 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.4 t -94.07 152.76 3.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.842 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 62.2 m -98.3 128.01 44.52 Favored 'General case' 0 C--N 1.315 -0.896 0 O-C-N 121.451 -0.78 . . . . 0.0 111.99 -178.493 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.729 ' CD1' ' HB3' ' A' ' 20' ' ' LYS . 37.8 m-85 -128.14 154.65 45.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.392 178.737 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.465 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 34.9 ptt180 -113.78 154.97 26.49 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.78 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.58 35.55 26.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 0.0 110.745 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.76 -78.87 0.3 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.56 -0.829 . . . . 0.0 113.738 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.0 m -137.08 33.44 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.441 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -95.63 115.23 65.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.7 Cg_endo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.24 1.96 . . . . 0.0 111.781 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.9 p . . . . . 0 C--O 1.227 -0.086 0 CA-C-O 121.017 0.437 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 71.69 29.04 68.11 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.507 -0.77 . . . . 0.0 114.291 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.908 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 23.5 mt-10 -123.32 163.8 20.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.028 0.442 . . . . 0.0 110.415 178.473 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.34 126.14 16.12 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.557 178.454 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.721 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 4.9 p -102.17 34.27 2.78 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 122.381 1.086 . . . . 0.0 109.245 179.563 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.737 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 47.6 t -68.28 -40.62 82.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.637 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -109.67 -41.25 4.6 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.94 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.721 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.7 pt -137.74 152.89 73.42 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.462 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 36.7 Cg_exo -59.48 148.58 86.38 Favored 'Trans proline' 0 C--N 1.332 -0.309 0 C-N-CA 123.682 2.921 . . . . 0.0 112.432 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 m -54.46 147.05 14.64 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.857 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.4 mm -89.21 -44.43 15.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.904 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.589 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.03 39.14 0.49 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.444 0.64 . . . . 0.0 110.901 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 77.7 m -67.15 -25.44 66.17 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 177.777 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 69.2 mt -63.04 -41.28 99.46 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.533 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.49 -41.79 62.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.238 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.571 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 147.6 13.76 0.15 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.57 -0.824 . . . . 0.0 113.04 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.589 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 96.3 m -74.76 88.1 2.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.3 0.572 . . . . 0.0 110.835 179.733 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 58.9 p -88.32 135.45 33.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.839 179.486 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.5 t -64.3 119.33 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.445 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.434 ' HE2' ' HB2' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -136.44 117.78 14.64 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.524 -179.743 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.85 34.39 24.68 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 109.423 -179.304 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.737 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 15.4 mtpt 69.99 8.42 6.68 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.801 -179.29 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.415 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 24.8 t -116.87 143.36 27.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 177.419 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.908 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -95.95 127.53 42.05 Favored 'General case' 0 C--N 1.313 -0.991 0 O-C-N 121.434 -0.791 . . . . 0.0 112.865 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.415 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 18.9 m-85 -130.45 151.21 51.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.201 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.571 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 37.7 ptt180 -114.84 154.14 29.15 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.187 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.431 ' HB3' HD12 ' A' ' 30' ' ' ILE . 2.1 t-20 57.94 33.31 23.06 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 123.656 0.597 . . . . 0.0 111.135 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 111.64 -86.53 0.43 Allowed Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.956 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.7 m -134.57 32.46 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -179.051 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.459 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 62.4 mt -93.15 110.31 45.41 Favored Pre-proline 0 C--N 1.327 -0.399 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo . . . . . 0 C--N 1.341 0.155 0 C-N-CA 122.222 1.948 . . . . 0.0 112.02 -179.356 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 71.5 m . . . . . 0 CA--C 1.516 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.34 -6.08 65.62 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -177.482 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.651 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.4 mt-10 -87.6 164.3 16.14 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 114.277 -0.961 . . . . 0.0 110.484 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.444 ' HB3' HG23 ' A' ' 6' ' ' VAL . 0.9 OUTLIER -148.85 135.48 19.63 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.219 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.5 OUTLIER -105.25 26.21 9.66 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 122.644 1.211 . . . . 0.0 108.911 179.911 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.444 HG23 ' HB3' ' A' ' 4' ' ' SER . 55.4 t -55.41 -43.18 70.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.124 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -107.03 -42.87 4.78 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.255 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.64 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.7 pt -145.95 158.45 48.84 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.07 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -58.73 145.44 95.96 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 123.622 2.881 . . . . 0.0 111.832 179.514 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.589 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 24.1 m -75.23 161.28 29.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.196 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.442 ' C ' ' H ' ' A' ' 13' ' ' THR . 56.1 mt -87.34 -36.15 9.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.45 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.415 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 8.5 t -77.31 30.92 0.14 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.678 0.751 . . . . 0.0 111.36 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.442 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.8 OUTLIER -71.06 -26.85 63.25 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.194 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.4 mt -64.41 -41.18 96.77 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.558 178.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -71.42 -42.18 68.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.435 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 22.72 0.24 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.429 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.404 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -82.16 93.85 7.14 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.388 0.614 . . . . 0.0 110.385 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 m -88.27 139.21 30.73 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.897 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.471 ' SG ' ' HA ' ' A' ' 22' ' ' LYS . 50.2 t -75.66 116.37 16.3 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.106 0.479 . . . . 0.0 111.275 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -128.01 127.77 43.79 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 177.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 56.85 33.56 23.31 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-O 121.69 0.757 . . . . 0.0 109.103 -178.225 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.471 ' HA ' ' SG ' ' A' ' 19' ' ' CYS . 14.4 mmmm 69.9 6.56 5.8 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 114.798 -1.092 . . . . 0.0 111.964 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -117.79 138.77 47.4 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.651 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 7.3 m -89.35 129.49 35.87 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -177.86 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -130.94 152.5 50.19 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.125 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 30.7 ptt85 -116.17 154.31 30.25 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.888 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 59.52 33.39 22.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.842 0.829 . . . . 0.0 110.402 -179.318 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.41 -55.69 4.5 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 115.113 0.805 . . . . 0.0 115.113 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.7 m -140.47 38.19 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -177.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.0 mt -112.44 110.54 52.91 Favored Pre-proline 0 C--N 1.318 -0.774 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 177.685 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo . . . . . 0 N--CA 1.464 -0.207 0 C-N-CA 122.598 2.199 . . . . 0.0 113.316 -178.615 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.532 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 74.4 m . . . . . 0 CA--C 1.517 -0.315 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.03 -7.32 58.74 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -177.749 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.819 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 26.3 mt-10 -88.89 165.66 14.48 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.119 -1.04 . . . . 0.0 110.835 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -146.31 127.7 14.94 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.037 178.269 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.774 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.9 p -104.64 34.35 3.18 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.17 0.985 . . . . 0.0 109.488 179.484 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.907 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -62.14 -39.24 83.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.369 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -114.43 -40.26 3.66 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.146 179.483 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.774 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 17.5 pt -134.0 149.6 72.08 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.855 -179.234 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -56.62 152.85 38.89 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 124.255 3.303 . . . . 0.0 113.649 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.47 ' HB2' HG23 ' A' ' 13' ' ' THR . 4.2 m -60.1 149.94 31.02 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.592 -179.663 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 62.0 mt -89.6 -41.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.486 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.556 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.39 40.83 0.67 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.538 0.685 . . . . 0.0 110.67 179.876 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.47 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.7 OUTLIER -69.44 -27.11 64.97 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 177.682 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.5 mt -63.39 -40.64 97.78 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 113.773 -1.558 . . . . 0.0 110.62 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -73.51 -47.25 42.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.462 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.92 23.73 0.09 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.959 179.196 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.556 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 85.9 m -82.47 119.46 24.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.964 0.411 . . . . 0.0 110.165 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -116.61 156.1 27.6 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.937 -179.031 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.9 m -68.94 105.15 2.29 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.761 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.553 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 17.5 tptm -117.99 103.65 10.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.483 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 38.3 t-20 61.96 32.63 17.74 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -178.143 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.907 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 28.1 mttt 78.31 -10.38 1.36 Allowed 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.348 -1.296 . . . . 0.0 111.754 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.796 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -97.12 143.87 11.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.753 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.819 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 71.0 m -88.81 122.34 32.11 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -177.196 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.796 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 5.7 m-85 -129.66 151.71 49.96 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.03 177.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.664 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 7.0 ptt180 -116.29 157.07 25.53 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.568 179.324 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.611 ' HB2' HD13 ' A' ' 30' ' ' ILE . 73.4 m-20 58.82 34.43 23.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.135 0.493 . . . . 0.0 111.463 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.51 -56.99 3.47 Favored Glycine 0 N--CA 1.45 -0.426 0 N-CA-C 114.963 0.745 . . . . 0.0 114.963 178.44 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.2 m -145.62 38.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.664 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 1.9 mp -106.84 112.51 63.38 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.68 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo . . . . . 0 C--O 1.232 0.191 0 C-N-CA 122.665 2.243 . . . . 0.0 113.787 -178.33 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.9 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.27 -5.01 60.72 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 -178.211 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.935 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.4 mt-10 -88.21 162.79 16.47 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 114.66 -0.77 . . . . 0.0 110.691 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.26 128.4 20.86 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 177.36 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.712 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.3 p -102.46 31.84 3.86 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.924 0.869 . . . . 0.0 110.203 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.0 t -68.48 -38.97 80.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.393 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -106.77 -41.35 5.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.008 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.712 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.3 pt -142.7 152.18 58.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.604 -179.388 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 34.5 Cg_exo -58.86 150.93 68.44 Favored 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.915 3.077 . . . . 0.0 112.621 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.439 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.7 m -58.57 144.76 41.75 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.653 -179.503 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.7 mm -90.93 -37.96 10.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.461 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.6 t -75.95 40.48 0.2 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.227 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 p -66.19 -25.67 67.04 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.835 0.826 . . . . 0.0 108.801 177.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.34 -35.97 76.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.429 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -92.17 19.94 6.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.654 179.573 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 71.34 30.21 67.34 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.856 -0.611 . . . . 0.0 114.004 178.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 99.9 m -84.0 127.48 33.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 117.289 0.544 . . . . 0.0 109.915 178.709 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 41.2 m -139.25 164.87 28.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.95 -178.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -67.76 101.31 1.04 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.019 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.534 ' HE2' HG12 ' A' ' 29' ' ' VAL . 7.8 tmtm? -128.53 118.99 23.97 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.492 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.47 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 30.7 t30 62.63 39.04 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -178.722 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.47 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 17.5 pttp 56.53 27.67 12.67 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.787 -179.03 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.929 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 44.4 t -142.83 155.04 17.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.935 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 79.6 m -89.61 119.93 30.46 Favored 'General case' 0 C--N 1.313 -0.978 0 O-C-N 121.485 -0.76 . . . . 0.0 112.294 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.929 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -126.79 154.89 43.66 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.019 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.504 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 13.2 ptt180 -116.23 156.42 26.59 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.207 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 56.94 34.53 25.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.15 0.5 . . . . 0.0 111.29 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 83.86 -55.53 5.02 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 114.759 0.663 . . . . 0.0 114.759 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.534 HG12 ' HE2' ' A' ' 20' ' ' LYS . 10.8 m -139.8 40.48 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -178.011 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.504 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.5 mm -113.22 106.44 54.7 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo . . . . . 0 C--O 1.233 0.239 0 C-N-CA 122.883 2.389 . . . . 0.0 113.785 -178.172 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.561 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 58.4 m . . . . . 0 CA--C 1.517 -0.306 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.2 -7.44 56.71 Favored Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -177.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.851 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.4 mt-10 -88.01 165.22 15.34 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.116 -1.042 . . . . 0.0 110.68 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -145.28 131.9 19.9 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.744 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -108.7 31.89 5.29 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.201 1.001 . . . . 0.0 109.606 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.2 t -60.32 -43.3 93.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.076 -1.42 . . . . 0.0 110.239 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.73 -41.94 5.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.261 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.744 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -135.31 150.77 73.52 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.883 -179.194 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 52.6 Cg_exo -55.79 153.38 30.93 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 124.271 3.314 . . . . 0.0 113.773 -179.168 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 9.0 m -59.93 152.67 22.97 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.755 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.8 mt -93.71 -42.37 12.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.56 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.605 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.07 43.29 0.7 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.435 0.635 . . . . 0.0 110.714 179.909 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -68.0 -26.74 66.06 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.9 mt -62.43 -41.36 98.66 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.623 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.401 HD22 ' HA ' ' A' ' 15' ' ' LEU . 1.8 tm? -73.49 -43.95 58.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.304 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 140.69 26.08 0.22 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.819 179.176 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.605 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 77.1 m -82.95 121.24 26.73 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.853 0.358 . . . . 0.0 110.116 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 12.9 t -118.24 164.01 15.82 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 -178.71 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.7 m -73.36 74.05 1.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.644 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.679 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 13.2 tmtt? -89.15 103.79 16.39 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.457 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 23.4 t30 60.19 33.8 21.05 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.267 -178.611 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 22.9 mmtp 74.37 2.71 4.18 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.704 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.834 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -109.17 140.07 29.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.546 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.851 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 82.9 m -88.1 121.42 30.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -176.632 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.834 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -127.26 150.51 49.53 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 177.577 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.595 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 9.1 ptt180 -115.27 153.53 30.75 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.369 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.753 ' HB3' HD13 ' A' ' 30' ' ' ILE . 0.1 OUTLIER 58.79 36.81 24.95 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.361 0.6 . . . . 0.0 111.16 179.829 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.85 -62.53 0.79 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.581 -0.819 . . . . 0.0 114.663 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -150.58 37.36 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-O 121.674 0.749 . . . . 0.0 112.693 -178.117 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.753 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -100.06 112.19 63.56 Favored Pre-proline 0 C--N 1.323 -0.577 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 177.601 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 C--O 1.232 0.197 0 C-N-CA 122.628 2.219 . . . . 0.0 113.551 -178.391 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 30.3 p . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.718 0.294 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 111.09 -12.27 29.07 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.937 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.841 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 5.6 mm-40 -85.1 159.94 20.07 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.545 0.688 . . . . 0.0 111.151 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.79 134.77 30.69 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.853 -1.067 . . . . 0.0 109.13 178.538 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.702 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 15.1 p -115.91 34.13 5.13 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 122.088 0.947 . . . . 0.0 109.231 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.614 ' HA ' ' HB3' ' A' ' 22' ' ' LYS . 28.9 t -63.92 -40.46 89.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 113.881 -1.509 . . . . 0.0 111.244 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -114.53 -38.94 3.9 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.065 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.702 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -136.51 153.43 76.09 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.504 -179.267 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -58.52 148.66 79.97 Favored 'Trans proline' 0 C--N 1.332 -0.328 0 C-N-CA 123.717 2.945 . . . . 0.0 112.265 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -56.67 143.97 34.15 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.469 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 4.3 mp -89.75 -42.43 14.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.618 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.24 39.11 0.19 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.363 179.854 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 58.2 m -69.53 -23.42 63.59 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 177.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 77.2 mt -63.06 -40.83 98.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.489 178.528 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.455 HD22 ' HA ' ' A' ' 15' ' ' LEU . 1.0 OUTLIER -73.12 -39.72 65.51 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.396 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.46 23.87 0.44 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.535 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.618 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 89.7 m -76.64 98.06 4.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.094 0.473 . . . . 0.0 110.669 179.532 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.459 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 13.6 m -88.56 132.93 34.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.937 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.2 t -73.82 117.2 15.32 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.087 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.672 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 11.6 tmtt? -141.97 119.1 11.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.525 0.679 . . . . 0.0 110.843 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 55.07 37.17 28.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.3 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.614 ' HB3' ' HA ' ' A' ' 6' ' ' VAL . 26.3 mtmm 75.88 1.43 3.51 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.08 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.7 t -118.32 137.25 52.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.001 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.841 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 30.1 m -95.52 128.37 42.33 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.702 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.672 ' CE1' ' HD2' ' A' ' 20' ' ' LYS . 2.1 m-85 -122.35 163.54 19.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.653 179.429 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.5 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.2 ptt180 -131.94 155.51 47.79 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 61.79 31.55 18.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.305 0.574 . . . . 0.0 111.211 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 109.69 -71.93 0.2 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.536 -0.84 . . . . 0.0 113.931 178.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 p -150.23 36.85 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 122.069 0.938 . . . . 0.0 111.099 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.5 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.9 mm -101.17 113.83 65.8 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.407 178.434 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.5 Cg_endo . . . . . 0 N--CA 1.463 -0.268 0 C-N-CA 122.203 1.935 . . . . 0.0 111.4 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.473 ' HB3' ' HD3' ' A' ' 26' ' ' ARG . 1.7 p . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.018 0.437 . . . . 0.0 110.828 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.33 31.6 80.98 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.491 -0.777 . . . . 0.0 113.166 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.88 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.5 mt-10 -124.42 165.93 16.88 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.074 0.464 . . . . 0.0 110.4 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.89 134.07 17.19 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.771 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.7 p -107.45 31.29 5.53 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 122.36 1.076 . . . . 0.0 109.605 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.902 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 46.7 t -61.72 -44.47 98.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 113.933 -1.485 . . . . 0.0 110.177 179.475 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -104.66 -43.59 5.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.158 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.771 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.5 pt -136.09 153.8 77.03 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.003 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 51.4 Cg_exo -55.45 153.98 26.34 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 124.11 3.207 . . . . 0.0 113.379 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.62 ' HB2' HG23 ' A' ' 13' ' ' THR . 7.3 m -58.69 149.74 25.31 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.698 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.406 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.2 mp -89.53 -46.35 15.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.859 179.324 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.694 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -79.24 41.24 0.45 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.442 0.639 . . . . 0.0 110.539 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.62 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.6 OUTLIER -68.61 -26.5 65.39 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.8 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.4 mt -61.98 -40.93 97.29 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 113.81 -1.541 . . . . 0.0 110.453 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -75.36 -46.33 33.82 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.455 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.58 26.38 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.543 -0.836 . . . . 0.0 113.259 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.694 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.1 m -80.35 120.96 25.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 117.169 0.485 . . . . 0.0 110.006 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.5 m -119.12 159.79 23.31 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.181 -178.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.2 m -69.35 84.96 0.4 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.752 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.57 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 46.7 tptt -96.66 98.4 10.15 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.596 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 38.7 t-20 60.94 33.52 19.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.395 -0.82 . . . . 0.0 108.811 -178.362 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.902 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 40.4 mmtt 82.29 -10.99 1.05 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.319 -1.309 . . . . 0.0 112.414 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.823 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -99.22 141.45 16.64 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.165 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.88 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 73.1 m -89.65 122.54 32.87 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.823 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -127.43 151.07 49.29 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.726 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.473 ' HD3' ' HB3' ' A' ' 1' ' ' CYS . 28.1 ptt180 -112.24 153.61 26.86 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.115 179.876 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.3 t30 60.12 33.49 21.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.287 0.565 . . . . 0.0 111.264 179.709 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.89 -64.59 0.73 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.621 -0.8 . . . . 0.0 114.615 178.672 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.3 m -143.12 33.59 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.437 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 59.0 mt -101.56 108.42 55.54 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo . . . . . 0 N--CA 1.464 -0.238 0 C-N-CA 122.212 1.942 . . . . 0.0 112.347 -179.09 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 CA--C 1.516 -0.362 0 CA-C-O 121.372 0.606 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.48 -5.75 67.63 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -177.539 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.638 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 21.2 mt-10 -87.25 160.11 18.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 114.494 -0.853 . . . . 0.0 110.387 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.425 ' HA ' ' HA ' ' A' ' 23' ' ' VAL . 0.7 OUTLIER -144.46 133.36 22.58 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.471 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.488 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.7 OUTLIER -98.68 26.97 5.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 122.157 0.98 . . . . 0.0 109.905 -179.572 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.7 t -61.03 -39.74 83.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 114.26 -1.336 . . . . 0.0 111.715 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -108.33 -42.03 4.71 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.44 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.488 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 13.5 pt -149.96 159.38 35.74 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.679 -178.688 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -59.55 143.6 99.64 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 123.342 2.695 . . . . 0.0 111.302 179.17 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.538 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 18.2 m -71.18 161.42 31.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.79 -178.229 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 57.8 mt -87.03 -40.01 13.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.356 -0.838 . . . . 0.0 112.711 -178.082 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.594 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 3.1 t -79.32 35.87 0.28 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.714 0.768 . . . . 0.0 111.345 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -70.52 -25.12 62.98 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 177.419 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 81.0 mt -63.86 -42.85 97.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 113.898 -1.501 . . . . 0.0 110.716 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -71.43 -43.31 66.97 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.584 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.465 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 144.46 20.66 0.17 Allowed Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.697 179.256 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -77.8 83.75 4.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.401 0.619 . . . . 0.0 110.425 179.491 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.4 m -86.18 136.2 33.29 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.454 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.6 t -68.6 127.94 34.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.162 0.506 . . . . 0.0 111.222 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -144.99 130.24 18.6 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.746 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 31.2 t30 56.81 38.93 29.79 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.304 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.746 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 2.1 pttm 60.84 13.3 4.34 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.156 1.382 . . . . 0.0 112.115 -179.159 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 4' ' ' SER . 58.5 t -128.31 141.62 46.01 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.638 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 1.7 m -88.93 131.67 35.04 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.034 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -132.45 146.27 51.82 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.17 -0.923 . . . . 0.0 108.853 177.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.465 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 41.4 ptt85 -110.53 157.84 19.19 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.305 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 57.62 30.81 19.4 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.672 0.607 . . . . 0.0 111.256 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.59 -74.5 0.22 Allowed Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.548 -0.834 . . . . 0.0 113.462 179.283 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.51 32.52 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.423 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -92.44 113.1 58.35 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.197 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo . . . . . 0 N--CA 1.464 -0.227 0 C-N-CA 122.704 2.269 . . . . 0.0 113.558 -178.459 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.9 m . . . . . 0 CA--C 1.517 -0.313 0 CA-C-O 121.275 0.56 . . . . 0.0 109.721 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.21 -2.64 63.57 Favored Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.95 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 41.2 mt-10 -86.93 158.92 19.19 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.774 -0.713 . . . . 0.0 110.422 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.54 125.64 29.32 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.156 178.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.665 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.6 p -103.13 34.81 2.75 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 122.368 1.08 . . . . 0.0 109.047 179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.936 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 47.7 t -66.53 -42.93 90.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 113.759 -1.564 . . . . 0.0 110.667 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -109.34 -40.95 4.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.665 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.3 pt -134.89 153.08 78.44 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.063 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_exo -60.63 150.54 81.49 Favored 'Trans proline' 0 C--N 1.332 -0.331 0 C-N-CA 123.855 3.037 . . . . 0.0 112.27 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.478 ' HB2' HG23 ' A' ' 13' ' ' THR . 2.5 m -53.71 146.08 14.26 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.786 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.41 ' N ' HD12 ' A' ' 11' ' ' ILE . 4.1 mp -88.2 -39.9 13.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.837 179.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.414 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.4 40.19 0.63 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.608 0.718 . . . . 0.0 110.514 179.421 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.478 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.5 OUTLIER -68.48 -26.5 65.51 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.798 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 75.8 mt -63.16 -39.95 96.15 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.831 -1.531 . . . . 0.0 110.493 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.2 tm? -72.91 -40.43 65.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.236 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 139.86 13.47 0.61 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.414 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.6 m -75.52 105.14 6.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.359 0.599 . . . . 0.0 110.346 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.5 m -97.3 143.32 28.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.737 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.85 115.93 12.74 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.953 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.3 ttmm -140.73 121.71 14.59 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.818 0.342 . . . . 0.0 110.945 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 42.3 t30 60.06 34.12 21.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.674 0.749 . . . . 0.0 109.583 -179.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.936 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 69.46 6.55 5.75 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.757 -179.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.482 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.6 t -119.29 144.33 28.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.098 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.95 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -94.68 127.55 40.73 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 -177.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.482 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 16.4 m-85 -132.41 148.42 52.41 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.093 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.402 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 26.6 ptt180 -109.81 158.12 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.587 178.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 55.67 35.58 25.54 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.687 0.756 . . . . 0.0 110.748 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.17 -60.34 3.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.849 -0.691 . . . . 0.0 114.781 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.9 m -140.44 34.88 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -178.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 51.0 mm -103.03 110.28 63.26 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 177.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.1 Cg_endo . . . . . 0 N--CA 1.464 -0.252 0 C-N-CA 122.578 2.185 . . . . 0.0 113.389 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.5 m . . . . . 0 CA--C 1.518 -0.262 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.0 -3.96 60.68 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.961 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.6 mt-10 -88.14 164.77 15.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.617 -0.792 . . . . 0.0 111.059 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.97 126.34 15.77 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 177.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.726 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -105.34 34.27 3.32 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 122.275 1.036 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.964 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 44.3 t -61.98 -44.2 98.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 114.092 -1.413 . . . . 0.0 110.099 179.326 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -105.65 -42.62 5.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.207 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.726 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.3 pt -135.65 150.75 72.86 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 -179.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -57.84 154.6 37.1 Favored 'Trans proline' 0 N--CA 1.473 0.296 0 C-N-CA 124.243 3.296 . . . . 0.0 113.35 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.482 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.8 m -61.01 145.3 51.22 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.257 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.2 mt -93.98 -35.32 6.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.955 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -76.83 44.33 0.38 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.018 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.7 m -64.23 -25.78 68.22 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.4 mt -59.72 -36.87 77.43 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.003 -1.453 . . . . 0.0 110.995 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -89.59 16.82 7.14 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.839 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 71.44 28.95 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.508 179.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 80.7 m -80.57 128.18 33.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.04 0.42 . . . . 0.0 110.135 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -133.14 155.51 49.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 47.9 m -62.5 118.47 7.6 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.998 -0.546 . . . . 0.0 112.184 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.663 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 12.7 tppt? -132.76 101.63 5.35 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.587 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.546 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 46.6 t30 61.54 34.31 17.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.873 -178.005 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.964 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 46.0 mmtt 80.73 -16.52 0.64 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.15 -1.387 . . . . 0.0 112.157 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.679 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.4 t -94.88 143.13 12.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 177.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.961 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -89.29 124.25 34.24 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 112.673 0.62 . . . . 0.0 112.673 -177.505 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.679 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 12.1 m-85 -130.03 150.22 51.4 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.46 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 23.1 ptt180 -112.28 161.01 17.08 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.854 179.383 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 55.55 33.14 20.5 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.187 0.518 . . . . 0.0 111.406 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.449 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 95.43 -64.05 1.35 Allowed Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.812 -0.708 . . . . 0.0 113.963 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.2 m -142.78 37.73 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 112.909 0.707 . . . . 0.0 112.909 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.46 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 49.6 mm -101.17 112.13 64.55 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 178.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 10.7 Cg_endo . . . . . 0 C--O 1.231 0.15 0 C-N-CA 122.932 2.422 . . . . 0.0 113.963 -178.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.2 m . . . . . 0 CA--C 1.517 -0.319 0 CA-C-O 121.345 0.593 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.71 -3.77 53.24 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 109.751 -1.339 . . . . 0.0 109.751 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.986 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.1 mt-10 -86.84 161.61 18.23 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 114.659 -0.771 . . . . 0.0 110.546 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -135.19 124.62 24.87 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.802 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.692 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.8 p -105.84 33.33 3.82 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 122.048 0.928 . . . . 0.0 109.503 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.703 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 36.9 t -61.43 -44.06 97.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.768 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -112.34 -39.89 4.29 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.431 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.692 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 22.3 pt -129.11 151.73 78.17 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.169 0.509 . . . . 0.0 111.556 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 25.4 Cg_exo -61.52 150.25 86.13 Favored 'Trans proline' 0 C--N 1.333 -0.275 0 C-N-CA 124.012 3.141 . . . . 0.0 112.537 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.415 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 2.6 m -57.09 146.05 28.87 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.81 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.401 ' C ' ' H ' ' A' ' 13' ' ' THR . 59.9 mt -89.05 -37.31 9.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.624 179.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.434 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 8.4 t -77.7 38.02 0.24 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.592 0.711 . . . . 0.0 111.006 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.401 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.7 OUTLIER -71.02 -25.73 62.8 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 177.635 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.3 mt -62.79 -41.54 99.31 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.829 -1.532 . . . . 0.0 110.536 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -74.31 -43.41 56.86 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.291 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.89 30.18 0.22 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.647 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.434 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.2 m -88.45 117.07 27.12 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.025 0.441 . . . . 0.0 110.189 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -104.47 147.73 27.25 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.572 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -77.95 112.97 15.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.505 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.452 ' O ' ' HD3' ' A' ' 20' ' ' LYS . 12.8 tmtt? -139.34 125.16 19.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.089 0.471 . . . . 0.0 110.949 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 58.54 33.59 23.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.089 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.791 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 10.5 mmpt? 71.64 0.83 3.64 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 115.355 -0.838 . . . . 0.0 111.646 -179.415 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.495 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 26.2 t -115.2 146.53 19.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.986 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.3 m -97.25 126.18 42.29 Favored 'General case' 0 C--N 1.312 -1.027 0 O-C-N 121.977 -0.452 . . . . 0.0 111.848 -178.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.495 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -127.26 152.07 47.9 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.172 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.592 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 29.6 ptt85 -116.33 150.44 37.67 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.339 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.644 ' HB3' HD13 ' A' ' 30' ' ' ILE . 1.8 t-20 59.71 34.05 21.98 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.692 0.62 . . . . 0.0 110.948 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.92 -88.38 0.53 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.376 -0.916 . . . . 0.0 113.339 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.8 m -128.68 32.87 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.021 0.748 . . . . 0.0 113.021 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.644 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.9 mp -94.3 110.8 50.66 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.041 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo . . . . . 0 C--O 1.232 0.184 0 C-N-CA 122.576 2.184 . . . . 0.0 113.691 -178.489 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.2 m . . . . . 0 CA--C 1.519 -0.231 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 94.61 -9.41 71.29 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.799 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 98.3 mt-10 -88.49 167.55 13.35 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.621 -0.789 . . . . 0.0 110.934 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -150.49 132.07 14.84 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.796 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.0 p -102.23 33.06 3.24 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.295 1.045 . . . . 0.0 109.37 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.541 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 45.7 t -62.48 -42.86 97.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.02 -1.445 . . . . 0.0 110.186 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -111.07 -40.35 4.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.099 179.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.796 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.0 pt -135.7 151.18 73.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.761 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 41.9 Cg_exo -57.19 154.6 33.28 Favored 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 124.128 3.219 . . . . 0.0 113.335 -179.445 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.469 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 7.0 m -59.76 150.2 28.72 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.585 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.3 mt -94.09 -46.23 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.201 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.543 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.54 44.12 0.51 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.645 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -62.93 -25.57 68.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.863 0.84 . . . . 0.0 108.926 178.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 66.3 mt -59.24 -37.68 78.15 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 113.925 -1.489 . . . . 0.0 110.893 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 15' ' ' LEU . 4.2 mm? -89.96 19.85 4.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.043 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 73.1 25.12 74.31 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.868 -0.605 . . . . 0.0 113.81 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 93.6 m -75.38 110.71 9.97 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.412 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 13.4 m -114.6 164.3 14.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.658 -178.113 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -71.17 82.04 0.71 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.109 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.607 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 41.5 tptt -94.03 102.36 14.43 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 62.94 34.3 14.25 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -177.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.541 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 10.6 mtpt 73.88 -3.94 2.39 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 114.203 -1.362 . . . . 0.0 111.801 -178.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.887 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 15.7 t -101.52 144.42 13.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 177.552 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.799 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 72.3 m -87.96 117.5 26.87 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.887 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.5 m-85 -126.84 151.14 48.75 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-N 115.204 -0.907 . . . . 0.0 108.579 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.506 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 11.8 ptp180 -112.98 156.62 22.72 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.555 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.783 ' HB3' HD13 ' A' ' 30' ' ' ILE . 1.7 t-20 55.77 34.54 23.62 Favored 'General case' 0 C--N 1.326 -0.414 0 O-C-N 123.771 0.669 . . . . 0.0 111.376 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.75 -63.06 0.68 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.648 -0.787 . . . . 0.0 114.812 178.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.8 m -146.35 38.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.783 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -102.88 114.58 65.17 Favored Pre-proline 0 C--N 1.324 -0.536 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.152 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.434 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.4 Cg_endo . . . . . 0 CA--C 1.528 0.213 0 C-N-CA 122.747 2.298 . . . . 0.0 113.884 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.435 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 63.2 m . . . . . 0 CA--C 1.518 -0.281 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.97 -7.3 58.84 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -177.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.888 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 95.9 mt-10 -88.44 166.3 14.32 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.01 -1.095 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -146.58 133.15 19.79 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 177.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.758 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 30.5 p -104.77 30.79 5.19 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 122.134 0.969 . . . . 0.0 109.896 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.545 HG22 ' HB3' ' A' ' 22' ' ' LYS . 46.4 t -68.3 -39.09 80.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 113.991 -1.459 . . . . 0.0 110.377 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -111.18 -39.77 4.64 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.103 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.758 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -139.01 151.79 68.77 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.611 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.9 Cg_exo -57.55 154.48 36.09 Favored 'Trans proline' 0 C--N 1.333 -0.271 0 C-N-CA 123.993 3.129 . . . . 0.0 112.865 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.411 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 11.4 m -57.6 151.28 17.38 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.661 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.402 ' C ' ' H ' ' A' ' 13' ' ' THR . 61.3 mt -93.72 -49.41 12.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.402 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.692 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.29 38.15 0.28 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.515 0.674 . . . . 0.0 110.895 -179.858 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.402 ' H ' ' C ' ' A' ' 11' ' ' ILE . 27.0 m -67.99 -26.09 65.74 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 177.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.1 mt -63.04 -38.87 92.93 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 113.93 -1.486 . . . . 0.0 110.466 178.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -76.83 -46.78 23.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.322 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.63 24.69 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.082 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.692 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 87.7 m -84.85 131.94 34.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.957 0.378 . . . . 0.0 110.165 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -139.01 160.2 40.33 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.041 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.4 m -62.17 113.49 2.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.487 0.661 . . . . 0.0 112.043 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.68 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 13.4 tppt? -131.69 104.75 7.09 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.323 178.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.8 t30 62.17 32.22 17.41 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.219 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.545 ' HB3' HG22 ' A' ' 6' ' ' VAL . 30.6 mtmm 82.35 -19.57 0.4 Allowed 'General case' 0 N--CA 1.477 0.89 0 CA-C-N 114.581 -1.19 . . . . 0.0 110.894 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.812 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.7 t -93.44 149.03 4.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.888 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 91.9 m -89.97 121.28 31.92 Favored 'General case' 0 C--N 1.312 -1.038 0 O-C-N 121.796 -0.565 . . . . 0.0 112.221 -178.163 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.812 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.8 m-85 -124.9 152.19 44.39 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.495 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 11.6 ptt180 -114.19 157.12 23.08 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.807 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 55.81 38.34 29.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.679 0.752 . . . . 0.0 110.803 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.494 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 87.68 -62.05 4.04 Favored Glycine 0 N--CA 1.447 -0.568 0 CA-C-N 115.719 -0.673 . . . . 0.0 114.681 178.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.09 41.38 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -178.047 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.472 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.1 mm -109.15 112.64 59.58 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.1 Cg_endo . . . . . 0 C--O 1.234 0.289 0 C-N-CA 122.568 2.179 . . . . 0.0 113.643 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 62.5 m . . . . . 0 CA--C 1.519 -0.22 0 CA-C-O 121.309 0.576 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.33 63.3 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -178.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.938 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.8 mt-10 -87.28 165.19 15.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 114.765 -0.718 . . . . 0.0 110.675 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.38 127.6 16.7 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.745 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 32.1 p -103.98 32.07 4.16 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-O 121.943 0.878 . . . . 0.0 110.208 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.443 HG22 ' HB3' ' A' ' 22' ' ' LYS . 46.3 t -66.12 -37.96 80.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 114.196 -1.365 . . . . 0.0 110.188 179.121 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -111.3 -40.45 4.41 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.087 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.745 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.1 pt -139.38 150.01 62.46 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.723 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 33.9 Cg_exo -58.94 152.2 59.91 Favored 'Trans proline' 0 C--N 1.334 -0.221 0 C-N-CA 124.049 3.166 . . . . 0.0 112.963 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.7 m -61.21 144.49 53.64 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.987 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 47.4 mm -93.0 -35.67 6.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.715 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.0 t -75.7 42.76 0.24 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.266 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 m -63.77 -26.21 68.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.006 0.908 . . . . 0.0 108.582 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.1 mt -59.34 -38.94 81.62 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 113.888 -1.506 . . . . 0.0 111.092 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -88.53 16.33 6.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.15 26.44 68.53 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.359 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.3 m -80.76 129.33 34.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 117.097 0.448 . . . . 0.0 109.959 179.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.8 t -140.45 166.87 23.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.442 -179.156 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 m -65.53 111.74 3.26 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.821 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.524 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtp? -133.86 105.1 6.59 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.413 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 44.8 t30 64.8 31.54 11.63 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.402 -178.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.443 ' HB3' HG22 ' A' ' 6' ' ' VAL . 31.0 mtmm 81.75 -20.28 0.37 Allowed 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 114.747 -1.115 . . . . 0.0 110.878 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.792 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.8 t -95.3 149.78 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.938 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -90.87 121.43 32.72 Favored 'General case' 0 C--N 1.313 -0.989 0 O-C-N 121.834 -0.541 . . . . 0.0 112.144 -178.311 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.792 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.4 m-85 -128.1 155.75 43.92 Favored 'General case' 0 CA--C 1.512 -0.486 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.43 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.5 ptt85 -119.0 158.65 25.36 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.118 178.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 57.96 31.9 21.24 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.216 0.532 . . . . 0.0 110.939 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.17 -50.08 4.24 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 114.704 0.642 . . . . 0.0 114.704 179.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.473 HG12 ' NZ ' ' A' ' 20' ' ' LYS . 16.4 m -141.13 38.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -177.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.43 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 47.3 mm -114.52 107.33 51.25 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.176 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 14.8 Cg_endo . . . . . 0 N--CA 1.465 -0.203 0 C-N-CA 122.81 2.34 . . . . 0.0 113.652 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 65.2 m . . . . . 0 CA--C 1.519 -0.243 0 CA-C-O 121.363 0.601 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.2 -4.49 64.96 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -178.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.855 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.0 mt-10 -87.88 163.33 16.45 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.878 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.07 127.3 30.08 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.322 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.681 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.4 p -107.45 32.36 4.73 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.055 0.931 . . . . 0.0 109.32 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.647 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.6 t -61.92 -43.77 97.95 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 114.096 -1.411 . . . . 0.0 110.942 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -110.08 -40.98 4.57 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.479 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.681 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 23.4 pt -130.04 154.22 81.2 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.323 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -59.12 153.08 54.72 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 123.975 3.116 . . . . 0.0 112.597 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 12.2 m -57.53 152.53 14.67 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.014 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 61.8 mt -95.77 -46.06 13.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.044 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.526 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.6 t -76.18 41.89 0.25 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.966 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.9 m -64.49 -23.46 67.29 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.8 mt -61.36 -37.52 83.66 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 114.074 -1.421 . . . . 0.0 110.379 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.432 HD13 ' HA ' ' A' ' 15' ' ' LEU . 4.0 mm? -89.38 15.05 9.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.563 179.414 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.446 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 77.43 26.44 61.36 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.711 -0.677 . . . . 0.0 113.766 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.5 m -79.73 112.48 17.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 117.425 0.613 . . . . 0.0 109.472 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 t -108.52 153.82 22.8 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.564 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.5 t -71.51 107.67 4.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.814 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.491 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 19.4 tptp -130.53 113.24 14.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.144 0.497 . . . . 0.0 111.205 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.438 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 5.8 t-20 60.22 35.54 20.94 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.431 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.77 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 9.9 mmpt? 74.45 -6.65 1.84 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.969 -1.014 . . . . 0.0 111.844 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.589 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.5 t -107.36 146.36 13.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.855 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 88.2 m -93.09 121.72 34.73 Favored 'General case' 0 C--N 1.315 -0.927 0 O-C-N 121.922 -0.486 . . . . 0.0 112.107 -178.344 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.589 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 21.8 m-85 -128.93 149.22 50.88 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.473 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 46.2 ptt85 -116.12 164.34 14.62 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.395 -0.821 . . . . 0.0 109.447 179.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 11.2 m120 57.92 27.41 14.64 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 123.382 0.426 . . . . 0.0 111.442 179.3 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.85 -64.26 0.64 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.863 -0.685 . . . . 0.0 113.638 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.28 37.3 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.419 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.4 mm -101.93 112.74 65.69 Favored Pre-proline 0 C--N 1.323 -0.562 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.574 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo . . . . . 0 N--CA 1.464 -0.213 0 C-N-CA 122.662 2.242 . . . . 0.0 113.653 -178.682 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.0 m . . . . . 0 CA--C 1.518 -0.277 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 105.04 -7.62 44.54 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -177.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.807 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 99.5 mt-10 -88.66 171.24 10.15 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.434 -0.883 . . . . 0.0 111.083 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.1 m -148.61 135.73 20.13 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 178.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.754 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 23.6 p -107.66 29.54 7.12 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.202 1.001 . . . . 0.0 109.543 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.45 HG22 ' HB3' ' A' ' 22' ' ' LYS . 61.6 t -66.41 -39.56 84.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 113.77 -1.559 . . . . 0.0 110.72 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -110.47 -40.73 4.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.716 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.754 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.8 pt -139.38 152.5 69.33 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.673 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 31.7 Cg_exo -57.94 155.37 33.6 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 123.989 3.126 . . . . 0.0 113.054 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.439 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 5.9 m -59.44 149.57 29.1 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.482 -179.581 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 66.0 mt -96.96 -46.02 12.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.988 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.455 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -77.87 40.69 0.33 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.683 179.65 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.6 m -64.06 -23.09 67.2 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.065 0.936 . . . . 0.0 108.487 178.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.4 mt -61.58 -33.98 74.81 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.437 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 90.4 mt -94.52 23.3 5.38 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.738 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 74.18 26.24 68.97 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.651 -0.704 . . . . 0.0 114.332 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.2 m -82.68 131.09 35.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.652 0.726 . . . . 0.0 109.785 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.9 m -145.66 169.16 19.0 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.564 -178.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.5 m -63.2 106.31 0.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.982 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.472 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtm? -126.89 99.91 5.94 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.461 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 51.2 t30 65.58 33.27 8.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.792 -178.033 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 41.7 mtmt 80.22 -19.63 0.43 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 114.264 -1.335 . . . . 0.0 111.066 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.894 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -93.33 150.7 3.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.807 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 94.9 m -89.33 116.77 27.79 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 120.141 -0.624 . . . . 0.0 112.362 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.894 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -122.47 156.43 34.11 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.828 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.528 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 14.2 ptt180 -117.76 156.67 27.88 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.088 179.133 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 57.37 34.5 24.77 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.068 0.461 . . . . 0.0 111.304 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 81.61 -50.2 4.19 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 115.0 0.76 . . . . 0.0 115.0 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 m -143.08 41.16 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -178.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.486 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.3 mm -116.64 107.23 46.95 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.173 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo . . . . . 0 CA--C 1.528 0.207 0 C-N-CA 122.603 2.202 . . . . 0.0 113.627 -178.115 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 75.9 m . . . . . 0 CA--C 1.519 -0.236 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.31 -3.28 59.73 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.955 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 40.3 mt-10 -87.96 161.51 17.39 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.59 -0.805 . . . . 0.0 110.83 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.95 126.48 30.43 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.4 178.334 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.704 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 13.3 p -107.55 35.54 3.04 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.374 1.083 . . . . 0.0 109.055 179.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.46 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -64.94 -41.97 93.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 113.816 -1.538 . . . . 0.0 110.713 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -113.04 -39.91 4.09 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.156 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.704 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.6 pt -131.72 151.62 78.93 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.178 -179.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -60.24 152.14 68.52 Favored 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.953 3.102 . . . . 0.0 112.667 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -55.01 148.31 13.91 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 112.083 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.0 mt -89.18 -39.09 12.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.156 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.437 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 2.3 t -80.75 40.84 0.54 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.553 0.692 . . . . 0.0 110.696 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -70.4 -25.22 63.14 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.88 -41.23 97.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.902 -1.499 . . . . 0.0 110.451 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -74.33 -45.76 45.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.266 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 27.46 0.18 Allowed Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.537 -0.84 . . . . 0.0 112.979 179.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.437 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 90.2 m -84.86 113.28 21.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.377 0.608 . . . . 0.0 110.147 179.374 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 35.5 t -99.3 140.82 32.9 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.639 -179.308 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 45.9 t -70.79 117.97 12.99 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.989 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.417 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 0.3 OUTLIER -136.07 114.92 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.811 -179.257 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 59.17 31.87 21.6 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.643 0.735 . . . . 0.0 109.464 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.46 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 55.2 mttm 70.86 13.35 7.1 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.705 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -121.34 136.6 57.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 176.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.955 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 76.8 m -89.9 126.46 35.73 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.417 ' CD1' ' HB3' ' A' ' 20' ' ' LYS . 32.5 m-85 -131.51 147.65 52.56 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.702 178.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.586 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 20.2 ptt85 -111.79 155.23 23.88 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.421 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.748 ' HB3' HD13 ' A' ' 30' ' ' ILE . 3.8 t-20 58.25 33.49 23.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.85 -76.74 0.23 Allowed Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.681 179.289 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.8 m -139.64 32.49 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.748 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -91.34 113.87 59.87 Favored Pre-proline 0 C--N 1.325 -0.473 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.802 2.335 . . . . 0.0 114.348 -178.102 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.9 m . . . . . 0 CA--C 1.516 -0.342 0 CA-C-O 121.396 0.617 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.6 -6.82 57.55 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -177.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.859 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 97.6 mt-10 -87.54 165.2 15.66 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.196 -1.002 . . . . 0.0 110.509 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.26 127.35 14.66 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.164 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.818 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 20.3 p -100.86 34.96 2.31 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 122.395 1.093 . . . . 0.0 109.296 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.893 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 40.2 t -63.13 -44.14 99.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 113.912 -1.494 . . . . 0.0 110.176 179.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -114.62 -39.7 3.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.957 179.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.818 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -128.6 149.83 72.98 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.853 -179.291 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 31.2 Cg_exo -58.93 158.57 24.42 Favored 'Trans proline' 0 C--N 1.332 -0.314 0 C-N-CA 124.142 3.228 . . . . 0.0 113.259 -179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.457 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 8.9 m -60.82 154.77 21.1 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.011 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 61.4 mt -100.42 -48.38 11.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.039 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.702 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.9 t -77.17 41.49 0.3 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.357 0.599 . . . . 0.0 111.304 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 28.5 m -67.86 -24.57 65.26 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 73.0 mt -60.49 -41.01 93.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 114.151 -1.386 . . . . 0.0 110.14 178.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.522 HD12 ' HD2' ' A' ' 26' ' ' ARG . 1.8 tm? -76.94 -42.62 38.56 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.35 20.33 0.15 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.175 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.702 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 71.2 m -78.68 126.34 30.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.193 0.52 . . . . 0.0 110.426 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -140.0 154.73 47.23 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.901 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.9 m -55.82 121.67 9.76 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -179.107 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.611 ' HB2' ' CD1' ' A' ' 25' ' ' TYR . 39.3 mmtm -140.47 106.06 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.669 177.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.46 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 5.1 t-20 62.53 34.32 15.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.772 -177.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.893 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 30.0 mmmt 77.15 -17.05 0.59 Allowed 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.557 -1.202 . . . . 0.0 111.451 -178.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.856 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.0 t -92.45 153.99 3.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.859 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 99.2 m -96.81 123.84 40.62 Favored 'General case' 0 C--N 1.314 -0.945 0 O-C-N 121.372 -0.83 . . . . 0.0 112.327 -178.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.856 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.0 m-85 -126.52 153.86 44.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.219 178.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.559 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 28.9 ptt85 -116.59 156.32 27.21 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.952 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.763 ' HB3' HD13 ' A' ' 30' ' ' ILE . 3.6 t-20 58.3 33.37 23.07 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.539 0.685 . . . . 0.0 110.888 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.47 -66.73 0.27 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.898 179.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 p -150.99 39.25 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-O 121.738 0.78 . . . . 0.0 112.209 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.763 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.1 mp -98.39 116.25 65.55 Favored Pre-proline 0 C--N 1.322 -0.596 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 177.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 CA--C 1.528 0.225 0 C-N-CA 122.816 2.344 . . . . 0.0 114.228 -178.049 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.54 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 57.4 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.68 -5.92 64.64 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.853 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.7 mt-10 -89.09 165.8 14.27 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.166 -1.017 . . . . 0.0 110.653 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.32 134.5 21.67 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.746 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 31.3 p -106.5 30.65 5.83 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 122.018 0.913 . . . . 0.0 109.925 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.421 HG22 ' HB3' ' A' ' 22' ' ' LYS . 47.2 t -66.53 -38.41 81.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.985 -1.461 . . . . 0.0 110.394 179.203 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -110.78 -40.28 4.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.988 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.746 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 15.6 pt -140.56 151.4 63.53 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.609 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.4 Cg_exo -57.42 152.4 47.17 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 124.112 3.208 . . . . 0.0 112.947 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.603 ' HB2' HG23 ' A' ' 13' ' ' THR . 3.7 m -58.2 148.16 27.94 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.536 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.1 mm -89.1 -41.16 13.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.161 179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.532 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.1 t -83.2 40.02 0.68 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.483 0.659 . . . . 0.0 110.416 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.603 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.6 OUTLIER -68.8 -27.64 66.05 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 177.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.68 -39.6 94.73 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 113.725 -1.579 . . . . 0.0 110.758 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -74.98 -47.36 29.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.634 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.22 20.76 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.983 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 82.1 m -85.42 130.54 34.56 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.358 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.8 t -137.02 168.36 19.74 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.588 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.5 m -67.48 100.36 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.821 -179.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.561 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.3 tmtp? -119.08 102.38 8.69 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.467 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 9.0 t-20 62.88 36.33 12.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.946 -1.024 . . . . 0.0 108.795 -177.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 7.7 mtmp? 79.31 -17.58 0.58 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.556 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.798 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 19.5 t -97.81 147.79 6.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.192 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.853 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 96.6 m -89.15 120.41 30.51 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -178.116 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.798 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.4 m-85 -127.67 154.09 45.7 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.406 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.54 ' CZ ' ' HA ' ' A' ' 1' ' ' CYS . 5.6 ptt180 -112.65 149.34 32.98 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.778 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 58.01 37.22 26.6 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.635 0.731 . . . . 0.0 110.11 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 78.35 -48.19 3.08 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 115.523 0.969 . . . . 0.0 115.523 178.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.517 HG12 ' NZ ' ' A' ' 20' ' ' LYS . 18.5 m -138.59 35.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 114.887 1.44 . . . . 0.0 114.887 -177.288 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.453 ' HB ' ' HG3' ' A' ' 26' ' ' ARG . 63.1 mt -112.46 110.17 53.13 Favored Pre-proline 0 C--N 1.318 -0.797 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 177.392 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo . . . . . 0 C--O 1.232 0.204 0 C-N-CA 122.655 2.236 . . . . 0.0 113.458 -178.28 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.5 p . . . . . 0 N--CA 1.457 -0.122 0 CA-C-O 120.755 0.312 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 69.99 37.82 74.03 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.72 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.842 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 3.9 mm-40 -135.5 165.74 24.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.014 0.435 . . . . 0.0 110.271 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.55 126.4 8.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.508 178.411 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.685 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.7 p -106.2 36.74 2.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 122.383 1.087 . . . . 0.0 109.218 179.316 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.966 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 43.3 t -64.09 -44.3 97.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 113.854 -1.521 . . . . 0.0 110.751 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -104.12 -42.99 5.37 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.011 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.685 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.6 pt -138.1 156.07 74.12 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.104 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -55.91 150.18 47.67 Favored 'Trans proline' 0 C--O 1.234 0.275 0 C-N-CA 123.624 2.882 . . . . 0.0 112.487 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -58.92 146.0 39.34 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.127 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 47.5 mm -88.88 -39.82 12.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.731 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.63 40.64 0.24 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.25 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 80.0 m -68.93 -23.76 64.21 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.7 mt -61.72 -41.02 97.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.432 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -75.3 -42.1 55.46 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 137.78 28.94 0.28 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.635 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.731 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 67.4 m -75.28 100.74 4.46 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.088 0.471 . . . . 0.0 110.698 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.3 m -101.3 139.31 37.14 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.108 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.0 m -61.29 121.79 13.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.231 0.539 . . . . 0.0 111.561 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.729 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -142.87 110.67 5.89 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.158 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.445 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.3 t30 61.84 32.58 18.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 109.104 -178.303 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.966 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 77.45 -15.99 0.69 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.461 -179.232 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.511 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.4 t -94.07 152.76 3.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.842 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 62.2 m -98.3 128.01 44.52 Favored 'General case' 0 C--N 1.315 -0.896 0 O-C-N 121.451 -0.78 . . . . 0.0 111.99 -178.493 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.729 ' CD1' ' HB3' ' A' ' 20' ' ' LYS . 37.8 m-85 -128.14 154.65 45.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.392 178.737 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.465 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 34.9 ptt180 -113.78 154.97 26.49 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.78 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 56.58 35.55 26.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 0.0 110.745 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.76 -78.87 0.3 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.56 -0.829 . . . . 0.0 113.738 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.0 m -137.08 33.44 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -95.63 115.23 65.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.7 Cg_endo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.24 1.96 . . . . 0.0 111.781 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.9 p . . . . . 0 C--O 1.227 -0.086 0 CA-C-O 121.017 0.437 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 71.69 29.04 68.11 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.507 -0.77 . . . . 0.0 114.291 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.908 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 23.5 mt-10 -123.32 163.8 20.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.028 0.442 . . . . 0.0 110.415 178.473 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.34 126.14 16.12 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.557 178.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.721 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 4.9 p -102.17 34.27 2.78 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 122.381 1.086 . . . . 0.0 109.245 179.563 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.737 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 47.6 t -68.28 -40.62 82.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.637 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -109.67 -41.25 4.6 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.94 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.721 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.7 pt -137.74 152.89 73.42 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.462 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 36.7 Cg_exo -59.48 148.58 86.38 Favored 'Trans proline' 0 C--N 1.332 -0.309 0 C-N-CA 123.682 2.921 . . . . 0.0 112.432 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 m -54.46 147.05 14.64 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.857 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.4 mm -89.21 -44.43 15.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.904 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.589 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.03 39.14 0.49 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.444 0.64 . . . . 0.0 110.901 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 77.7 m -67.15 -25.44 66.17 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 177.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 69.2 mt -63.04 -41.28 99.46 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.533 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.49 -41.79 62.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.238 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.571 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 147.6 13.76 0.15 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.57 -0.824 . . . . 0.0 113.04 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.589 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 96.3 m -74.76 88.1 2.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.3 0.572 . . . . 0.0 110.835 179.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 58.9 p -88.32 135.45 33.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.839 179.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.5 t -64.3 119.33 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.445 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.434 ' HE2' ' HB2' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -136.44 117.78 14.64 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.524 -179.743 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 56.85 34.39 24.68 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 109.423 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.737 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 15.4 mtpt 69.99 8.42 6.68 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.801 -179.29 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.415 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 24.8 t -116.87 143.36 27.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 177.419 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.908 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -95.95 127.53 42.05 Favored 'General case' 0 C--N 1.313 -0.991 0 O-C-N 121.434 -0.791 . . . . 0.0 112.865 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.415 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 18.9 m-85 -130.45 151.21 51.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.201 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.571 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 37.7 ptt180 -114.84 154.14 29.15 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.187 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.431 ' HB3' HD12 ' A' ' 30' ' ' ILE . 2.1 t-20 57.94 33.31 23.06 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 123.656 0.597 . . . . 0.0 111.135 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 111.64 -86.53 0.43 Allowed Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.956 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.7 m -134.57 32.46 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -179.051 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.459 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 62.4 mt -93.15 110.31 45.41 Favored Pre-proline 0 C--N 1.327 -0.399 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo . . . . . 0 C--N 1.341 0.155 0 C-N-CA 122.222 1.948 . . . . 0.0 112.02 -179.356 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 71.5 m . . . . . 0 CA--C 1.516 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.34 -6.08 65.62 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -177.482 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.651 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.4 mt-10 -87.6 164.3 16.14 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 114.277 -0.961 . . . . 0.0 110.484 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . 0.444 ' HB3' HG23 ' A' ' 6' ' ' VAL . 0.9 OUTLIER -148.85 135.48 19.63 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.219 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.5 OUTLIER -105.25 26.21 9.66 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 122.644 1.211 . . . . 0.0 108.911 179.911 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.444 HG23 ' HB3' ' A' ' 4' ' ' SER . 55.4 t -55.41 -43.18 70.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.124 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -107.03 -42.87 4.78 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.255 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.64 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.7 pt -145.95 158.45 48.84 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.07 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -58.73 145.44 95.96 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 123.622 2.881 . . . . 0.0 111.832 179.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.589 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 24.1 m -75.23 161.28 29.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.196 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.442 ' C ' ' H ' ' A' ' 13' ' ' THR . 56.1 mt -87.34 -36.15 9.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.45 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.415 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 8.5 t -77.31 30.92 0.14 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.678 0.751 . . . . 0.0 111.36 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.442 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.8 OUTLIER -71.06 -26.85 63.25 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.194 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.4 mt -64.41 -41.18 96.77 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.558 178.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -71.42 -42.18 68.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.435 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 22.72 0.24 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.429 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.404 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -82.16 93.85 7.14 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.388 0.614 . . . . 0.0 110.385 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 m -88.27 139.21 30.73 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.897 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.471 ' SG ' ' HA ' ' A' ' 22' ' ' LYS . 50.2 t -75.66 116.37 16.3 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.106 0.479 . . . . 0.0 111.275 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -128.01 127.77 43.79 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 177.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 56.85 33.56 23.31 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-O 121.69 0.757 . . . . 0.0 109.103 -178.225 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.471 ' HA ' ' SG ' ' A' ' 19' ' ' CYS . 14.4 mmmm 69.9 6.56 5.8 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 114.798 -1.092 . . . . 0.0 111.964 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -117.79 138.77 47.4 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.651 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 7.3 m -89.35 129.49 35.87 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -177.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -130.94 152.5 50.19 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.125 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 30.7 ptt85 -116.17 154.31 30.25 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.888 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 59.52 33.39 22.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.842 0.829 . . . . 0.0 110.402 -179.318 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.41 -55.69 4.5 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 115.113 0.805 . . . . 0.0 115.113 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.7 m -140.47 38.19 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -177.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.0 mt -112.44 110.54 52.91 Favored Pre-proline 0 C--N 1.318 -0.774 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 177.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo . . . . . 0 N--CA 1.464 -0.207 0 C-N-CA 122.598 2.199 . . . . 0.0 113.316 -178.615 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.532 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 74.4 m . . . . . 0 CA--C 1.517 -0.315 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.03 -7.32 58.74 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -177.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.819 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 26.3 mt-10 -88.89 165.66 14.48 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.119 -1.04 . . . . 0.0 110.835 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -146.31 127.7 14.94 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.037 178.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.774 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.9 p -104.64 34.35 3.18 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.17 0.985 . . . . 0.0 109.488 179.484 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.907 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -62.14 -39.24 83.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.369 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -114.43 -40.26 3.66 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.146 179.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.774 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 17.5 pt -134.0 149.6 72.08 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.855 -179.234 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -56.62 152.85 38.89 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 124.255 3.303 . . . . 0.0 113.649 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.47 ' HB2' HG23 ' A' ' 13' ' ' THR . 4.2 m -60.1 149.94 31.02 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.592 -179.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 62.0 mt -89.6 -41.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.486 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.556 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.39 40.83 0.67 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.538 0.685 . . . . 0.0 110.67 179.876 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.47 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.7 OUTLIER -69.44 -27.11 64.97 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 177.682 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.5 mt -63.39 -40.64 97.78 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 113.773 -1.558 . . . . 0.0 110.62 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -73.51 -47.25 42.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.462 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.92 23.73 0.09 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.959 179.196 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.556 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 85.9 m -82.47 119.46 24.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.964 0.411 . . . . 0.0 110.165 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -116.61 156.1 27.6 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.937 -179.031 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.9 m -68.94 105.15 2.29 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.761 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.553 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 17.5 tptm -117.99 103.65 10.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.483 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 0.6 OUTLIER 61.96 32.63 17.74 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -178.143 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.907 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 28.1 mttt 78.31 -10.38 1.36 Allowed 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.348 -1.296 . . . . 0.0 111.754 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.796 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -97.12 143.87 11.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.753 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.819 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 71.0 m -88.81 122.34 32.11 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -177.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.796 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 5.7 m-85 -129.66 151.71 49.96 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.03 177.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.664 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 7.0 ptt180 -116.29 157.07 25.53 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.568 179.324 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.611 ' HB2' HD13 ' A' ' 30' ' ' ILE . 73.4 m-20 58.82 34.43 23.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.135 0.493 . . . . 0.0 111.463 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.51 -56.99 3.47 Favored Glycine 0 N--CA 1.45 -0.426 0 N-CA-C 114.963 0.745 . . . . 0.0 114.963 178.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.2 m -145.62 38.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.664 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 1.9 mp -106.84 112.51 63.38 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.68 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo . . . . . 0 C--O 1.232 0.191 0 C-N-CA 122.665 2.243 . . . . 0.0 113.787 -178.33 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.9 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.27 -5.01 60.72 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 -178.211 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.935 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.4 mt-10 -88.21 162.79 16.47 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 114.66 -0.77 . . . . 0.0 110.691 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.26 128.4 20.86 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 177.36 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.712 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.3 p -102.46 31.84 3.86 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.924 0.869 . . . . 0.0 110.203 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.0 t -68.48 -38.97 80.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.393 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -106.77 -41.35 5.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.008 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.712 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.3 pt -142.7 152.18 58.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.604 -179.388 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 34.5 Cg_exo -58.86 150.93 68.44 Favored 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.915 3.077 . . . . 0.0 112.621 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.439 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.7 m -58.57 144.76 41.75 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.653 -179.503 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.7 mm -90.93 -37.96 10.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.461 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.6 t -75.95 40.48 0.2 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.227 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 p -66.19 -25.67 67.04 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.835 0.826 . . . . 0.0 108.801 177.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.34 -35.97 76.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.429 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -92.17 19.94 6.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.654 179.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 71.34 30.21 67.34 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.856 -0.611 . . . . 0.0 114.004 178.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 99.9 m -84.0 127.48 33.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 117.289 0.544 . . . . 0.0 109.915 178.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 41.2 m -139.25 164.87 28.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.95 -178.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -67.76 101.31 1.04 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.019 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.534 ' HE2' HG12 ' A' ' 29' ' ' VAL . 7.8 tmtm? -128.53 118.99 23.97 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.492 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.47 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 30.7 t30 62.63 39.04 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -178.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.47 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 17.5 pttp 56.53 27.67 12.67 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.787 -179.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.929 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 44.4 t -142.83 155.04 17.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.935 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 79.6 m -89.61 119.93 30.46 Favored 'General case' 0 C--N 1.313 -0.978 0 O-C-N 121.485 -0.76 . . . . 0.0 112.294 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.929 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -126.79 154.89 43.66 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.019 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.504 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 13.2 ptt180 -116.23 156.42 26.59 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.207 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 56.94 34.53 25.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.15 0.5 . . . . 0.0 111.29 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 83.86 -55.53 5.02 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 114.759 0.663 . . . . 0.0 114.759 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.534 HG12 ' HE2' ' A' ' 20' ' ' LYS . 10.8 m -139.8 40.48 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -178.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.504 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.5 mm -113.22 106.44 54.7 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo . . . . . 0 C--O 1.233 0.239 0 C-N-CA 122.883 2.389 . . . . 0.0 113.785 -178.172 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.561 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 58.4 m . . . . . 0 CA--C 1.517 -0.306 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.2 -7.44 56.71 Favored Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -177.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.851 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.4 mt-10 -88.01 165.22 15.34 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.116 -1.042 . . . . 0.0 110.68 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -145.28 131.9 19.9 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.744 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -108.7 31.89 5.29 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.201 1.001 . . . . 0.0 109.606 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.2 t -60.32 -43.3 93.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.076 -1.42 . . . . 0.0 110.239 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.73 -41.94 5.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.261 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.744 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -135.31 150.77 73.52 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.883 -179.194 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 52.6 Cg_exo -55.79 153.38 30.93 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 124.271 3.314 . . . . 0.0 113.773 -179.168 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 9.0 m -59.93 152.67 22.97 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.755 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.8 mt -93.71 -42.37 12.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.56 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.605 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.07 43.29 0.7 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.435 0.635 . . . . 0.0 110.714 179.909 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -68.0 -26.74 66.06 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.9 mt -62.43 -41.36 98.66 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.623 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.401 HD22 ' HA ' ' A' ' 15' ' ' LEU . 1.8 tm? -73.49 -43.95 58.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.304 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 140.69 26.08 0.22 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.819 179.176 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.605 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 77.1 m -82.95 121.24 26.73 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.853 0.358 . . . . 0.0 110.116 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 12.9 t -118.24 164.01 15.82 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 -178.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.7 m -73.36 74.05 1.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.644 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.679 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 13.2 tmtt? -89.15 103.79 16.39 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.457 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 23.4 t30 60.19 33.8 21.05 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.267 -178.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 22.9 mmtp 74.37 2.71 4.18 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.704 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.834 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -109.17 140.07 29.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.851 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 82.9 m -88.1 121.42 30.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -176.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.834 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -127.26 150.51 49.53 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 177.577 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.595 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 9.1 ptt180 -115.27 153.53 30.75 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.369 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.753 ' HB3' HD13 ' A' ' 30' ' ' ILE . 3.4 t-20 58.79 36.81 24.95 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.361 0.6 . . . . 0.0 111.16 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.85 -62.53 0.79 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.581 -0.819 . . . . 0.0 114.663 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -150.58 37.36 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-O 121.674 0.749 . . . . 0.0 112.693 -178.117 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.753 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -100.06 112.19 63.56 Favored Pre-proline 0 C--N 1.323 -0.577 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 177.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 C--O 1.232 0.197 0 C-N-CA 122.628 2.219 . . . . 0.0 113.551 -178.391 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 30.3 p . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.718 0.294 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 111.09 -12.27 29.07 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.937 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.841 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 5.6 mm-40 -85.1 159.94 20.07 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.545 0.688 . . . . 0.0 111.151 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.79 134.77 30.69 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.853 -1.067 . . . . 0.0 109.13 178.538 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.702 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 15.1 p -115.91 34.13 5.13 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 122.088 0.947 . . . . 0.0 109.231 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.614 ' HA ' ' HB3' ' A' ' 22' ' ' LYS . 28.9 t -63.92 -40.46 89.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 113.881 -1.509 . . . . 0.0 111.244 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -114.53 -38.94 3.9 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.065 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.702 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -136.51 153.43 76.09 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.504 -179.267 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -58.52 148.66 79.97 Favored 'Trans proline' 0 C--N 1.332 -0.328 0 C-N-CA 123.717 2.945 . . . . 0.0 112.265 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -56.67 143.97 34.15 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.469 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 4.3 mp -89.75 -42.43 14.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.618 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.24 39.11 0.19 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.363 179.854 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 58.2 m -69.53 -23.42 63.59 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 177.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 77.2 mt -63.06 -40.83 98.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.489 178.528 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.455 HD22 ' HA ' ' A' ' 15' ' ' LEU . 1.0 OUTLIER -73.12 -39.72 65.51 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.396 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.46 23.87 0.44 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.535 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.618 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 89.7 m -76.64 98.06 4.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.094 0.473 . . . . 0.0 110.669 179.532 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.459 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 13.6 m -88.56 132.93 34.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.937 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.2 t -73.82 117.2 15.32 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.087 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.672 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 11.6 tmtt? -141.97 119.1 11.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.525 0.679 . . . . 0.0 110.843 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 55.07 37.17 28.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.3 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.614 ' HB3' ' HA ' ' A' ' 6' ' ' VAL . 26.3 mtmm 75.88 1.43 3.51 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.08 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.7 t -118.32 137.25 52.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.841 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 30.1 m -95.52 128.37 42.33 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.702 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.672 ' CE1' ' HD2' ' A' ' 20' ' ' LYS . 2.1 m-85 -122.35 163.54 19.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.653 179.429 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.5 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.2 ptt180 -131.94 155.51 47.79 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 61.79 31.55 18.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.305 0.574 . . . . 0.0 111.211 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 109.69 -71.93 0.2 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.536 -0.84 . . . . 0.0 113.931 178.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 p -150.23 36.85 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 122.069 0.938 . . . . 0.0 111.099 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.5 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.9 mm -101.17 113.83 65.8 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.407 178.434 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.5 Cg_endo . . . . . 0 N--CA 1.463 -0.268 0 C-N-CA 122.203 1.935 . . . . 0.0 111.4 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.473 ' HB3' ' HD3' ' A' ' 26' ' ' ARG . 1.7 p . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.018 0.437 . . . . 0.0 110.828 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.33 31.6 80.98 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.491 -0.777 . . . . 0.0 113.166 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.88 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.5 mt-10 -124.42 165.93 16.88 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.074 0.464 . . . . 0.0 110.4 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.89 134.07 17.19 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.771 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.7 p -107.45 31.29 5.53 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 122.36 1.076 . . . . 0.0 109.605 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.902 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 46.7 t -61.72 -44.47 98.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 113.933 -1.485 . . . . 0.0 110.177 179.475 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -104.66 -43.59 5.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.158 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.771 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.5 pt -136.09 153.8 77.03 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.003 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 51.4 Cg_exo -55.45 153.98 26.34 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 124.11 3.207 . . . . 0.0 113.379 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.62 ' HB2' HG23 ' A' ' 13' ' ' THR . 7.3 m -58.69 149.74 25.31 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.698 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.406 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.2 mp -89.53 -46.35 15.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.859 179.324 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.694 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -79.24 41.24 0.45 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.442 0.639 . . . . 0.0 110.539 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.62 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.6 OUTLIER -68.61 -26.5 65.39 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.8 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.4 mt -61.98 -40.93 97.29 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 113.81 -1.541 . . . . 0.0 110.453 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -75.36 -46.33 33.82 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.455 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.58 26.38 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.543 -0.836 . . . . 0.0 113.259 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.694 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.1 m -80.35 120.96 25.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 117.169 0.485 . . . . 0.0 110.006 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.5 m -119.12 159.79 23.31 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.181 -178.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.2 m -69.35 84.96 0.4 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.752 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.57 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 46.7 tptt -96.66 98.4 10.15 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.596 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 0.6 OUTLIER 60.94 33.52 19.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.395 -0.82 . . . . 0.0 108.811 -178.362 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.902 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 40.4 mmtt 82.29 -10.99 1.05 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.319 -1.309 . . . . 0.0 112.414 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.823 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -99.22 141.45 16.64 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.165 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.88 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 73.1 m -89.65 122.54 32.87 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.823 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -127.43 151.07 49.29 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.726 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.473 ' HD3' ' HB3' ' A' ' 1' ' ' CYS . 28.1 ptt180 -112.24 153.61 26.86 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.115 179.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.3 t30 60.12 33.49 21.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.287 0.565 . . . . 0.0 111.264 179.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.89 -64.59 0.73 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.621 -0.8 . . . . 0.0 114.615 178.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.3 m -143.12 33.59 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.437 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 59.0 mt -101.56 108.42 55.54 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo . . . . . 0 N--CA 1.464 -0.238 0 C-N-CA 122.212 1.942 . . . . 0.0 112.347 -179.09 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 CA--C 1.516 -0.362 0 CA-C-O 121.372 0.606 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.48 -5.75 67.63 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -177.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.638 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 21.2 mt-10 -87.25 160.11 18.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 114.494 -0.853 . . . . 0.0 110.387 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . 0.425 ' HA ' ' HA ' ' A' ' 23' ' ' VAL . 0.7 OUTLIER -144.46 133.36 22.58 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.471 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.488 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.7 OUTLIER -98.68 26.97 5.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 122.157 0.98 . . . . 0.0 109.905 -179.572 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.7 t -61.03 -39.74 83.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 114.26 -1.336 . . . . 0.0 111.715 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -108.33 -42.03 4.71 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.44 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.488 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 13.5 pt -149.96 159.38 35.74 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.679 -178.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -59.55 143.6 99.64 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 123.342 2.695 . . . . 0.0 111.302 179.17 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.538 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 18.2 m -71.18 161.42 31.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.79 -178.229 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 57.8 mt -87.03 -40.01 13.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.356 -0.838 . . . . 0.0 112.711 -178.082 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.594 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 3.1 t -79.32 35.87 0.28 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.714 0.768 . . . . 0.0 111.345 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -70.52 -25.12 62.98 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 177.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 81.0 mt -63.86 -42.85 97.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 113.898 -1.501 . . . . 0.0 110.716 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -71.43 -43.31 66.97 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.465 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 144.46 20.66 0.17 Allowed Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.697 179.256 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -77.8 83.75 4.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.401 0.619 . . . . 0.0 110.425 179.491 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.4 m -86.18 136.2 33.29 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.454 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.6 t -68.6 127.94 34.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.162 0.506 . . . . 0.0 111.222 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -144.99 130.24 18.6 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.746 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 31.2 t30 56.81 38.93 29.79 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.304 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.746 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 2.1 pttm 60.84 13.3 4.34 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.156 1.382 . . . . 0.0 112.115 -179.159 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 4' ' ' SER . 58.5 t -128.31 141.62 46.01 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.638 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 1.7 m -88.93 131.67 35.04 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.034 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -132.45 146.27 51.82 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.17 -0.923 . . . . 0.0 108.853 177.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.465 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 41.4 ptt85 -110.53 157.84 19.19 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.305 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 57.62 30.81 19.4 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.672 0.607 . . . . 0.0 111.256 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.59 -74.5 0.22 Allowed Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.548 -0.834 . . . . 0.0 113.462 179.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.51 32.52 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.423 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -92.44 113.1 58.35 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.197 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo . . . . . 0 N--CA 1.464 -0.227 0 C-N-CA 122.704 2.269 . . . . 0.0 113.558 -178.459 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.9 m . . . . . 0 CA--C 1.517 -0.313 0 CA-C-O 121.275 0.56 . . . . 0.0 109.721 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.21 -2.64 63.57 Favored Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.95 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 41.2 mt-10 -86.93 158.92 19.19 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.774 -0.713 . . . . 0.0 110.422 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.54 125.64 29.32 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.156 178.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.665 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.6 p -103.13 34.81 2.75 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 122.368 1.08 . . . . 0.0 109.047 179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.936 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 47.7 t -66.53 -42.93 90.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 113.759 -1.564 . . . . 0.0 110.667 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -109.34 -40.95 4.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.665 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.3 pt -134.89 153.08 78.44 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.063 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_exo -60.63 150.54 81.49 Favored 'Trans proline' 0 C--N 1.332 -0.331 0 C-N-CA 123.855 3.037 . . . . 0.0 112.27 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.478 ' HB2' HG23 ' A' ' 13' ' ' THR . 2.5 m -53.71 146.08 14.26 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.786 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.41 ' N ' HD12 ' A' ' 11' ' ' ILE . 4.1 mp -88.2 -39.9 13.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.837 179.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.414 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.4 40.19 0.63 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.608 0.718 . . . . 0.0 110.514 179.421 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.478 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.5 OUTLIER -68.48 -26.5 65.51 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.798 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 75.8 mt -63.16 -39.95 96.15 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.831 -1.531 . . . . 0.0 110.493 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.2 tm? -72.91 -40.43 65.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.236 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 139.86 13.47 0.61 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.414 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.6 m -75.52 105.14 6.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.359 0.599 . . . . 0.0 110.346 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.5 m -97.3 143.32 28.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.737 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.85 115.93 12.74 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.953 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.3 ttmm -140.73 121.71 14.59 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.818 0.342 . . . . 0.0 110.945 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 42.3 t30 60.06 34.12 21.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.674 0.749 . . . . 0.0 109.583 -179.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.936 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 69.46 6.55 5.75 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.757 -179.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.482 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.6 t -119.29 144.33 28.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.098 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.95 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -94.68 127.55 40.73 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 -177.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.482 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 16.4 m-85 -132.41 148.42 52.41 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.093 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.402 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 26.6 ptt180 -109.81 158.12 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.587 178.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 55.67 35.58 25.54 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.687 0.756 . . . . 0.0 110.748 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.17 -60.34 3.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.849 -0.691 . . . . 0.0 114.781 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.9 m -140.44 34.88 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -178.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 51.0 mm -103.03 110.28 63.26 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 177.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.1 Cg_endo . . . . . 0 N--CA 1.464 -0.252 0 C-N-CA 122.578 2.185 . . . . 0.0 113.389 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.5 m . . . . . 0 CA--C 1.518 -0.262 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.0 -3.96 60.68 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.961 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.6 mt-10 -88.14 164.77 15.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.617 -0.792 . . . . 0.0 111.059 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.97 126.34 15.77 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 177.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.726 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -105.34 34.27 3.32 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 122.275 1.036 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.964 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 44.3 t -61.98 -44.2 98.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 114.092 -1.413 . . . . 0.0 110.099 179.326 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -105.65 -42.62 5.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.207 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.726 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.3 pt -135.65 150.75 72.86 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 -179.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -57.84 154.6 37.1 Favored 'Trans proline' 0 N--CA 1.473 0.296 0 C-N-CA 124.243 3.296 . . . . 0.0 113.35 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.482 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.8 m -61.01 145.3 51.22 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.257 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.2 mt -93.98 -35.32 6.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.955 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -76.83 44.33 0.38 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.018 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.7 m -64.23 -25.78 68.22 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.4 mt -59.72 -36.87 77.43 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.003 -1.453 . . . . 0.0 110.995 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -89.59 16.82 7.14 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.839 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 71.44 28.95 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.508 179.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 80.7 m -80.57 128.18 33.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.04 0.42 . . . . 0.0 110.135 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -133.14 155.51 49.15 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 47.9 m -62.5 118.47 7.6 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.998 -0.546 . . . . 0.0 112.184 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.663 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 12.7 tppt? -132.76 101.63 5.35 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.587 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.546 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 46.6 t30 61.54 34.31 17.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.873 -178.005 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.964 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 46.0 mmtt 80.73 -16.52 0.64 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.15 -1.387 . . . . 0.0 112.157 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.679 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.4 t -94.88 143.13 12.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 177.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.961 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -89.29 124.25 34.24 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 112.673 0.62 . . . . 0.0 112.673 -177.505 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.679 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 12.1 m-85 -130.03 150.22 51.4 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.46 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 23.1 ptt180 -112.28 161.01 17.08 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.854 179.383 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 55.55 33.14 20.5 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.187 0.518 . . . . 0.0 111.406 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.449 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 95.43 -64.05 1.35 Allowed Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.812 -0.708 . . . . 0.0 113.963 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.2 m -142.78 37.73 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 112.909 0.707 . . . . 0.0 112.909 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.46 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 49.6 mm -101.17 112.13 64.55 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 108.866 -0.791 . . . . 0.0 108.866 178.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 10.7 Cg_endo . . . . . 0 C--O 1.231 0.15 0 C-N-CA 122.932 2.422 . . . . 0.0 113.963 -178.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.2 m . . . . . 0 CA--C 1.517 -0.319 0 CA-C-O 121.345 0.593 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.71 -3.77 53.24 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 109.751 -1.339 . . . . 0.0 109.751 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.986 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.1 mt-10 -86.84 161.61 18.23 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 114.659 -0.771 . . . . 0.0 110.546 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -135.19 124.62 24.87 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.802 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.692 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.8 p -105.84 33.33 3.82 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 122.048 0.928 . . . . 0.0 109.503 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.703 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 36.9 t -61.43 -44.06 97.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.768 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -112.34 -39.89 4.29 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.431 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.692 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 22.3 pt -129.11 151.73 78.17 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.169 0.509 . . . . 0.0 111.556 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 25.4 Cg_exo -61.52 150.25 86.13 Favored 'Trans proline' 0 C--N 1.333 -0.275 0 C-N-CA 124.012 3.141 . . . . 0.0 112.537 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.415 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 2.6 m -57.09 146.05 28.87 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.81 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.401 ' C ' ' H ' ' A' ' 13' ' ' THR . 59.9 mt -89.05 -37.31 9.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.624 179.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.434 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 8.4 t -77.7 38.02 0.24 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.592 0.711 . . . . 0.0 111.006 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.401 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.7 OUTLIER -71.02 -25.73 62.8 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 177.635 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.3 mt -62.79 -41.54 99.31 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.829 -1.532 . . . . 0.0 110.536 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -74.31 -43.41 56.86 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.291 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.89 30.18 0.22 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.647 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.434 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.2 m -88.45 117.07 27.12 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.025 0.441 . . . . 0.0 110.189 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -104.47 147.73 27.25 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.572 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -77.95 112.97 15.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.505 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.452 ' O ' ' HD3' ' A' ' 20' ' ' LYS . 12.8 tmtt? -139.34 125.16 19.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.089 0.471 . . . . 0.0 110.949 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 58.54 33.59 23.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.089 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.791 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 10.5 mmpt? 71.64 0.83 3.64 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 115.355 -0.838 . . . . 0.0 111.646 -179.415 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.495 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 26.2 t -115.2 146.53 19.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.986 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.3 m -97.25 126.18 42.29 Favored 'General case' 0 C--N 1.312 -1.027 0 O-C-N 121.977 -0.452 . . . . 0.0 111.848 -178.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.495 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -127.26 152.07 47.9 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.172 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.592 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 29.6 ptt85 -116.33 150.44 37.67 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.339 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.644 ' HB3' HD13 ' A' ' 30' ' ' ILE . 1.8 t-20 59.71 34.05 21.98 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.692 0.62 . . . . 0.0 110.948 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.92 -88.38 0.53 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.376 -0.916 . . . . 0.0 113.339 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.8 m -128.68 32.87 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.021 0.748 . . . . 0.0 113.021 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.644 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.9 mp -94.3 110.8 50.66 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.041 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo . . . . . 0 C--O 1.232 0.184 0 C-N-CA 122.576 2.184 . . . . 0.0 113.691 -178.489 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 84.2 m . . . . . 0 CA--C 1.519 -0.231 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 94.61 -9.41 71.29 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.799 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 98.3 mt-10 -88.49 167.55 13.35 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.621 -0.789 . . . . 0.0 110.934 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -150.49 132.07 14.84 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.796 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.0 p -102.23 33.06 3.24 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.295 1.045 . . . . 0.0 109.37 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.541 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 45.7 t -62.48 -42.86 97.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.02 -1.445 . . . . 0.0 110.186 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -111.07 -40.35 4.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.099 179.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.796 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.0 pt -135.7 151.18 73.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.761 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 41.9 Cg_exo -57.19 154.6 33.28 Favored 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 124.128 3.219 . . . . 0.0 113.335 -179.445 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.469 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 7.0 m -59.76 150.2 28.72 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.585 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.3 mt -94.09 -46.23 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.201 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.543 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.54 44.12 0.51 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.645 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -62.93 -25.57 68.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.863 0.84 . . . . 0.0 108.926 178.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 66.3 mt -59.24 -37.68 78.15 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 113.925 -1.489 . . . . 0.0 110.893 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 15' ' ' LEU . 4.2 mm? -89.96 19.85 4.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.043 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 73.1 25.12 74.31 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.868 -0.605 . . . . 0.0 113.81 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 93.6 m -75.38 110.71 9.97 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.412 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 13.4 m -114.6 164.3 14.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.658 -178.113 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -71.17 82.04 0.71 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.109 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.607 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 41.5 tptt -94.03 102.36 14.43 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 62.94 34.3 14.25 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -177.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.541 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 10.6 mtpt 73.88 -3.94 2.39 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 114.203 -1.362 . . . . 0.0 111.801 -178.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.887 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 15.7 t -101.52 144.42 13.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 177.552 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.799 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 72.3 m -87.96 117.5 26.87 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.887 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.5 m-85 -126.84 151.14 48.75 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-N 115.204 -0.907 . . . . 0.0 108.579 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.506 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 11.8 ptp180 -112.98 156.62 22.72 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.555 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.783 ' HB3' HD13 ' A' ' 30' ' ' ILE . 1.7 t-20 55.77 34.54 23.62 Favored 'General case' 0 C--N 1.326 -0.414 0 O-C-N 123.771 0.669 . . . . 0.0 111.376 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.75 -63.06 0.68 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.648 -0.787 . . . . 0.0 114.812 178.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.8 m -146.35 38.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.783 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -102.88 114.58 65.17 Favored Pre-proline 0 C--N 1.324 -0.536 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.152 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.434 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.4 Cg_endo . . . . . 0 CA--C 1.528 0.213 0 C-N-CA 122.747 2.298 . . . . 0.0 113.884 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.435 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 63.2 m . . . . . 0 CA--C 1.518 -0.281 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.97 -7.3 58.84 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -177.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.888 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 95.9 mt-10 -88.44 166.3 14.32 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.01 -1.095 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -146.58 133.15 19.79 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 177.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.758 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 30.5 p -104.77 30.79 5.19 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 122.134 0.969 . . . . 0.0 109.896 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.545 HG22 ' HB3' ' A' ' 22' ' ' LYS . 46.4 t -68.3 -39.09 80.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 113.991 -1.459 . . . . 0.0 110.377 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -111.18 -39.77 4.64 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.103 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.758 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -139.01 151.79 68.77 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.611 -179.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.9 Cg_exo -57.55 154.48 36.09 Favored 'Trans proline' 0 C--N 1.333 -0.271 0 C-N-CA 123.993 3.129 . . . . 0.0 112.865 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.411 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 11.4 m -57.6 151.28 17.38 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.661 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.402 ' C ' ' H ' ' A' ' 13' ' ' THR . 61.3 mt -93.72 -49.41 12.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.402 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.692 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -78.29 38.15 0.28 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.515 0.674 . . . . 0.0 110.895 -179.858 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.402 ' H ' ' C ' ' A' ' 11' ' ' ILE . 27.0 m -67.99 -26.09 65.74 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 177.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 70.1 mt -63.04 -38.87 92.93 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 113.93 -1.486 . . . . 0.0 110.466 178.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -76.83 -46.78 23.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.322 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.63 24.69 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.082 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.692 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 87.7 m -84.85 131.94 34.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.957 0.378 . . . . 0.0 110.165 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.0 t -139.01 160.2 40.33 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.041 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.4 m -62.17 113.49 2.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.487 0.661 . . . . 0.0 112.043 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.68 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 13.4 tppt? -131.69 104.75 7.09 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.323 178.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.8 t30 62.17 32.22 17.41 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.219 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.545 ' HB3' HG22 ' A' ' 6' ' ' VAL . 30.6 mtmm 82.35 -19.57 0.4 Allowed 'General case' 0 N--CA 1.477 0.89 0 CA-C-N 114.581 -1.19 . . . . 0.0 110.894 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.812 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.7 t -93.44 149.03 4.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.888 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 91.9 m -89.97 121.28 31.92 Favored 'General case' 0 C--N 1.312 -1.038 0 O-C-N 121.796 -0.565 . . . . 0.0 112.221 -178.163 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.812 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.8 m-85 -124.9 152.19 44.39 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.495 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 11.6 ptt180 -114.19 157.12 23.08 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.807 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 55.81 38.34 29.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.679 0.752 . . . . 0.0 110.803 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.494 ' O ' ' HE3' ' A' ' 20' ' ' LYS . . . 87.68 -62.05 4.04 Favored Glycine 0 N--CA 1.447 -0.568 0 CA-C-N 115.719 -0.673 . . . . 0.0 114.681 178.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.09 41.38 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -178.047 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.472 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.1 mm -109.15 112.64 59.58 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 11.1 Cg_endo . . . . . 0 C--O 1.234 0.289 0 C-N-CA 122.568 2.179 . . . . 0.0 113.643 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 62.5 m . . . . . 0 CA--C 1.519 -0.22 0 CA-C-O 121.309 0.576 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.33 63.3 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -178.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.938 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.8 mt-10 -87.28 165.19 15.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 114.765 -0.718 . . . . 0.0 110.675 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.38 127.6 16.7 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.745 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 32.1 p -103.98 32.07 4.16 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-O 121.943 0.878 . . . . 0.0 110.208 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.443 HG22 ' HB3' ' A' ' 22' ' ' LYS . 46.3 t -66.12 -37.96 80.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 114.196 -1.365 . . . . 0.0 110.188 179.121 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -111.3 -40.45 4.41 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.087 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.745 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.1 pt -139.38 150.01 62.46 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.723 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 33.9 Cg_exo -58.94 152.2 59.91 Favored 'Trans proline' 0 C--N 1.334 -0.221 0 C-N-CA 124.049 3.166 . . . . 0.0 112.963 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.7 m -61.21 144.49 53.64 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.987 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 47.4 mm -93.0 -35.67 6.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.715 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.0 t -75.7 42.76 0.24 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.266 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 m -63.77 -26.21 68.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.006 0.908 . . . . 0.0 108.582 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.1 mt -59.34 -38.94 81.62 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 113.888 -1.506 . . . . 0.0 111.092 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -88.53 16.33 6.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.15 26.44 68.53 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.359 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.3 m -80.76 129.33 34.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 117.097 0.448 . . . . 0.0 109.959 179.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.8 t -140.45 166.87 23.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.442 -179.156 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 m -65.53 111.74 3.26 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.821 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.524 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtp? -133.86 105.1 6.59 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.413 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 44.8 t30 64.8 31.54 11.63 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.402 -178.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.443 ' HB3' HG22 ' A' ' 6' ' ' VAL . 31.0 mtmm 81.75 -20.28 0.37 Allowed 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 114.747 -1.115 . . . . 0.0 110.878 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.792 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 21.8 t -95.3 149.78 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.938 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 95.4 m -90.87 121.43 32.72 Favored 'General case' 0 C--N 1.313 -0.989 0 O-C-N 121.834 -0.541 . . . . 0.0 112.144 -178.311 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.792 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.4 m-85 -128.1 155.75 43.92 Favored 'General case' 0 CA--C 1.512 -0.486 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.43 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.5 ptt85 -119.0 158.65 25.36 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.118 178.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 57.96 31.9 21.24 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.216 0.532 . . . . 0.0 110.939 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.17 -50.08 4.24 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 114.704 0.642 . . . . 0.0 114.704 179.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.473 HG12 ' NZ ' ' A' ' 20' ' ' LYS . 16.4 m -141.13 38.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -177.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.43 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 47.3 mm -114.52 107.33 51.25 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.176 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 14.8 Cg_endo . . . . . 0 N--CA 1.465 -0.203 0 C-N-CA 122.81 2.34 . . . . 0.0 113.652 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 65.2 m . . . . . 0 CA--C 1.519 -0.243 0 CA-C-O 121.363 0.601 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.2 -4.49 64.96 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -178.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.855 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.0 mt-10 -87.88 163.33 16.45 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.878 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.07 127.3 30.08 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.322 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.681 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 25.4 p -107.45 32.36 4.73 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.055 0.931 . . . . 0.0 109.32 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.647 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.6 t -61.92 -43.77 97.95 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 114.096 -1.411 . . . . 0.0 110.942 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -110.08 -40.98 4.57 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.479 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.681 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 23.4 pt -130.04 154.22 81.2 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.323 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -59.12 153.08 54.72 Favored 'Trans proline' 0 C--O 1.233 0.251 0 C-N-CA 123.975 3.116 . . . . 0.0 112.597 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 12.2 m -57.53 152.53 14.67 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.014 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 61.8 mt -95.77 -46.06 13.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.044 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.526 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.6 t -76.18 41.89 0.25 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.966 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.9 m -64.49 -23.46 67.29 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.8 mt -61.36 -37.52 83.66 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 114.074 -1.421 . . . . 0.0 110.379 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.432 HD13 ' HA ' ' A' ' 15' ' ' LEU . 4.0 mm? -89.38 15.05 9.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.563 179.414 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.446 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 77.43 26.44 61.36 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.711 -0.677 . . . . 0.0 113.766 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.5 m -79.73 112.48 17.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 117.425 0.613 . . . . 0.0 109.472 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 t -108.52 153.82 22.8 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.564 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.5 t -71.51 107.67 4.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.814 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.491 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 19.4 tptp -130.53 113.24 14.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.144 0.497 . . . . 0.0 111.205 -178.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.438 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 5.8 t-20 60.22 35.54 20.94 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.431 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.77 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 9.9 mmpt? 74.45 -6.65 1.84 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.969 -1.014 . . . . 0.0 111.844 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.589 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.5 t -107.36 146.36 13.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.855 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 88.2 m -93.09 121.72 34.73 Favored 'General case' 0 C--N 1.315 -0.927 0 O-C-N 121.922 -0.486 . . . . 0.0 112.107 -178.344 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.589 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 21.8 m-85 -128.93 149.22 50.88 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.473 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 46.2 ptt85 -116.12 164.34 14.62 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.395 -0.821 . . . . 0.0 109.447 179.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 11.2 m120 57.92 27.41 14.64 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 123.382 0.426 . . . . 0.0 111.442 179.3 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.85 -64.26 0.64 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.863 -0.685 . . . . 0.0 113.638 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.28 37.3 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.419 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.4 mm -101.93 112.74 65.69 Favored Pre-proline 0 C--N 1.323 -0.562 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.574 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo . . . . . 0 N--CA 1.464 -0.213 0 C-N-CA 122.662 2.242 . . . . 0.0 113.653 -178.682 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.0 m . . . . . 0 CA--C 1.518 -0.277 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 105.04 -7.62 44.54 Favored Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -177.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.807 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 99.5 mt-10 -88.66 171.24 10.15 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.434 -0.883 . . . . 0.0 111.083 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.1 m -148.61 135.73 20.13 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 178.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.754 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 23.6 p -107.66 29.54 7.12 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.202 1.001 . . . . 0.0 109.543 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.45 HG22 ' HB3' ' A' ' 22' ' ' LYS . 61.6 t -66.41 -39.56 84.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 113.77 -1.559 . . . . 0.0 110.72 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -110.47 -40.73 4.54 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.716 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.754 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.8 pt -139.38 152.5 69.33 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.673 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 31.7 Cg_exo -57.94 155.37 33.6 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 123.989 3.126 . . . . 0.0 113.054 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.439 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 5.9 m -59.44 149.57 29.1 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.482 -179.581 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 66.0 mt -96.96 -46.02 12.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.988 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.455 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -77.87 40.69 0.33 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.683 179.65 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.6 m -64.06 -23.09 67.2 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.065 0.936 . . . . 0.0 108.487 178.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.4 mt -61.58 -33.98 74.81 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.437 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 90.4 mt -94.52 23.3 5.38 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.738 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 74.18 26.24 68.97 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.651 -0.704 . . . . 0.0 114.332 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 80.2 m -82.68 131.09 35.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.652 0.726 . . . . 0.0 109.785 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.9 m -145.66 169.16 19.0 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.564 -178.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 55.5 m -63.2 106.31 0.85 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.982 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.472 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.6 tmtm? -126.89 99.91 5.94 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.461 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 51.2 t30 65.58 33.27 8.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.792 -178.033 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 41.7 mtmt 80.22 -19.63 0.43 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 114.264 -1.335 . . . . 0.0 111.066 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.894 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -93.33 150.7 3.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.807 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 94.9 m -89.33 116.77 27.79 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 120.141 -0.624 . . . . 0.0 112.362 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.894 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -122.47 156.43 34.11 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.828 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.528 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 14.2 ptt180 -117.76 156.67 27.88 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.088 179.133 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 57.37 34.5 24.77 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.068 0.461 . . . . 0.0 111.304 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 81.61 -50.2 4.19 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 115.0 0.76 . . . . 0.0 115.0 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 m -143.08 41.16 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 -178.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.486 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.3 mm -116.64 107.23 46.95 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.173 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo . . . . . 0 CA--C 1.528 0.207 0 C-N-CA 122.603 2.202 . . . . 0.0 113.627 -178.115 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 75.9 m . . . . . 0 CA--C 1.519 -0.236 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.31 -3.28 59.73 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.955 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 40.3 mt-10 -87.96 161.51 17.39 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.59 -0.805 . . . . 0.0 110.83 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.95 126.48 30.43 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.4 178.334 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.704 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 13.3 p -107.55 35.54 3.04 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 122.374 1.083 . . . . 0.0 109.055 179.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.46 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -64.94 -41.97 93.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 113.816 -1.538 . . . . 0.0 110.713 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -113.04 -39.91 4.09 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.156 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.704 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.6 pt -131.72 151.62 78.93 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.178 -179.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -60.24 152.14 68.52 Favored 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.953 3.102 . . . . 0.0 112.667 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -55.01 148.31 13.91 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 112.083 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 59.0 mt -89.18 -39.09 12.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.156 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.437 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 2.3 t -80.75 40.84 0.54 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.553 0.692 . . . . 0.0 110.696 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -70.4 -25.22 63.14 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.88 -41.23 97.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 113.902 -1.499 . . . . 0.0 110.451 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -74.33 -45.76 45.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.266 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 27.46 0.18 Allowed Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.537 -0.84 . . . . 0.0 112.979 179.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.437 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 90.2 m -84.86 113.28 21.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.377 0.608 . . . . 0.0 110.147 179.374 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 35.5 t -99.3 140.82 32.9 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.639 -179.308 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 45.9 t -70.79 117.97 12.99 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.989 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.417 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 0.3 OUTLIER -136.07 114.92 12.12 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.811 -179.257 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 59.17 31.87 21.6 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.643 0.735 . . . . 0.0 109.464 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.46 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 55.2 mttm 70.86 13.35 7.1 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.705 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -121.34 136.6 57.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 176.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.955 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 76.8 m -89.9 126.46 35.73 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.417 ' CD1' ' HB3' ' A' ' 20' ' ' LYS . 32.5 m-85 -131.51 147.65 52.56 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.702 178.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.586 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 20.2 ptt85 -111.79 155.23 23.88 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.421 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.748 ' HB3' HD13 ' A' ' 30' ' ' ILE . 3.8 t-20 58.25 33.49 23.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.85 -76.74 0.23 Allowed Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.681 179.289 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.8 m -139.64 32.49 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.748 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -91.34 113.87 59.87 Favored Pre-proline 0 C--N 1.325 -0.473 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 178.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.802 2.335 . . . . 0.0 114.348 -178.102 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.9 m . . . . . 0 CA--C 1.516 -0.342 0 CA-C-O 121.396 0.617 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.6 -6.82 57.55 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -177.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.859 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 97.6 mt-10 -87.54 165.2 15.66 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.196 -1.002 . . . . 0.0 110.509 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.26 127.35 14.66 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.164 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.818 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 20.3 p -100.86 34.96 2.31 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 122.395 1.093 . . . . 0.0 109.296 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.893 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 40.2 t -63.13 -44.14 99.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 113.912 -1.494 . . . . 0.0 110.176 179.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -114.62 -39.7 3.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.957 179.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.818 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -128.6 149.83 72.98 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.853 -179.291 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 31.2 Cg_exo -58.93 158.57 24.42 Favored 'Trans proline' 0 C--N 1.332 -0.314 0 C-N-CA 124.142 3.228 . . . . 0.0 113.259 -179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.457 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 8.9 m -60.82 154.77 21.1 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.011 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 61.4 mt -100.42 -48.38 11.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.039 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.702 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.9 t -77.17 41.49 0.3 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.357 0.599 . . . . 0.0 111.304 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 28.5 m -67.86 -24.57 65.26 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 73.0 mt -60.49 -41.01 93.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 114.151 -1.386 . . . . 0.0 110.14 178.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.522 HD12 ' HD2' ' A' ' 26' ' ' ARG . 1.8 tm? -76.94 -42.62 38.56 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.35 20.33 0.15 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.175 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.702 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 71.2 m -78.68 126.34 30.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.193 0.52 . . . . 0.0 110.426 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -140.0 154.73 47.23 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.901 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.9 m -55.82 121.67 9.76 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -179.107 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.611 ' HB2' ' CD1' ' A' ' 25' ' ' TYR . 39.3 mmtm -140.47 106.06 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.669 177.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.46 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 5.1 t-20 62.53 34.32 15.33 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.772 -177.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.893 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 30.0 mmmt 77.15 -17.05 0.59 Allowed 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.557 -1.202 . . . . 0.0 111.451 -178.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.856 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.0 t -92.45 153.99 3.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.859 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 99.2 m -96.81 123.84 40.62 Favored 'General case' 0 C--N 1.314 -0.945 0 O-C-N 121.372 -0.83 . . . . 0.0 112.327 -178.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.856 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 2.0 m-85 -126.52 153.86 44.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.219 178.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.559 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 28.9 ptt85 -116.59 156.32 27.21 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.952 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.763 ' HB3' HD13 ' A' ' 30' ' ' ILE . 3.6 t-20 58.3 33.37 23.07 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.539 0.685 . . . . 0.0 110.888 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.47 -66.73 0.27 Allowed Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.898 179.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 p -150.99 39.25 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-O 121.738 0.78 . . . . 0.0 112.209 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.763 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.1 mp -98.39 116.25 65.55 Favored Pre-proline 0 C--N 1.322 -0.596 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 177.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 CA--C 1.528 0.225 0 C-N-CA 122.816 2.344 . . . . 0.0 114.228 -178.049 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.54 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 57.4 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.68 -5.92 64.64 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.853 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.7 mt-10 -89.09 165.8 14.27 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.166 -1.017 . . . . 0.0 110.653 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.32 134.5 21.67 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.746 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 31.3 p -106.5 30.65 5.83 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 122.018 0.913 . . . . 0.0 109.925 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.421 HG22 ' HB3' ' A' ' 22' ' ' LYS . 47.2 t -66.53 -38.41 81.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.985 -1.461 . . . . 0.0 110.394 179.203 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -110.78 -40.28 4.6 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.988 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.746 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 15.6 pt -140.56 151.4 63.53 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.609 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 35.4 Cg_exo -57.42 152.4 47.17 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 124.112 3.208 . . . . 0.0 112.947 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.603 ' HB2' HG23 ' A' ' 13' ' ' THR . 3.7 m -58.2 148.16 27.94 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.536 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.1 mm -89.1 -41.16 13.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.161 179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.532 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.1 t -83.2 40.02 0.68 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.483 0.659 . . . . 0.0 110.416 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.603 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.6 OUTLIER -68.8 -27.64 66.05 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 177.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.68 -39.6 94.73 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 113.725 -1.579 . . . . 0.0 110.758 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -74.98 -47.36 29.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.634 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 150.22 20.76 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.983 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 82.1 m -85.42 130.54 34.56 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.358 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.8 t -137.02 168.36 19.74 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.588 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.5 m -67.48 100.36 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.821 -179.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.561 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 1.3 tmtp? -119.08 102.38 8.69 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.467 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 9.0 t-20 62.88 36.33 12.9 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.946 -1.024 . . . . 0.0 108.795 -177.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 7.7 mtmp? 79.31 -17.58 0.58 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.556 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.798 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 19.5 t -97.81 147.79 6.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.192 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.853 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 96.6 m -89.15 120.41 30.51 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -178.116 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.798 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 4.4 m-85 -127.67 154.09 45.7 Favored 'General case' 0 CA--C 1.514 -0.417 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.406 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.54 ' CZ ' ' HA ' ' A' ' 1' ' ' CYS . 5.6 ptt180 -112.65 149.34 32.98 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.778 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 58.01 37.22 26.6 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.635 0.731 . . . . 0.0 110.11 -178.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 78.35 -48.19 3.08 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 115.523 0.969 . . . . 0.0 115.523 178.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.517 HG12 ' NZ ' ' A' ' 20' ' ' LYS . 18.5 m -138.59 35.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 114.887 1.44 . . . . 0.0 114.887 -177.288 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.453 ' HB ' ' HG3' ' A' ' 26' ' ' ARG . 63.1 mt -112.46 110.17 53.13 Favored Pre-proline 0 C--N 1.318 -0.797 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 177.392 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo . . . . . 0 C--O 1.232 0.204 0 C-N-CA 122.655 2.236 . . . . 0.0 113.458 -178.28 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.5 p . . . . . 0 N--CA 1.457 -0.122 0 CA-C-O 120.755 0.312 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 69.99 37.82 74.03 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.72 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.842 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 3.9 mm-40 -135.5 165.74 24.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.014 0.435 . . . . 0.0 110.271 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.55 126.4 8.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.508 178.411 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.685 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.7 p -106.2 36.74 2.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 122.383 1.087 . . . . 0.0 109.218 179.316 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.966 ' HA ' ' HE3' ' A' ' 22' ' ' LYS . 43.3 t -64.09 -44.3 97.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 113.854 -1.521 . . . . 0.0 110.751 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -104.12 -42.99 5.37 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.011 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.685 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.6 pt -138.1 156.07 74.12 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.104 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -55.91 150.18 47.67 Favored 'Trans proline' 0 C--O 1.234 0.275 0 C-N-CA 123.624 2.882 . . . . 0.0 112.487 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -58.92 146.0 39.34 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.127 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 47.5 mm -88.88 -39.82 12.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.731 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.63 40.64 0.24 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.25 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 80.0 m -68.93 -23.76 64.21 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.7 mt -61.72 -41.02 97.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.065 -1.425 . . . . 0.0 110.432 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -75.3 -42.1 55.46 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 137.78 28.94 0.28 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.635 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.731 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 67.4 m -75.28 100.74 4.46 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.088 0.471 . . . . 0.0 110.698 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.3 m -101.3 139.31 37.14 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.108 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.0 m -61.29 121.79 13.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.231 0.539 . . . . 0.0 111.561 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.729 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -142.87 110.67 5.89 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.158 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.445 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 43.3 t30 61.84 32.58 18.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 109.104 -178.303 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.966 ' HE3' ' HA ' ' A' ' 6' ' ' VAL . 29.7 mmmt 77.45 -15.99 0.69 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.461 -179.232 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.511 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 21.4 t -94.07 152.76 3.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.842 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 62.2 m -98.3 128.01 44.52 Favored 'General case' 0 C--N 1.315 -0.896 0 O-C-N 121.451 -0.78 . . . . 0.0 111.99 -178.493 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.729 ' CD1' ' HB3' ' A' ' 20' ' ' LYS . 37.8 m-85 -128.14 154.65 45.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.392 178.737 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.465 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 34.9 ptt180 -113.78 154.97 26.49 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.78 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 56.58 35.55 26.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 0.0 110.745 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.76 -78.87 0.3 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.56 -0.829 . . . . 0.0 113.738 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.0 m -137.08 33.44 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -95.63 115.23 65.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.263 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.7 Cg_endo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.24 1.96 . . . . 0.0 111.781 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.9 p . . . . . 0 C--O 1.227 -0.086 0 CA-C-O 121.017 0.437 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 71.69 29.04 68.11 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.507 -0.77 . . . . 0.0 114.291 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.908 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 23.5 mt-10 -123.32 163.8 20.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.028 0.442 . . . . 0.0 110.415 178.473 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.34 126.14 16.12 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.557 178.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.721 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 4.9 p -102.17 34.27 2.78 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 122.381 1.086 . . . . 0.0 109.245 179.563 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.737 ' HA ' ' HE2' ' A' ' 22' ' ' LYS . 47.6 t -68.28 -40.62 82.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.637 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -109.67 -41.25 4.6 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.94 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.721 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 18.7 pt -137.74 152.89 73.42 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.462 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 36.7 Cg_exo -59.48 148.58 86.38 Favored 'Trans proline' 0 C--N 1.332 -0.309 0 C-N-CA 123.682 2.921 . . . . 0.0 112.432 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 m -54.46 147.05 14.64 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.857 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.4 mm -89.21 -44.43 15.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.904 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.589 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.03 39.14 0.49 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.444 0.64 . . . . 0.0 110.901 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 77.7 m -67.15 -25.44 66.17 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 177.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 69.2 mt -63.04 -41.28 99.46 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.533 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.49 -41.79 62.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.238 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.571 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 147.6 13.76 0.15 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.57 -0.824 . . . . 0.0 113.04 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.589 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 96.3 m -74.76 88.1 2.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.3 0.572 . . . . 0.0 110.835 179.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 58.9 p -88.32 135.45 33.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.839 179.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.5 t -64.3 119.33 10.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.445 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.434 ' HE2' ' HB2' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -136.44 117.78 14.64 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.524 -179.743 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 56.85 34.39 24.68 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.604 0.716 . . . . 0.0 109.423 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.737 ' HE2' ' HA ' ' A' ' 6' ' ' VAL . 15.4 mtpt 69.99 8.42 6.68 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.801 -179.29 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.415 ' HB ' ' CE1' ' A' ' 25' ' ' TYR . 24.8 t -116.87 143.36 27.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 177.419 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.908 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 85.9 m -95.95 127.53 42.05 Favored 'General case' 0 C--N 1.313 -0.991 0 O-C-N 121.434 -0.791 . . . . 0.0 112.865 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.415 ' CE1' ' HB ' ' A' ' 23' ' ' VAL . 18.9 m-85 -130.45 151.21 51.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.201 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.571 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 37.7 ptt180 -114.84 154.14 29.15 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.187 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.431 ' HB3' HD12 ' A' ' 30' ' ' ILE . 2.1 t-20 57.94 33.31 23.06 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 123.656 0.597 . . . . 0.0 111.135 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 111.64 -86.53 0.43 Allowed Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.956 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.7 m -134.57 32.46 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -179.051 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.459 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 62.4 mt -93.15 110.31 45.41 Favored Pre-proline 0 C--N 1.327 -0.399 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo . . . . . 0 C--N 1.341 0.155 0 C-N-CA 122.222 1.948 . . . . 0.0 112.02 -179.356 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 71.5 m . . . . . 0 CA--C 1.516 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 96.34 -6.08 65.62 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -177.482 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.651 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 55.4 mt-10 -87.6 164.3 16.14 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 114.277 -0.961 . . . . 0.0 110.484 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.444 ' HB3' HG23 ' A' ' 6' ' ' VAL . 0.9 OUTLIER -148.85 135.48 19.63 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.219 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.64 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.5 OUTLIER -105.25 26.21 9.66 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 122.644 1.211 . . . . 0.0 108.911 179.911 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.444 HG23 ' HB3' ' A' ' 4' ' ' SER . 55.4 t -55.41 -43.18 70.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.124 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -107.03 -42.87 4.78 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.255 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.64 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.7 pt -145.95 158.45 48.84 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.07 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -58.73 145.44 95.96 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 123.622 2.881 . . . . 0.0 111.832 179.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.589 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 24.1 m -75.23 161.28 29.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.196 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.442 ' C ' ' H ' ' A' ' 13' ' ' THR . 56.1 mt -87.34 -36.15 9.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.45 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.415 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 8.5 t -77.31 30.92 0.14 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.678 0.751 . . . . 0.0 111.36 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.442 ' H ' ' C ' ' A' ' 11' ' ' ILE . 0.8 OUTLIER -71.06 -26.85 63.25 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.194 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 83.4 mt -64.41 -41.18 96.77 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.558 178.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -71.42 -42.18 68.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.435 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.62 22.72 0.24 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.429 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.404 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -82.16 93.85 7.14 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.388 0.614 . . . . 0.0 110.385 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 m -88.27 139.21 30.73 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.897 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.471 ' SG ' ' HA ' ' A' ' 22' ' ' LYS . 50.2 t -75.66 116.37 16.3 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.106 0.479 . . . . 0.0 111.275 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -128.01 127.77 43.79 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 177.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 56.85 33.56 23.31 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-O 121.69 0.757 . . . . 0.0 109.103 -178.225 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.471 ' HA ' ' SG ' ' A' ' 19' ' ' CYS . 14.4 mmmm 69.9 6.56 5.8 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 114.798 -1.092 . . . . 0.0 111.964 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -117.79 138.77 47.4 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.477 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.651 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 7.3 m -89.35 129.49 35.87 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -177.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -130.94 152.5 50.19 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.125 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 30.7 ptt85 -116.17 154.31 30.25 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.888 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 59.52 33.39 22.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.842 0.829 . . . . 0.0 110.402 -179.318 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.41 -55.69 4.5 Favored Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 115.113 0.805 . . . . 0.0 115.113 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.7 m -140.47 38.19 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -177.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.0 mt -112.44 110.54 52.91 Favored Pre-proline 0 C--N 1.318 -0.774 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 177.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo . . . . . 0 N--CA 1.464 -0.207 0 C-N-CA 122.598 2.199 . . . . 0.0 113.316 -178.615 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.532 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 74.4 m . . . . . 0 CA--C 1.517 -0.315 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.03 -7.32 58.74 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -177.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.819 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 26.3 mt-10 -88.89 165.66 14.48 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.119 -1.04 . . . . 0.0 110.835 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -146.31 127.7 14.94 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.037 178.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.774 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.9 p -104.64 34.35 3.18 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.17 0.985 . . . . 0.0 109.488 179.484 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.907 ' HA ' ' HD3' ' A' ' 22' ' ' LYS . 40.1 t -62.14 -39.24 83.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.369 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -114.43 -40.26 3.66 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.146 179.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.774 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 17.5 pt -134.0 149.6 72.08 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.855 -179.234 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -56.62 152.85 38.89 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 124.255 3.303 . . . . 0.0 113.649 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.47 ' HB2' HG23 ' A' ' 13' ' ' THR . 4.2 m -60.1 149.94 31.02 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.592 -179.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 62.0 mt -89.6 -41.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.486 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.556 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -82.39 40.83 0.67 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.538 0.685 . . . . 0.0 110.67 179.876 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.47 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.7 OUTLIER -69.44 -27.11 64.97 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 177.682 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 79.5 mt -63.39 -40.64 97.78 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 113.773 -1.558 . . . . 0.0 110.62 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -73.51 -47.25 42.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.462 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.92 23.73 0.09 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.959 179.196 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.556 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 85.9 m -82.47 119.46 24.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.964 0.411 . . . . 0.0 110.165 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -116.61 156.1 27.6 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.937 -179.031 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.9 m -68.94 105.15 2.29 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.761 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.553 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 17.5 tptm -117.99 103.65 10.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.483 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 0.6 OUTLIER 61.96 32.63 17.74 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -178.143 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.907 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 28.1 mttt 78.31 -10.38 1.36 Allowed 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.348 -1.296 . . . . 0.0 111.754 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.796 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -97.12 143.87 11.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.753 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.819 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 71.0 m -88.81 122.34 32.11 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -177.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.796 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 5.7 m-85 -129.66 151.71 49.96 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.03 177.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.664 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 7.0 ptt180 -116.29 157.07 25.53 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.568 179.324 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.611 ' HB2' HD13 ' A' ' 30' ' ' ILE . 73.4 m-20 58.82 34.43 23.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.135 0.493 . . . . 0.0 111.463 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.51 -56.99 3.47 Favored Glycine 0 N--CA 1.45 -0.426 0 N-CA-C 114.963 0.745 . . . . 0.0 114.963 178.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.2 m -145.62 38.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.664 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 1.9 mp -106.84 112.51 63.38 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.68 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo . . . . . 0 C--O 1.232 0.191 0 C-N-CA 122.665 2.243 . . . . 0.0 113.787 -178.33 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.9 m . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.27 -5.01 60.72 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 -178.211 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.935 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 56.4 mt-10 -88.21 162.79 16.47 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 114.66 -0.77 . . . . 0.0 110.691 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.26 128.4 20.86 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 177.36 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.712 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 28.3 p -102.46 31.84 3.86 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.924 0.869 . . . . 0.0 110.203 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.0 t -68.48 -38.97 80.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.393 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -106.77 -41.35 5.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.008 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.712 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.3 pt -142.7 152.18 58.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.604 -179.388 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 34.5 Cg_exo -58.86 150.93 68.44 Favored 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.915 3.077 . . . . 0.0 112.621 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.439 ' HB3' ' OE1' ' A' ' 3' ' ' GLU . 1.7 m -58.57 144.76 41.75 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.653 -179.503 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.7 mm -90.93 -37.96 10.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.461 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.6 t -75.95 40.48 0.2 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.227 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 p -66.19 -25.67 67.04 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.835 0.826 . . . . 0.0 108.801 177.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.34 -35.97 76.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.429 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -92.17 19.94 6.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.654 179.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 71.34 30.21 67.34 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.856 -0.611 . . . . 0.0 114.004 178.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 99.9 m -84.0 127.48 33.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 117.289 0.544 . . . . 0.0 109.915 178.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 41.2 m -139.25 164.87 28.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.95 -178.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -67.76 101.31 1.04 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.019 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.534 ' HE2' HG12 ' A' ' 29' ' ' VAL . 7.8 tmtm? -128.53 118.99 23.97 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.492 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.47 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 30.7 t30 62.63 39.04 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -178.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.47 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 17.5 pttp 56.53 27.67 12.67 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.787 -179.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.929 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 44.4 t -142.83 155.04 17.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.935 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 79.6 m -89.61 119.93 30.46 Favored 'General case' 0 C--N 1.313 -0.978 0 O-C-N 121.485 -0.76 . . . . 0.0 112.294 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.929 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.8 OUTLIER -126.79 154.89 43.66 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.019 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.504 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 13.2 ptt180 -116.23 156.42 26.59 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.207 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 56.94 34.53 25.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.15 0.5 . . . . 0.0 111.29 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 83.86 -55.53 5.02 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 114.759 0.663 . . . . 0.0 114.759 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.534 HG12 ' HE2' ' A' ' 20' ' ' LYS . 10.8 m -139.8 40.48 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -178.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.504 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 50.5 mm -113.22 106.44 54.7 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo . . . . . 0 C--O 1.233 0.239 0 C-N-CA 122.883 2.389 . . . . 0.0 113.785 -178.172 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.561 ' HA ' ' CZ ' ' A' ' 26' ' ' ARG . 58.4 m . . . . . 0 CA--C 1.517 -0.306 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.2 -7.44 56.71 Favored Glycine 0 N--CA 1.444 -0.822 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -177.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.851 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 29.4 mt-10 -88.01 165.22 15.34 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.116 -1.042 . . . . 0.0 110.68 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -145.28 131.9 19.9 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.744 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 22.1 p -108.7 31.89 5.29 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.201 1.001 . . . . 0.0 109.606 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.2 t -60.32 -43.3 93.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.076 -1.42 . . . . 0.0 110.239 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.73 -41.94 5.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.261 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.744 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 16.9 pt -135.31 150.77 73.52 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.883 -179.194 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 52.6 Cg_exo -55.79 153.38 30.93 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 124.271 3.314 . . . . 0.0 113.773 -179.168 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 9.0 m -59.93 152.67 22.97 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.755 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.8 mt -93.71 -42.37 12.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.56 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.605 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -81.07 43.29 0.7 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.435 0.635 . . . . 0.0 110.714 179.909 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -68.0 -26.74 66.06 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.9 mt -62.43 -41.36 98.66 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.623 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.401 HD22 ' HA ' ' A' ' 15' ' ' LEU . 1.8 tm? -73.49 -43.95 58.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.304 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 140.69 26.08 0.22 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.819 179.176 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.605 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 77.1 m -82.95 121.24 26.73 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.853 0.358 . . . . 0.0 110.116 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 12.9 t -118.24 164.01 15.82 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 -178.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.7 m -73.36 74.05 1.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.644 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.679 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 13.2 tmtt? -89.15 103.79 16.39 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.457 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 23.4 t30 60.19 33.8 21.05 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.267 -178.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 21' ' ' ASN . 22.9 mmtp 74.37 2.71 4.18 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.704 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.834 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 18.2 t -109.17 140.07 29.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.851 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 82.9 m -88.1 121.42 30.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -176.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.834 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -127.26 150.51 49.53 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 177.577 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.595 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 9.1 ptt180 -115.27 153.53 30.75 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.369 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.753 ' HB3' HD13 ' A' ' 30' ' ' ILE . 3.4 t-20 58.79 36.81 24.95 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.361 0.6 . . . . 0.0 111.16 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.85 -62.53 0.79 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.581 -0.819 . . . . 0.0 114.663 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.6 p -150.58 37.36 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-O 121.674 0.749 . . . . 0.0 112.693 -178.117 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.753 HD13 ' HB3' ' A' ' 27' ' ' ASN . 2.2 mp -100.06 112.19 63.56 Favored Pre-proline 0 C--N 1.323 -0.577 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 177.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 C--O 1.232 0.197 0 C-N-CA 122.628 2.219 . . . . 0.0 113.551 -178.391 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 30.3 p . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.718 0.294 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 111.09 -12.27 29.07 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.552 -0.832 . . . . 0.0 111.937 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.841 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 5.6 mm-40 -85.1 159.94 20.07 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.545 0.688 . . . . 0.0 111.151 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.79 134.77 30.69 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.853 -1.067 . . . . 0.0 109.13 178.538 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.702 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 15.1 p -115.91 34.13 5.13 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 122.088 0.947 . . . . 0.0 109.231 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.614 ' HA ' ' HB3' ' A' ' 22' ' ' LYS . 28.9 t -63.92 -40.46 89.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 113.881 -1.509 . . . . 0.0 111.244 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -114.53 -38.94 3.9 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.065 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.702 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 20.2 pt -136.51 153.43 76.09 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.504 -179.267 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -58.52 148.66 79.97 Favored 'Trans proline' 0 C--N 1.332 -0.328 0 C-N-CA 123.717 2.945 . . . . 0.0 112.265 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.6 m -56.67 143.97 34.15 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.469 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 4.3 mp -89.75 -42.43 14.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.618 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 1.0 OUTLIER -76.24 39.11 0.19 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.363 179.854 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 58.2 m -69.53 -23.42 63.59 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 177.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 77.2 mt -63.06 -40.83 98.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 114.084 -1.416 . . . . 0.0 110.489 178.528 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.455 HD22 ' HA ' ' A' ' 15' ' ' LEU . 1.0 OUTLIER -73.12 -39.72 65.51 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.396 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.46 23.87 0.44 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.535 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.618 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 89.7 m -76.64 98.06 4.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.094 0.473 . . . . 0.0 110.669 179.532 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.459 ' O ' ' HA ' ' A' ' 24' ' ' CYS . 13.6 m -88.56 132.93 34.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.937 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.2 t -73.82 117.2 15.32 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.087 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.672 ' HD2' ' CE1' ' A' ' 25' ' ' TYR . 11.6 tmtt? -141.97 119.1 11.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.525 0.679 . . . . 0.0 110.843 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 55.07 37.17 28.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.3 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.614 ' HB3' ' HA ' ' A' ' 6' ' ' VAL . 26.3 mtmm 75.88 1.43 3.51 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.08 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.7 t -118.32 137.25 52.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.841 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 30.1 m -95.52 128.37 42.33 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.702 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.672 ' CE1' ' HD2' ' A' ' 20' ' ' LYS . 2.1 m-85 -122.35 163.54 19.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.653 179.429 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.5 ' O ' ' HB ' ' A' ' 30' ' ' ILE . 38.2 ptt180 -131.94 155.51 47.79 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 61.79 31.55 18.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.305 0.574 . . . . 0.0 111.211 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 109.69 -71.93 0.2 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.536 -0.84 . . . . 0.0 113.931 178.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.5 p -150.23 36.85 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 122.069 0.938 . . . . 0.0 111.099 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.5 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.9 mm -101.17 113.83 65.8 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.407 178.434 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 30' ' ' ILE . 9.5 Cg_endo . . . . . 0 N--CA 1.463 -0.268 0 C-N-CA 122.203 1.935 . . . . 0.0 111.4 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.473 ' HB3' ' HD3' ' A' ' 26' ' ' ARG . 1.7 p . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.018 0.437 . . . . 0.0 110.828 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.33 31.6 80.98 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.491 -0.777 . . . . 0.0 113.166 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.88 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 92.5 mt-10 -124.42 165.93 16.88 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.074 0.464 . . . . 0.0 110.4 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.89 134.07 17.19 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.771 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 18.7 p -107.45 31.29 5.53 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 122.36 1.076 . . . . 0.0 109.605 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.902 ' HA ' ' HD2' ' A' ' 22' ' ' LYS . 46.7 t -61.72 -44.47 98.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 113.933 -1.485 . . . . 0.0 110.177 179.475 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -104.66 -43.59 5.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.158 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.771 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 19.5 pt -136.09 153.8 77.03 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.003 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 51.4 Cg_exo -55.45 153.98 26.34 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 124.11 3.207 . . . . 0.0 113.379 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.62 ' HB2' HG23 ' A' ' 13' ' ' THR . 7.3 m -58.69 149.74 25.31 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.698 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.406 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.2 mp -89.53 -46.35 15.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.859 179.324 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.694 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.9 OUTLIER -79.24 41.24 0.45 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.442 0.639 . . . . 0.0 110.539 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.62 HG23 ' HB2' ' A' ' 10' ' ' CYS . 0.6 OUTLIER -68.61 -26.5 65.39 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 177.8 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 76.4 mt -61.98 -40.93 97.29 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 113.81 -1.541 . . . . 0.0 110.453 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -75.36 -46.33 33.82 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.455 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 145.58 26.38 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.543 -0.836 . . . . 0.0 113.259 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.694 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 97.1 m -80.35 120.96 25.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 117.169 0.485 . . . . 0.0 110.006 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.5 m -119.12 159.79 23.31 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.181 -178.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.2 m -69.35 84.96 0.4 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.752 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.57 ' HB3' ' CD1' ' A' ' 25' ' ' TYR . 46.7 tptt -96.66 98.4 10.15 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.596 ' O ' ' HB2' ' A' ' 22' ' ' LYS . 0.6 OUTLIER 60.94 33.52 19.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.395 -0.82 . . . . 0.0 108.811 -178.362 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.902 ' HD2' ' HA ' ' A' ' 6' ' ' VAL . 40.4 mmtt 82.29 -10.99 1.05 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.319 -1.309 . . . . 0.0 112.414 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.823 ' HB ' ' HE1' ' A' ' 25' ' ' TYR . 17.7 t -99.22 141.45 16.64 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.165 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.88 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 73.1 m -89.65 122.54 32.87 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.823 ' HE1' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -127.43 151.07 49.29 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 177.726 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.473 ' HD3' ' HB3' ' A' ' 1' ' ' CYS . 28.1 ptt180 -112.24 153.61 26.86 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.115 179.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.3 t30 60.12 33.49 21.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.287 0.565 . . . . 0.0 111.264 179.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.89 -64.59 0.73 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.621 -0.8 . . . . 0.0 114.615 178.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.3 m -143.12 33.59 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.437 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 59.0 mt -101.56 108.42 55.54 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo . . . . . 0 N--CA 1.464 -0.238 0 C-N-CA 122.212 1.942 . . . . 0.0 112.347 -179.09 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 CA--C 1.516 -0.362 0 CA-C-O 121.372 0.606 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.48 -5.75 67.63 Favored Glycine 0 N--CA 1.442 -0.908 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -177.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.638 ' HB2' ' HB2' ' A' ' 24' ' ' CYS . 21.2 mt-10 -87.25 160.11 18.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 114.494 -0.853 . . . . 0.0 110.387 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.425 ' HA ' ' HA ' ' A' ' 23' ' ' VAL . 0.7 OUTLIER -144.46 133.36 22.58 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.471 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.488 ' HA ' ' O ' ' A' ' 8' ' ' ILE . 0.7 OUTLIER -98.68 26.97 5.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 122.157 0.98 . . . . 0.0 109.905 -179.572 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.7 t -61.03 -39.74 83.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 114.26 -1.336 . . . . 0.0 111.715 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -108.33 -42.03 4.71 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.44 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.488 ' O ' ' HA ' ' A' ' 5' ' ' CYS . 13.5 pt -149.96 159.38 35.74 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.679 -178.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -59.55 143.6 99.64 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 123.342 2.695 . . . . 0.0 111.302 179.17 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.538 ' HB3' ' CD ' ' A' ' 3' ' ' GLU . 18.2 m -71.18 161.42 31.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.79 -178.229 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 57.8 mt -87.03 -40.01 13.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.356 -0.838 . . . . 0.0 112.711 -178.082 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.594 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 3.1 t -79.32 35.87 0.28 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.714 0.768 . . . . 0.0 111.345 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -70.52 -25.12 62.98 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 177.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 81.0 mt -63.86 -42.85 97.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 113.898 -1.501 . . . . 0.0 110.716 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -71.43 -43.31 66.97 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.465 ' O ' ' HA ' ' A' ' 26' ' ' ARG . . . 144.46 20.66 0.17 Allowed Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.697 179.256 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 12' ' ' SER . 84.9 m -77.8 83.75 4.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.401 0.619 . . . . 0.0 110.425 179.491 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.4 m -86.18 136.2 33.29 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.454 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.6 t -68.6 127.94 34.84 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.162 0.506 . . . . 0.0 111.222 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -144.99 130.24 18.6 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.746 ' O ' ' HG2' ' A' ' 22' ' ' LYS . 31.2 t30 56.81 38.93 29.79 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.304 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.746 ' HG2' ' O ' ' A' ' 21' ' ' ASN . 2.1 pttm 60.84 13.3 4.34 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.156 1.382 . . . . 0.0 112.115 -179.159 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 4' ' ' SER . 58.5 t -128.31 141.62 46.01 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.638 ' HB2' ' HB2' ' A' ' 3' ' ' GLU . 1.7 m -88.93 131.67 35.04 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -178.034 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -132.45 146.27 51.82 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.17 -0.923 . . . . 0.0 108.853 177.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.465 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 41.4 ptt85 -110.53 157.84 19.19 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.305 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 57.62 30.81 19.4 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.672 0.607 . . . . 0.0 111.256 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.59 -74.5 0.22 Allowed Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.548 -0.834 . . . . 0.0 113.462 179.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.51 32.52 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.423 ' HB ' ' O ' ' A' ' 26' ' ' ARG . 48.6 mm -92.44 113.1 58.35 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.197 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo . . . . . 0 N--CA 1.464 -0.227 0 C-N-CA 122.704 2.269 . . . . 0.0 113.558 -178.459 . . . . . . . . 0 0 . 1 stop_ save_